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PART 1: TOTAL SYNTHESIS OF CIS-SYLVATICIN 
PART 2: SYNTHETIC STUDIES TOWARDS ADJACENT THP-THF AND BIS-
THF ANNONACEOUS ACETOGENINS 
 
By Ian Spurr 
 
The total synthesis of potent antitumour agent cis-sylvaticin (1.100) has been 
completed. Notable steps included the alcoholytic kinetic resolution of epoxide 
2.2, two permanganate promoted oxidative cyclisation reactions, a tethered 
RCM to unite the two major fragments and the use of P4 phoshazene base to 
install the butenolide precursor. 
 
Synthesis of adjacent THP-THF and bis-THF cores via cascade oxidative 
cyclisation reactions with permanganate is an attractive route to many 
Annonaceous  acetogenins. Attempted synthesis of an adjacent THP-THF 
core and synthesis of an adjacent bis-THF core are discussed. 
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Chapter 1: Non Adjacent bis-THF and THF-THP 
Annonaceous Acetogenins  
This chapter will give a brief overview of the isolation, structure and 
bioactivity of the Annonaceous acetogenin family of natural products. The focus 
will be on the non-adjacant bis-THF and non-classical non-adjacant THF-THP 
classes. The chapter will then give an in depth review of the total synthesis of 
these classes of Annonaceous acetogenins.   
1.1  Introduction to Annonaceous Acetogenins 
Annonaceous acetogenins are a group of natural products isolated from 
the  Annonaceous  tropical plant family (custard apple family, 130 genera and 
2300 species).
1-9  The first Annonaceous acetogenin isolated and fully 
characterised was uvaricin in 1982.
10 Uvaricin’s biological activity caused great 
interest in Annonaceous acetogenins, leading to the isolation of more than 400 
acetogenins between 1982 and 2004.
2  
Structurally,  Annonaceous acetogenins have unbranched C32/34 fatty 
acid chains typically with a terminal γ-lactone. Biogenesis of Annonaceous 
acetogenins appears to be through the polyketide pathway. The biosynthetic 
sequence postulated for the acetogenins starts by installing the terminal γ-
lactone to a long chain unsaturated fatty acid (figure 1.1). 
O
HO OH
O
O
9 10 H H
9 10 9 10
O
OH
O
O
9 10
O
O
O O  
Figure 1.1 Postulated biosynthetic pathway for Annonaceous acetogenins. 
The core unsaturated units are then partially or completely epoxidised followed 
by possible intermolecular or intramolecular ring opening and closing reactions, 
resulting in characteristic structural features such as THF, and THP diols. In   2
addition to these cyclic ethers, other functional groups found in Annonaceous 
acetogenins include epoxides, ketones, alkenes and alkynes. 
Due to the large number of entries in this family of natural products a 
system of classification was introduced. The classification system groups 
acetogenins according to their core structures, the main classes are shown in 
figure 1.2. 
O O O
O O O O O O
(X)
HO R HO R
HO OH HO OH HO OH OH
R R
Mono-THF Adjacent bis-THF
Non adjacent bis-THF
Non THF-ring
Non classical non adjacent THF-THP Non classical adjacent THF-THP
O
HO
OH
Non classical THP
X = alkene, alkyne, ketone, 
hyroxyl, epoxide
R = H, OH  
Figure 1.2 Annonaceous acetogenin core classes. 
The core classes can be broken down into sub classes by the nature of the γ-
lactone, but commonly a methyl substituted α,β-unsaturated  γ-lactone 
(butenolide) is present with or without a hydroxyl group at C4 (figure 1.3). 
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Figure 1.3 Structure of (+)-gigantecin (1.1). 
Standardised numbering for Annonaceous acetogenins begins at the 
lactone carbonyl carbon, the numbering continues down the fatty acid backbone 
with the remaining lactone carbons numbered as shown.  
1.2 Biological  Activity 
The Annonaceous acetogenins have many interesting biological effects, 
including in vivo antitumor, anti-parasitic, pesticidal, antimalarial and antibacterial 
activities.
2-9 Most notably Annonaceous acetogenins act as cytotoxic and anti-
tumour agents. Interestingly this activity extends to multi-drug resistant (MDR) 
cancer cell lines.
11,12 The Annonaceous acetogenins trilobacin and asiminocin 
are amongst the most potent cytotoxic compounds known in several human   3
tumor cell lines (ED50 > 10
-12  μg/mL).
13,14 The cytotoxic and anti-tumour 
properties are thought to be due to Annonaceous acetogenins being among the 
most potent known inhibitors of mitochondrial complex 1.
15-18  
Mitochondrial complex 1 has an important role in the mitochondrial 
electron transport chain. The electron transport chain supplies aerobic energy to 
cells by driving synthesis of ATP (figure 1.4).  
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Figure 1.4 Mitochondrial electron transport chain. 
The mitochondrial complex 1 site is responsible for oxidation of NADH. The 
resulting redox energy drives protons into mitochondrial intermembrane space, 
causing a battery effect which drives ATP production. Cancerous cells have a 
higher demand for ATP than non-cancerous cells, and this might explain why 
Annonaceous acetogenins are selectively cytotoxic for cancerous cells. The 
exact nature of the complex 1 inhibition caused by Annonaceous acetogenins is 
not fully understood. It is believed that Annonaceous acetogenins bind to either 
complex 1 or proximate hydrophilic lipid membranes, with the terminal α,β-
unsaturated γ-lactone mimicking NADH and disturbing the mitochondrial electron 
transport chain. Although it is likely that cytotoxity in cancerous cells is related to 
complex 1 inhibition there has been no clear correlation found. This suggests 
Annonaceous acetogenins may also be involved in triggering further enzymatic 
pathways resulting in cell death.   
  Until the intricate nature of complex 1 and cell death pathways are fully 
understood, it will be difficult to fully assess the utility of Annonaceous 
acetogenins as candidates in drug research.    4
1.3  Isolation and Structural Assignment 
  Discussion will be focused on non-adjacent bis-THF and non-adjacent 
THF-THP acetogenins. Annonaceous  acetogenins are soluble in organic 
solvents so they can be extracted from dried plant material. The same 
acetogenin can be isolated from different plant sources. For instance (+)-
gigantecin (1.1) was isolated from two sources; the bark of Goniothalamus 
giganteus in southeast Asia and from the seeds of the Brazilian plant Annona 
coriacea.
19,20 A method of purification employed by McLaughlin was column 
chromatography with bioassay-guided fractionation (using brine shrimp lethality 
test) followed by HPLC.
21 Structural assignment is determined by various MS and 
NMR techniques. Molecular weight is established by ESI mass spectrometry, 
while THF/THP ring and hydroxyl positions on the alkyl chain are found by 
careful analysis of EI fragmentation mass spectrometry data (figure 1.5).
21  
O
C10H21 O
O
OTMS
H H
OTMS TMSO
H H
OTMS
3 O
213
243 683
313 613
545 381 (262)
(399)
* numbers in () denotes EIMS peak from un-derivatised cis-sylvaticin  
Figure 1.5 EIMS fragmentation for derivatised and un-derivatised cis-sylvaticin. 
Comparisons of NMR data from synthetic THF/THP cores with isolated 
acetogenins are used to determine relative stereochemistry.
22-26 An important 
observation from the 
1H NMR from cis-sylvaticin  indicated that of the three 
flanking hydroxyls, two had a threo and one had an erythro relative configuration, 
although exact positions could not be assigned purely from the 
1H NMR of cis-
sylvaticin (figure 1.6). The threo and erythro relative configuration could be 
concluded as it was known that carbinol peaks with a threo relative configuration 
come in the δ 3.4 – 3.6 ppm region, while carbinol peaks with an erythro relative 
configuration come at ~δ 3.8 ppm.
22   5
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H H
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Figure 1.6 
1H NMR for cis-sylvaticin.  
Absolute stereochemistry is the most difficult structural feature to verify, and total 
synthesis can be required to confirm absolute stereochemistry. In depth NMR 
studies of Mosher ester and acetal derivatives can be used to assign correctly 
absolute stereochemistry.
21,23,27 In the case of (+)-gigantecin (1.1) X-ray 
crystallography proved the relative and absolute stereochemistry.
20 However, this 
is unusual as Annonaceous acetogenins are characteristically waxy solids, which 
are unsuitable for X-ray analysis but derivatives can sometimes give crystals.       
1.4 Synthesis of Non Adjacent bis-THF  Annonaceous 
Acetogenins 
In the following section the synthesis of the above mentioned sub-class of 
Annonaceous acetogenins will be discussed. It might be of interest to directly 
compare the syntheses of (+)-4-deoxygigantecin (1.20), (+)-gigantecin (1.1) and 
(+)-squamostatin-C (1.79). They each comprise of an identical non adjacent bis-
THF core with respect to relative and absolute stereochemistry.   6
(+)-Squamostatin–D – Marshall (1998) 
Marshall’s approach uses a linear strategy in synthesising (+)-
squamostatin-D (1.2), which relied on building up from known aldehyde 1.3 
(scheme 1.1).
28  
(+)-Squamostatin-D (1.2)
H
OBn
O
OTBS
OTBS
1.3
O
OH HO
9 O
C10H21
HO
O
O
H H H H
1 12 20
 
Scheme 1.1 Retrosynthetic analysis employed by Marshall. 
Key reactions in this approach utilise chemistry developed by Marshall using 
chiral γ-oxygenated allylic tin and indium reagents.
29 Aldehyde 1.3 is available 
from 1,4-butanediol in 7 steps in 50% yield.
30-32  
The synthesis began by addition of γ-oxygenated allylic tin reagent 1.4 to 
aldehyde 1.3, this set up the erythreo configuration between C23 and C24 in (+)-
squamostatin-D (1.2) (scheme 1.2). The resulting secondary alcohol which was 
isolated as a single isomer was converted to tosylate 1.5. TBAF deprotection of 
silyl ethers 1.5 initiated cyclisation, with the resulting free hydroxyl protected as 
the MOM ether to give benzyl ether 1.6. Debenzylation of 1.6 and oxidation of the 
alcohol gave aldehyde 1.7, which set the stage for construction of the second 
THF ring.  
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Scheme 1.2 Synthesis of aldehyde 1.10. Reagents and conditions: a) 1.4, CH2Cl2, then 
BF3•OEt2; b) p-TsCl, pyridine; c) TBAF, THF; d) MOMCl, DIPEA, CH2Cl2; e) H2/Pd-C, EtOH; f) 
Dess-Martin periodinane, CH2Cl2; g) InCl3, EtOAc, then 1.8; h) MOMCl, DIPEA, CH2Cl2; i) H2/Rh-
Al2O3, EtOAc; j) TBAF, THF; l) Dess-Martin periodinane, CH2Cl2.   7
A  γ-oxygenated allylic indium reagent (derived from tin reagent 1.8) 
addition to aldehyde 1.7 set up the threo configuration between C15 and C16. 
The resulting secondary alcohol 1.9 which was isolated as a single isomer was 
protected as the MOM ether, followed by reduction of the alkene, and then TBAF 
deprotection of the silyl ether gave a primary alcohol which was oxidised to give 
aldehyde 1.10.  
An enantioselective organozinc addition to aldehyde 1.10 permitted 
control of the C12 stereogenic carbinol (Scheme 1.3).  
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Scheme 1.3 Total synthesis of (+)-squamostatin-D (1.2). Reagents and conditions: a) Et2BH; b) 
Et2Zn; c) 1.13, Ti(O-iPr)4, MePh, ∆, then 1.10; d) TBSCl, imidazole, DMF; e) H2/Pd-C, EtOH; f) p-
TsCl, pyridine; g) TBAF, THF; h) LDA, THF, then 1.17; i) TBAF, THF; j) Tf2O, Et3N, CH2Cl2; k) 
HCl, THF, MeOH. 
Following the Knochel protocol, addition of the zinc reagent 1.12 to 
aldehyde 1.10 selectively provided alcohol 1.14 with high stereoselectivity (dr > 
95:5 by 
1H NMR).
33 Alcohol 1.14 was silylated, the BOM group was selectively 
removed with the resulting alcohol converted to tosylate 1.15. TBAF desilylation 
of tosylate 1.15 resulted in cyclisation to give MOM ether 1.16. The butenolide 
portion was installed using chemistry described by Wu.
34 The lithium enolate of 
ester 1.16 was reacted with aldehyde 1.17 to give an aldol product, which when 
desilylated delivered lactone 1.18. Dehydration of lactone 1.18 was achieved with 
triflic anhydride and triethylamine to give butenolide 1.19 which was deprotected 
to give (+)-squamostatin-D (1.2). (+)-Squamostatin-D (1.2) was synthesised in 27 
linear steps from 1,4-butanediol in a total yield of 5.5%.    8
 
Key aspects of Marshall’s synthesis are:- 
-  Linear approach was adopted with the non-adjacent bis-THF core built 
up from aldehyde 1.3. 
-  Use of reagent-based stereocontrol through additions of chiral non-
racemic organometallics to aldehydes.
29 
- Formation  of  trans-THF rings by intramolecular nucleophilic 
substitution. 
-  Butenolide portion was installed by a modified aldol condensation.
34  
(+)-4-Deoxygigantecin – Makabe (1998) 
The Makabe group synthesis of (+)-4-deoxygigantecin (1.20) couples 2 
main fragments (scheme 1.4).
35 Bis-THF alkyne 1.21 was synthesised in a linear 
fashion from mono-THF acetogenin derivative (–)-muricatacin (1.23), avaliable in 
7 steps from propargylic alcohol in a 27% yield.
36,37 
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Scheme 1.4 Retrosynthetic analysis employed by Makabe. 
  The synthesis starts with a MOM protection of (–)-muricatacin (1.23), then 
DIBAL-H reduction to give a lactol, which underwent a Wittig reaction delivering 
alkene 1.24 (scheme 1.5) as a single isomer.   9
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Scheme 1.5 Synthesis of bis-THF alkyne 1.21. Reagents and conditions: a) MOMCl, DIPEA, 
CH2Cl2; b) DIBAL-H, CH2Cl2; c) HC≡C(CH2)3Ph3P
+I
–, NaOMe, DMF; d) m-CPBA, CH2Cl2; e) BzCl, 
pyridine; f) NaOH, MeOH; g) MOMCl, DIPEA, CH2Cl2; h) n-BuLi, THF, then  1.31; i) Na/NH3, t-
BuOH, THF; j) 60% AcOH, ∆; l) TBSCI, Et3N, DMAP, CH2CI2; m) MsCI, Et3N, CH2CI2; n) TBAF, 
THF, then 10% NaOH; o) TMSC≡CH, n-BuLi, BF3•Et2O, THF; p) TBAF, THF; q) MsCI, Et3N, 
CH2CI2; r) AD-mix-α, t-BuOH/H2O; s) Triton B, MeOH. 
  Epoxidation of alkene 1.24 in a non-selective manner followed by 
cyclisation gave an inseparable mixture of THF products 1.25a/b (1.25a:1.25b 
3:2). Benzoylation of THF products 1.25a/b then allowed separation to give 
benzoate 1.26 as a single diastereoisomer.
37 Debenzoylation followed by MOM 
protection gave alkyne 1.27, which was alkylated with iodide 1.31 to give acetal 
1.28. A Birch reduction of alkyne 1.28, followed by acid hydrolysis of the 
acetonide returned a terminal diol, which was converted to terminal epoxide 1.29 
with inversion of stereochemistry. Epoxide 1.29 was then reacted with lithiated 
TMS acetylene in the presence of BF3•OEt2, followed by TBAF desilylation to 
deliver alcohol 1.30. Mesylation of alcohol 1.30, then asymmetric dihydroxylation 
of the E-alkene followed by base induced cyclisation gave bis-THF alkyne 1.21. 
Fragment  1.21  was synthesised in 25 steps from propargylic alcohol  in 1.9% 
yield. 
The synthesis of butenolide fragment 1.22 began by alkylation of lactone 
1.36 with iodide 1.32 (scheme 1.6).
38 A THP deprotection of the resulting ether 
gave sulphide 1.33.   10
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Scheme 1.6 Synthesis of butenolide fragment 1.22 Reagents and conditions: a) 1.36, NaHMDS, 
THF/HMPA, then 1.32; b) p-TsOH, MeOH; c) m-CPBA, then ∆; d) Dess-Martin periodinane, 
ClCH2CH2Cl; e) CrCl2, CHI3, THF. 
 Oxidation  of  sulfide  1.33 to the sulfoxide then thermal elimination gave 
α,β-unsaturated γ-lactone 1.34. Oxidation of primary alcohol 1.34 followed by a 
Takai olefination gave butenolide fragment 1.22.
39 Fragment 1.22  was 
synthesised in 12 steps from ethyl (S)-lactate in a 14.6% yield.  
Fragment  1.21 and 1.22 were successfully coupled using Sonogashira 
chemistry to give enyne 1.37 (scheme 1.7).
40 
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Scheme 1.7 Total synthesis of (+)-4-deoxygigantecin (1.20).  Reagents and conditions: a) 
Pd(PPh3)4, CuI, Et3N, MePh; b) H2, Rh(PPh3)3Cl, benzene; c) BF3•OEt2, Me2S. 
  Selective catalytic hydrogenation followed by global deprotection gave (+)-
4-deoxygigantecin (1.20). (+)-4-Deoxygigantecin (1.20) was synthesised in 28 
linear steps from propargylic alcohol in a total 1.2% yield.  
Key aspects of Makabe synthesis are:- 
-  The strategy involves a convergent 2 fragment approach with 
fragments 1.21 and 1.22 coupled using Sonogashira chemistry.
40  
-  A linear approach to synthesising the non-adjacent bis-THF core, 
building up from (–)-muricatacin (1.23).
37 
- Established  trans-THF rings nucleophilic by Williams-type substitution, 
C18-20 THF ring synthesised in a non-stereoselective fashion. Key 
stereochemistry for the C10-13 THF ring set-up by asymmetric 
dihydroxylation and Sharpless asymmetric epoxidation. 
-  Construction of the butenolide by alkylation of White’s lactone 1.36.
38   11
(+)-Gigantecin 
There have been two total syntheses of (+)-gigantecin (1.1) reported by 
the groups of Crimmins and Hoye.
41,42 These syntheses will be discussed in the 
ensuing section.  
(+)-Gigantecin – Crimmins (2004) 
Crimmins’ synthesis of (+)-gigantecin (1.1) adopts a convergent 3 
fragment approach (scheme 1.8).
41 Crimmins takes advantage of a Carreira type 
coupling of fragments 1.38 and 1.39 to construct the non-adjacent bis-THF core. 
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Scheme 1.8 Retrosynthetic analysis employed by Crimmins. 
The key reaction in synthesising both THF fragments was chemistry 
developed by Crimmins, an extension of the asymmetric glycolate aldol 
reaction.
43 Fragment 1.39 required synthesis of glycolate 1.42, which was 
achieved in 3 steps from (S)-benzyl glycidyl ether 1.41 (scheme 1.9). 
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Scheme 1.9 Synthesis of alkyne fragment 1.39. Reagents and conditions: a) Me3S
+I
–, n-BuLi, 
THF, –10 °C → 25 °C; b) NaH, BrCH2CO2H, THF; c) Me3CCOCl, Et3N, THF, –78 °C → 0 °C, (S)-
lithio-4-benzyl-oxazolidin-2-one; d) TiCl4, DIPEA, NMP, triisopropylsilanyl-propynal, CH2Cl2, –78 
°C → –40 °C; e)  MeOCH2Cl, DIPEA, CH2Cl2, DMAP; f) LiBH4, MeOH, Et2O, 0 °C; g) (COCl)2, 
DMSO, Et3N, CH2Cl2; h) Ph3P=CH2, THF; i) Cl2(Cy3P)(IMes)Ru=CHPh (5 mol %), CH2Cl2, 40 °C; 
j) TBAF, THF.   12
With glycolate 1.42  in hand and under their optimum conditions, the 
asymmetric glycolate aldol reaction with triisopropylsilanyl-propynal gave alcohol 
1.43 with high selectivity (>20:1 major:all other isomers). Secondary alcohol 1.43 
was protected as its MOM ether and the chiral auxiliary was reductively cleaved 
affording alcohol 1.44. Swern oxidation of primary alcohol 1.44 followed by 
olefination returned diene 1.45. RCM reaction was then carried out on diene 1.45 
using second generation Grubbs catalyst which provided dihydrofuran 1.46. The 
synthesis of fragment 1.39 was completed by desilylisation of alkyne 1.46. 
Fragment 1.39 was synthesised in 10 steps from (S)-benzyl glycidyl ether 1.41 in 
52% overall yield. 
Fragment 1.38 was synthesised in an analogous manner to fragment 1.39 
(scheme 1.10). Under the same conditions (scheme 1.9, steps a – c) glycolate 
ent-1.42 was synthesised from (R)-benzyl glycidyl ether (ent-1.41). Under 
optimum conditions but with glycolate ent-1.42 and tridecanal, the asymmetric 
glycolate aldol reaction delivered alcohol 1.47 with high selectivity (>15:1 
major:all other isomers). Secondary alcohol 1.47 was protected as its MOM ether 
and the chiral auxiliary was reductively cleaved providing alcohol 1.48. Swern 
oxidation of primary alcohol 1.48 followed by olefination gave diene 1.49. 
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Scheme 1.10 Synthesis of alkyne fragment 1.38. Reagents and conditions: a) TiCl4, DIPEA, 
NMP, tridecanal, CH2Cl2, –78 °C → –40 °C; b) MeOCH2Cl, DIPEA, CH2Cl2, DMAP; c) LiBH4, 
MeOH, Et2O, 0 °C; d) (COCl)2, DMSO, Et3N, CH2Cl2; e) Ph3P=CH2, THF; f) 
Cl2(Cy3P)(IMes)Ru=CHPh (5 mol %), CH2Cl2, 40 °C; g) H2, Pd/C, EtOH; h) (COCl)2, DMSO, Et3N, 
CH2Cl2. 
A RCM reaction was then performed using diene 1.49 and Grubbs catalyst 
(2
nd generation) which furnished dihydrofuran 1.50. Under an atmosphere of 
hydrogen in the presence of Pd/C reduction of the alkene and debenzylation of 
dihydrofuran  1.50 was achieved yielding alcohol 1.51. Swern oxidation on   13
primary alcohol 1.51 gave the crude fragment 1.38. Fragment 1.38  was 
synthesised in 11 steps from (R)-benzyl glycidyl ether (ent-1.5) with 38% overall 
yield up to alcohol 1.51. 
Fragment  1.40 synthesis began from glycolate 1.52, which  was 
synthesised in 2 steps from 4-methoxybenzyl alcohol in good yield (scheme 
1.11). The key step involved a diastereoselective alkylation of the sodium enolate 
of glycolate 1.52, which proceeded with high facial selectivity (dr >98:2).
44 
Reductive cleavage of the chiral auxiliary from bromide 1.54  and subsequent 
silylation afforded vinyl bromide 1.55. 
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Scheme 1.11 Synthesis of butenolide fragment 1.40. Reagents and conditions: a)  NaHMDS, 
THF, –78 °C → –45 °C, iodide 1.53; b) NaBH4, THF, H2O; c) TBSCl, imidazole, CH2Cl2; d) t-BuLi, 
THF, –78 °C; CO2; e) DEAD, Ph3P, THF, alcohol 1.56; f) Cl2(Cy3P)(IMes)Ru=CHPh (6 mol %), 
CH2Cl2, 40 °C; g) 3HF•Et3N, CH3CN; h) (COCl)2, DMSO, Et3N, CH2Cl2; i) CHI3, CrCl2, THF. 
Lithium-halogen exchange of bromide 1.55 followed by a quench with CO2 
gave an acrylic acid, which was used to invert secondary alcohol 1.56 using 
Mitsunobu conditions providing diene 1.57.
45 RCM reaction on diene 1.57 with 
second generation Grubbs catalyst delivered butenolide 1.58. Desilylation of 
butenolide  1.58, oxidation of the corresponding primary alcohol gave an 
aldehyde which when submitted to Takai olefination conditions returning the 
desired butenolide fragment 1.40.
39 Fragment 1.40 was synthesised in 11 steps 
from 4-methoxybenzyl alcohol.  
With the 3 desired fragments in hand, the stage was set for the total 
synthesis (scheme 1.12). An asymmetric acetylide addition using protocol 
described by Carreira successful coupled aldehyde 1.38 and alkyne 1.39 
delivering alcohol 1.59 as a single detectable stereoisomer.
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Scheme 1.12 Total synthesis of (+)-Gigantecin (1.1). Reagents and conditions: a) Zn(OTf)2, (–)-
N-methylephedrine, PhCH3, 1.39 then 1.38; b) MeOCH2Cl, DIPEA, CH2Cl2, DMAP; c) H2, Pd/C, 
EtOH; d) Tf2O, Et3N, CH2Cl2; e) Me3SiCCH, n-BuLi, THF, HMPA, –78 °C, then MeOH, 25 °C; f) 
iodide  1.40, Pd(PPh3)4, CuI, DIPEA, THF; g) H2, Rh(PPh3)3Cl, C6H6, EtOH, LiI; h) BF3•OEt2, 
Me2S, 0 °C. 
  The secondary hydroxyl was protected as the MOM ether, then exposure 
to Pd/C under a hydrogen atmosphere achieved global reduction and 
debenzylation which gave primary alcohol 1.60. Primary alcohol 1.60 was 
converted to a triflate which was alkylated delivering alkyne 1.61. To this point a 
total of 16 linear steps were required from benzyl glycidyl ether, proceeding in 
23.8% yield. Alkyne 1.61 was then successfully coupled with vinyl iodide 1.40 
under Sonogashira conditions to afford enyne 1.62.
40 Selective hydrogenation of 
enyne 1.62 followed by global deprotection provided (+)-gigantecin (1.1).
48 (+)-
Gigantecin (1.1) was synthesised in 19 linear steps from benzyl glycidyl ether in 
a total yield of 6.5%. 
 
Key aspects of Crimmins synthesis are:- 
- Non-adjacent  bis-THF core constructed by an asymmetric acetylide 
addition to aldehyde 1.38.
46,47 
-  Trans-THF ring stereochemistry was established using asymmetric 
glycolate aldol reaction.
43 
-  Construction of the butenolide, with C4 hydroxyl stereochemistry set 
up by diastereoselective alkylation of glycolate 1.52.
44  
   15
(+)-Gigantecin – Hoye (2006) 
Hoye’s approach to (+)-gigantecin (1.1) also exploited a convergent three 
fragment approach (scheme 1.13).
42 The key reaction is a one-pot double 
metathesis reaction, which was used to install the non-adjacent bis-THF core and 
couple the butenolide portion. 
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Scheme 1.13 Hoye’s retrosynthetic analysis of (+)-gigantecin (1.1). 
The synthesis of fragment 1.65 starts from lactone 1.67 (lactone 1.67 
available in 4 steps from tridecanal in a 73% yield) (scheme 1.14).
49 DIBAL-H 
reduction of lactone 1.67 gave a lactol which underwent olenfination to give α,β-
unsaturated ester 1.68. 
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Scheme 1.14 Synthesis of THF fragment 1.65. Reagents and conditions: a) DIBAL-H, PhMe, –78 
°C; b) Ph3PCHCO2Et, PhMe, 60 °C; c) DIBAL-H, PhMe, 0 °C; d) I2, K2CO3, THF, –78 °C; e) 
Me3S
+I
–, n-BuLi, THF, –45 °C → rt. 
Complete reduction of α,β-unsaturated ester 1.68 provided an allylic 
alcohol which was then submitted to iodoetherification, resulting in the iodohydrin 
1.69 (trans:cis selectivity 4:1 with respect to THF ring). Iodohydrin 1.69 was then 
converted to the inverted allylic alcohol 1.65 with dimethylsulfonium methylide   16
(Me2S=CH2).
50,51 Fragment 1.65 was synthesised in 9 steps from tridecanal in a 
total yield of 19.3%. 
The synthesis of fragment 1.66 began with aldehyde 1.70 (aldehyde 1.70 
available in 3 steps from γ-butyrolactone in a approximate 46% yield) (scheme 
1.15).
52 A Leighton asymmetric allylation on aldehyde 1.70 gave ester 1.72 as a 
single isomer.
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Scheme 1.15 Synthesis of THF fragment 1.66. Reagents and conditions: a) (S,S)-1.71, CH2Cl2, –
20 °C; b) DIBAL-H, PhMe, 0 °C → rt; c) I2, K2CO3, THF, –78 °C; d) Me3S
+I
–, n-BuLi, THF, –45 °C 
→ rt. 
  Reduction of ester 1.72 afforded an allylic alcohol which, underwent 
iodoetherification to give iodohydrin 1.73 as a single isomer. Iodohydrin 1.73 was 
then converted to the inverted allylic alcohol 1.66 with dimethylsulfonium 
methylide. Fragment 1.66  was synthesised in 7 steps from γ-butyrolactone in 
approximately 9.4% yield. 
 Butenolide  fragment  1.64 was synthesised through modification of a 
known route (scheme 1.16).
54 Epoxide 1.74 (available in 1 step from racemic 1,2-
epoxy-5-hexene) was opened with the lithiated alkyne 1.75 delivering alcohol 
1.76.
55  
O
Me
OTBS
HO
Me
TBSO
TIPSO
I
Me
HO
TIPSO
O O
a b, c, d e
(73%) (77%) (84%)
1.64 1.74 1.75 1.76 1.77
 
Scheme 1.16 Synthesis of butenolide fragment 1.64. Reagents and conditions: a) 1.75, n-BuLi, 
BF3•OEt2, THF, then 1.74, –78 °C → rt; b) TIPSOTf, 2,6-lutidine, CH2Cl2, rt; c) PPTS, EtOH; d) (i) 
Red-Al, THF, 0 °C, (ii) EtOAc, 0 °C, (iii) I2, –78 °C; e) CO (45 PSI), Pd(PPh3)2Cl2, K2CO3, 
H2NNH2, THF, 40 °C.   17
 From  alcohol  1.76  protecting group manipulations followed by selective 
reduction and iodine treatment provided silyl ether 1.77. A catalytic palladium-
catalysed carbonylation on silyl ether 1.77  afforded butenolide fragment 1.64. 
The butenolide fragment 1.64  was synthesised in 6 steps from racemic 1,2-
epoxy-5-hexene in a total yield of 21%, with the 3 desired fragments in hand, the 
synthesis then entered the end game (scheme 1.17).  
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Scheme 1.17 Total synthesis of (+)-gigantecin (1.1). Reagents and conditions: a) 1.65 (1 equiv.), 
Ph2SiCl2, pyridine, PhMe, 0 °C → rt, then 1.66 (1 equiv.), pyridine, PhMe, 0 °C → rt; b) 1.64 (4 
equiv.), Cl2(Cy3P)(IMes)Ru=CHPh (20 mol %), CH2Cl2, 45 °C, syringe pump addition (9 h); c) 
TsNHNH2, NaOAc, H2O, DME, ∆; d) 5% HF/MeCN, CH2Cl2, rt.  
 Allylic  alcohols  1.65 and 1.66 were successfully coupled with a 
diphenylsilyl tether which gave triene 1.63.  Double metathesis reaction 
successfully coupled triene 1.63 and butenolide fragment 1.64 to give lactone 
1.78. The key point from this reaction is that the CM between the type 1 alkene 
from triene 1.63 and butenolide fragment 1.64 takes place before the RCM 
reaction preventing by-product formation.
56 This is achieved by reacting triene 
1.63 (1 equiv.) with butenolide fragment 1.64 (4 equiv.) with gradual addition of 
second generation Grubbs catalyst. Selective reduction of lactone 1.78 with 
diimide followed by global deprotection gave (+)-gigantecin (1.1). (+)-Gigantecin 
(1.1) was synthesised in 13 linear steps from tridecanal in a total yield of 4.4%. 
 
Key aspects of Hoye’s synthesis are:- 
- (+)-Gigantecin  (1.1) is constructed by a one-pot double metathesis 
reaction. The non-adjacent bis-THF core is assembled by silicon 
tethered RCM, while the complete butenolide portion is coupled by 
CM.  
-  Trans selective iodoetherification reaction used to establish both trans-
THF rings.   18
-  Butenolide fragment with C4 hydroxyl synthesised through a 
modification of Hoye’s earlier route.
54 
(+)-Squamostatin-C (Bullatanocin) – Mootoo (2004) 
Mootoo’s group synthesis of (+)-squamostatin-C (1.79) ultilised a CM 
approach requiring 3 main fragments (scheme 1.18).
57,58 The key reaction for 
installing the THF moiety in fragments 1.80 and 1.81 was iodoetherification, 
methodology developed by Mootoo.
59-62 The coupling strategy was to join firstly 
the two THF fragments 1.80 and 1.81  by cross-metathesis, and secondly to 
couple the butenolide fragment 1.82 by Wittig reaction. 
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Scheme 1.18 Retrosynthetic analysis employed by Mootoo. 
   Fragment  1.80 synthesis began with (E)-ethyl hepta-4,6-dienoate (1.83) 
which is synthesised in one step from 1,4-pentadien-3-ol by Claisen-Johnson 
rearrangement in a 73% yield (scheme 1.19).
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Scheme 1.19 Synthesis of THF fragment 1.80. Reagents and conditions: a) AD-mix-β, t-BuOH-
H2O, MeSO2NH2; b) DIBAL-H, THF; c) (MeO)2CMe2, CSA, CH2Cl2; d) PCC, CH2Cl2; e) 
Ph3P=CHCO2Me; f) DIBAL-H, CH2Cl2; g) iodonium dicollidine perchlorate, MeCN; h) K2CO3, 
MeOH; i) TBSCl, imidazole, CH2Cl2; j) CH3(CH2)8MgBr, CuBr, THF; k) MOMCl, DIPEA, CH2Cl2; l) 
TBAF, THF. 
A poorly-regioselective asymmetric dihydroxylation on (E)-ethyl hepta-4,6-
dienoate (1.83), then DIBAL-H reduction followed by acetal protection gave   19
alcohol 1.84 (ee > 92% by Mosher ester NMR analysis). Oxidation of primary 
alcohol 1.84 yielded an aldehyde which underwent Wittig olefination to deliver an 
α,β-unsaturated ester which was reduced with DIBAL-H to afford alcohol 1.85. 
The alcohol 1.85  was set up for the key iodoetherfication reaction. Using 
iodonium dicollidine perchlorate (IDCP) in acetonitrile, gave THF iodohydrin 1.86 
(single  trans isomer). Iodohydrin 1.86 was closed to the epoxide under basic 
conditions and the free hydroxyl was silylated to give epoxide 1.87. Cuprate 
addition to epoxide 1.87 installed the alkyl chain, followed by protection of the 
free hydroxyl as its MOM ether and desilylation gave fragment 1.80. Fragment 
1.80  was synthesised in 13 steps from 1,4-pentadien-3-ol  in a 12.4% overall 
yield. 
Fragment 1.81 synthesis began with (E)-ethyl hepta-4,6-dienoate (1.83) 
(scheme 1.20). 
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Scheme 1.20 Synthesis of THF fragment 1.81. Reagents and conditions: a) AD-mix-α, t-BuOH-
H2O, MeSONH2; b) DIBAL-H, THF; c) (MeO)2CMe2, CSA, CH2Cl2; d) Swern oxidation; e) 
Ph3P=CH(CH2)3OLi, MePh; f) PivCl, pyridine, DMAP; g) iodonium dicollidine perchlorate, MeCN; 
h) Bu3SnH, MePh, AIBN, ∆; i) Ac2O, EtOAc, DMAP. 
Primary alcohol ent-1.84 was synthesised analogously to primary alcohol 
1.84, by switching to AD-mix-α for the dihydroxylation. Swern oxidation of alcohol 
ent-1.84 followed by Wittig olefination of the corresponding aldehyde gave alkene 
1.88  with low selectivity (Z:E  3:1). Submitting alkene 1.88  to their optimum 
iodoetherification conditions returned THF alcohol 1.89 as mixture of 
diastereoisomers (dr  trans:cis  11:1 
1H NMR from deiodonated derivative of 
alcohol 1.89). A radical deiodonation of alcohol 1.89 followed by conversion of 
the free hydroxyl to acetate provided fragment 1.81. Fragment 1.81  was 
synthesised in 10 steps from 1,4-pentadien-3-ol in a 10.2% yield.  
Synthesis of butenolide fragment 1.82 began with diene 1.90 which is 
synthesised in 1 step from 6-iodo-1-hexene  in 86% yield (scheme 1.21). A   20
dihydroxylation of diene 1.90  followed by successive recrystallisation afforded 
tetraol 1.91 (S:R 20:1 by Mosher ester anaylsis).
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Scheme 1.21 Synthesis of butenolide portion 1.82. Reagents and conditions: a) AD-mix-α; b) 
TsCl, pyridine; c) K2CO3, MeOH; d) allylMgBr, CuI; d) TBSCl, imidazole, CH2Cl2; e) CAN, CH3CN-
H2O ;  f )  P C C ,  C H 2Cl2; g) NaClO2, H2O2; h) MeOH, DCC, DMAP; i) LDA, THF, then (S)-2-
(tetrahydropyran-2-yloxy)propanal; j) p-TsOH, MeOH; k) MsCl, Et3N, CH2Cl2; l) AD-mix-β,  t-
BuOH-H2O; m) NaIO4, H2O, CH2Cl2/acetone. 
Conversion of tetraol 1.91 to bis-epoxide, then cuprate addition followed 
by silylation furnished silyl ether 1.92. Removal of the phenol gave alcohol 1.93 
which was oxidised in 2 steps to the carboxylic acid and converted to ester 1.94. 
Using protocol described by Sinha and Keinan ester 1.94 was converted to 
butenolide fragment 1.82.
65 Butenolide fragment 1.82  was synthesised in 14 
steps from 6-iodo-1-hexene in a 2.9% yield. 
To complete the synthesis, the key step was the CM reaction between 
alkenes 1.80 and 1.81 using Grubbs second generation catalyst (scheme 1.22).
56 
The CM process relied on using an excess of allylic alcohol ester 1.81 with allylic 
alcohol  1.80. The best results were obtained using 4:1 and 3:1 ratios of 
fragments 1.81 and 1.80 which gave 98% and 75% yields respectively, (based 
on fragment 1.80).   21
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Scheme 1.22 Total synthesis of (+)-squamostatin-C (1.79). Reagents and conditions: a) Method 
A:  1.80  (1 eq.), 1.81 (4 eq.), Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %), CH2Cl2,  ∆, 18h, then 
Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %), rt, 4h; Method B: 1.80 (1 eq.), 1.81 (3 eq.), 
Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %), CH2Cl2, rt, 18h, then Cl2(Cy3P)(IMes)Ru=CHPh (10 mol 
%), rt, 18h; b) H2, Pd/C, EtOAc; c) K2CO3, MeOH; d) MOMCl, DIPEA, CH2Cl2; e) NaOMe, MeOH; 
f) Ph3P, I2, imidazole, benzene; g) Ph3P, DIPEA, MeCN; h) 1.98, n-BuLi, THF, then 1.82; i) H2, 
Rh(PPh3)3Cl; j) AcCl, MeOH-CH2Cl2. 
    Hydrogenation of CM product 1.96, selective hydrolysis of the acetate 
followed by global MOM protection, and then hydrolysis of the pivalate provided 
alcohol 1.97. Wittig salt 1.98 was synthesised from alcohol 1.97 via the iodide. 
Wittig reaction with the butenolide fragment 1.82 afforded alkene 1.99. Selective 
hydrogenation and deprotection gave (+)-squamostatin-C (1.79) in 23 steps from 
(E)-ethyl hepta-4,6-dienoate (1.83) in a total yield 2.2%.   
Key aspects of Mootoo’s synthesis are:- 
- The  non-adjacent  bis-THF core was assembled by CM, while the 
butenolide portion was coupled by Wittig olenfination.  
- Highly  trans selective iodoetherification reaction used to establish both 
trans-THF rings.
59-62  
- Butenolide  fragment  with  C4 hydroxyl synthesised through a modified 
route described by Sinha and Keinan.
64,65 
 
 
 
 
   22
(+)-cis-Sylvaticin – Donohoe (2006) 
The first total synthesis of cis-sylvaticin (1.100) was reported by Donohoe 
and the approach is based on a convergent coupling strategy with 2 main 
fragments (scheme 1.23).
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Scheme 1.23 Retrosynthetic analysis employed by Donohoe. 
The key reaction in synthesising the non-adjacent bis-THF core (fragment 
1.101) was an osmium tetraoxide catalysed oxidative cyclisation reaction.
67 The 
synthesis of bis-THF fragment 1.101 began with commercially available 
tetradecatetraene  1.103 which is a mixture of isomers (EE,  EZ,  ZZ). 
Dihydroxylation of the tetraene followed by in-situ protection selectively gave 
diene 1.104 (ee > 98% through Mosher ester analysis, dr > 95:5), in modest yield 
(scheme 1.24).
68  
O
O O
O
HO
OH
O
O
O
O
O
O O
O C10H21
O
C10H21
O
H H
HO HO
H H
OH
OH
a, b c
d, e f
(18%) (59%)
(81%) (77%)
1.103 1.104 1.105
1.106 1.107
O
C10H21
O H H
OTBS TBSO
H H
OTBS
OH
1.108
O
C10H21
O H H
OTBS TBSO
H H
OTBS
1.101
g, h
(59%)
i, j
(79%)
 
Scheme 1.24 Synthesis of bis-THF fragment 1.101. Reagents and conditions: a) AD-mix-α; b) 
CH2=CH(OMe)CH3, CSA; c) AD-mix-β; d) NaIO4; e) C10H21CH=PPh3; f) OsO4 (5 mol %), acetone, 
H2O, Me3NO (5 eq.), TFA, cinnamic acid; g) TBSOTf, 2,6-lutidine; h) TBAF (1 eq.); i) TPAP, 
NMO; j) Ph3P=CH2, THF. 
  mono–Dihydroxylation of diene 1.104 gave a diol 1.105 which was then 
submitted to periodate cleavage conditions, affording an aldehyde which   23
underwent olefination delivering diene 1.106. With diene 1.106 in hand Donohoe 
was then set-up for the key oxidative cyclisation reaction. Under their optimum 
conditions diene 1.106 was converted to bis-THF  1.107 as a single 
diastereoisomer in high yield.
67 Global silylation of tetraol 1.107 followed by 
selective deprotection provided primary alcohol 1.108. Oxidation of primary 
alcohol 1.108 to an aldehyde followed by Wittig olenfination gave fragment 1.101. 
Fragment 1.101 was synthesised in 10 steps from tetradecatetraene 1.4 (EE, EZ, 
ZZ) in a total yield of 3.1%.  
The synthesis of the butenolide fragment 1.102 began with (R)-
epichlorohydrin (1.109) following work described by Lee (scheme 1.3).
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Scheme 1.25 Synthesis of butenolide fragment 1.102. Reagents and conditions: a) 
H2C=CH(CH2)4MgBr, CuCN; b) NaI; c) TBSOTf; d) 1.36, LDA, HMPA, then 1.110; e) m-CPBA, 
then ∆; f) AcCl, MeOH. 
  Cuprate addition to (R)-epichlorohydrin (1.109), followed by conversion of 
the chloride to the iodide then silylation of the secondary alcohol returned iodide 
1.110. The lithium enolate of lactone 1.36 was alkylated with iodide 1.110 to give 
sulfide  1.111.
38 Sulfide 1.111 was oxidised to the sulfoxide, and subsequent 
thermal elimination followed by desilylation afforded the butenolide fragment 
1.102. The butenolide fragment 1.102  was synthesised in 6 steps from (R)-
epichlorohydrin (1.109) in a total yield of 19.7%.  
Fragments 1.101 and 1.102 were successfully coupled by CM to give silyl 
ether  1.112  (scheme 1.4).
56 Successful CM was achieved following Lee’s 
protocol, by reacting  fragment 1.101 (1 eq.) with an excess of fragment 1.102 (4 
eq.) in the presence of second generation Grubbs catalyst.
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Scheme 1.26 Total synthesis of (+)-cis-sylvaticin (1.100). Reagents and conditions: a) 1.101 (1 
eq.), 1.102 (4 eq.), Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %); b) TsNHNH2, NaOAc; c) AcCl, MeOH.   24
 Selective  hydrogenation of silyl ether 1.112 followed by deprotection gave 
(+)-cis-sylvaticin (1.100). (+)-cis-Sylvaticin (1.100) was synthesised in 13 steps 
from tetradecatetraene 1.103 (EE, EZ, ZZ) in a total yield of 1.7%. 
Key aspects of Donohoe’s synthesis are:- 
-  Convergent 2 fragment approach, with fragment assembly carried out 
by CM.
56 
- The  non-adjacent  bis-THF core is constructed on tetraene alkyl 
skeleton.   
-  cis-THF rings assembled by osmium tetraoxide oxidative cyclisation.
67 
-  Butenolide fragment with C4 hydroxyl synthesised through route 
described by Lee.
69 
1.5 Synthesis of Non Adjacent THP/THF Annonaceous 
Acetogenins 
In the following section the total synthesises of (–)-mucocin (1.113) will be 
discussed. (–)-Mucocin (1.113) belongs to the non adjacent THP/THF sub-class 
of Annonaceous acetogenins, which is structurally related to the non adjacent 
bis-THF sub-class. As a result, strategies used in the synthesis of (–)-mucocin 
(1.113) could be applied to non adjacent bis-THF Annonaceous acetogenins. 
(–)-Mucocin 
(–)-Mucocin – Sinha and Keinan (1998) 
The first total synthesis by Sinha and Keinan group couples 2 main 
fragments 1.114 and 1.115 (scheme 1.27). 
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Scheme 1.27 Sinha and Keinan’s retrosynthetic analysis of (–)-mucocin (1.113).   25
  The synthesis of fragment 1.114 began with (E,E,E)-cyclododecatriene 
(1.116) using a “naked alkyl skeleton approach” (where the non adjacent 
THF/THP core is built on a tetraene alkyl skeleton) (scheme 1.28).
70-72 Selective 
dihydroxylation followed by periodate cleavage furnished dialdehyde 1.117. 
Double Horner-Wadsworth-Emmons olefination gave diester 1.118 which was 
reduced to diol 1.119. Sharpless asymmetric epoxidation of diol 1.119 delivered 
bis epoxide 1.120 in 98% ee. Desymmetrisation of the bis epoxide 1.120 was 
achieved by a mono silylation which afforded alcohol 1.121, oxidation of alcohol 
1.121 and subsequent Wittig reaction gave alkene 1.122  (Z  only). Selective 
double dihydroxylation of the central E alkene bonds gave tetraol 1.123 (dr not 
given).
73 With tetraol 1.123 in hand the stage was set for the key acid catalysed 
regioselective double cyclisation.
74,75 Under optimum condition the non-adjacent 
THP-THF core was constructed in one step from bis-epoxide  1.123 which 
provided ether 1.124.     
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Scheme 1.28 Synthesis of alkyne 1.114. Reagents and conditions: a) (i) OsO4, acetone/H2O; (ii) 
NaIO4, CH2Cl2/acetone; b) (EtO)2P(O)CH2CO2Et, NaH, THF; c) DIBAL-H, THF; d) Ti(Oi-Pr)4, (–)-
DET, TBHP, CH2Cl2; e) TBSCl, imidazole, DMF; f) SO3-pyridine, DMSO, Et3N, CH2Cl2; g) 
C9H19PPh3Br, KHMDS, HMPA/THF; h) AD-mix-α, MeSO2NH2, H2O/t-BuOH; i) p-TsOH, CH2Cl2; j) 
TsOH, CH2Cl2/MeOH; k) p-TsOH, 2,2-dimethoxypropane, CH2Cl2; l) p-TsOH, MeOH/H2O; m) 
MEM-Cl, DIPEA, CH2Cl2; n) AcOH/H2O; o) NaIO4, CH2Cl2/acetone; p) CBr4, PPh3, CH2Cl2; q) n-
BuLi, THF; 
  A 5 step protecting group manipulation of tetraol 1.124 furnished diol 
1.125 which was subject to an oxidative cleavage yielding aldehyde 1.126. Using   26
Corey-Fuchs protocol aldehyde 1.126  was converted to fragment 1.114.
76 
Fragment  1.114 was synthesised in 18 steps from (E,E,E)-cyclododecatriene 
(1.116) in a total yield of 1.3%. 
The synthesis of the butenolide fragment 1.115 began with alkene 1.127 
(scheme 1.29). Alkene 1.127 had previously been synthesised by Sinha and 
Keinan from (S)-dihydro-5-(hydroxymethyl)furan-2(3H)-one in 9 steps in an 
approximate yield of 12%.
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Scheme 1.29 Synthesis of vinyl iodide 1.115. Reagents and conditions: a) 9-BBN, THF; b) PCC, 
CH2Cl2; c) CHI3, CrCl2, THF. 
  A selective hydroboration of diene 1.127 followed by oxidation of alcohol 
1.128 provided aldehyde 1.129. Under Takai olefination conditions aldehyde 
1.129 was converted to fragment 1.115.
39  
 Fragments  1.114 and 1.115 were successfully coupled using Sonogashira 
chemistry to give enyne 1.130  (scheme 1.30).
40 Selective hydrogenation and 
global deprotection gave (–)-mucocin (1.113). (–)-Mucocin (1.113) was 
synthesised in 21 steps from (E,E,E)-cyclododecatriene (1.116) in a total yield of 
0.4%. 
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Scheme 1.30 Total synthesis of (–)-mucocin (1.113). Reagents and conditions: a) Pd(PPh3)2Cl2, 
CuI, Et3N, THF; b) H2, Rh(PPh3)3Cl, benzene, EtOH; c) AcCl, MeOH/CH2Cl2.  
Key aspects of Sinha’s synthesis are:- 
-  Sonogashira coupling of 2 major fragments.
40 
-  The non-adjacent THP-THF core constructed on a naked alkyl 
skeleton.
70-72 
- Established  non-adjacent  cis-THP-trans-THF core  by intramolecular 
nucleophilic substitution, with key stereochemistry set-up by Sharpless 
asymmetric epoxidation and asymmetric dihydroxylation.
74,75    27
(–)-Mucocin – Koert (1999) 
Koert group’s synthesis of muconin (1.113) couples 2 main fragments 
1.131  and  1.132  via enantioselective organometallic chemistry (scheme 
1.31).
77,78 
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Scheme 1.31 Koert’s retrosynthetic analysis of (–)-mucocin (1.113). 
  The synthesis of the THP fragment 1.131 began with (E)-dihydromuconic 
acid (1.133) (scheme 1.32), which was converted to its dimethyl ester, the diester 
was reduced to the diol where upon selective mono silylation was achieved, and 
the free hydroxyl was converted to a bromide to give alkene 1.134.  
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Scheme 1.32 Synthesis of fragment 1.131.  Reagents and conditions: a) TMSCl, MeOH; b) 
LiAlH4, THF; c) NaH, TBSCl, THF; d) p-TsCl, pyridine, CH2Cl2; e) LiBr, acetone; f) AD-mix-α, 
MeSO2NH2, H2O/t-BuOH; g) p-TsOH (5 mol%), 2,2-dimethoxypropane, CH2Cl2; h) propargyl 
alcohol, n-BuLi, NH3/THF/DMPU; i) Red-Al, THF; j) TBHP, (–)-DIPT, Ti(Oi-Pr)4, CH2Cl2; k) Dess-
Martin periodinane, pyridine, CH2Cl2; l) H19C9PPh3Br, NaHMDS, THF; m) CSA, CH2Cl2/i-PrOH; n) 
H2, 5% Pt/C, EtOAc; o) TBSOTf, 2,6-lutidine, CH2Cl2; p) CSA, CH2Cl2/MeOH; q) I2, PPh3, 
imidazole, CH2Cl2.   28
An asymmetric dihydroxylation of alkene 1.134  was followed by acetonide 
protection of the crude diol returning bromide 1.135  (ee 86%). Alkylation of 
lithiated propargylic alcohol with bromide 1.135 gave propargylic alcohol 1.136. 
Propargylic alcohol 1.136 was reduced to allylic alcohol 1.137  which was 
submitted to Sharpless asymmetric epoxidation to afford alcohol 1.138 (ee for 
epoxidation > 98%). Dess-Martin oxidation of 1.138 followed by Wittig olefination 
successfully installed the alkyl chain to give alkene 1.140 (E:Z 1:1). Alkene 1.140 
set the stage for the key THP forming reaction.
75 An acid deprotection then 
cyclisation favoured 6-endo cyclisation over 5-exo due to the stabilising effects of 
the alkene bond in the transition state providing THP diol 1.141. Alkene 1.141 
was reduced, global silylation then selective desilylation gave primary alcohol 
which was converted to the iodide, delivering fragment 1.131 in 17 steps from 
(E)-dihydromuconic acid (1.133) in 10.8% yield.  
The synthesis of the fragment 1.132 began with TIPS protected (R)-
glycidol 1.142 (scheme 1.33). Cuprate addition to glycidol 1.142 gave alcohol 
1.143. TIPS protection of alcohol 1.143 then ozonolysis of the terminal alkene 
furnished aldehyde 1.144. 
TIPSO
O
TIPSO
OH
H
TIPSO
TIPSO O
TIPSO
TIPSO HO
OPiv
4
HO
O OPiv
4
a b, c d
e, f g, h i
(91%) (94%) (70%)
(88%) (80%) (84%)
1.142 1.143 1.144 1.146 (dr 95:5)
1.147 1.148 1.149
OPiv
2
Zn NHTf
NHTf
PPh3
I
TESO
O 4
1.150 1.13 1.145
j
(*%)
* Wittig salt used crude in next step
H H
TESO
O OH
4 H H
TESO
O I
4 H H
H H
 
Scheme 1.33 Synthesis of Wittig salt 1.150. Reagents and conditions: a) H2C=CHCH2MgBr, CuI, 
THF b) TIPSOTf, 2,6-lutidine, CH2Cl2; c) O3, CH2Cl2, PPh3; d) 1.145, 1.13, Ti(Oi-Pr)4, xylenes, 
then 1.144; e) p-TsCl, pyridine, CH2Cl2; f) TBAF, THF; g) TESCl, imidazole, CH2Cl2; h) DIBAL-H, 
THF; i) I2, PPh3, imidazole, CH2Cl2; j) PPh3, CH3CN/toluene. 
  Following Knochel’s protocol, an asymmetric addition of diorganozinc 
reagent 1.145 to aldehyde 1.144 returned alcohol 1.146 (dr 95:5).
79 Tosylation of 
alcohol 1.146 followed by TBAF desilylation induced cyclisation which afforded 
THF alcohol 1.147 ( trans:cis  95:5 due to diastereoselectivity from the   
diorganozinc addition). Protecting adjustment  gave alcohol 1.148, which was   29
subjected to iodination conditions to yield iodide 1.149. Iodide 1.19 was then 
transformed to the Wittig salt 1.150 which was used crude in the next step.  
Synthesis of aldehyde 1.158 began with β-ketoester 1.151 (scheme 1.34). 
A selective alkylation of the β-ketoester  1.151  dianion followed by an 
enantioselective Noyori reduction of the ketone gave secondary alcohol 1.152 
(ee = 96% by chiral HPLC).
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Scheme 1.34 Synthesis of butenolide aldehyde 1.158. Reagents and conditions: a) NaH, n-BuLi, 
THF, then Br(CH2)2OBn; b) H2, Ru(II)-(S)-(–)-BINAP; c) BH3•SMe2, THF; d) TBSCl, imidazole, 
DMAP, CH2Cl2; e) H2, 10% Pd/C, EtOAc; f) Swern oxidation; g) NaOCl2, NaH2PO4•2H2O, methyl-
2-butene, H2O/t-BuOH; h) (i) LDA, THF, then (S)-(–)-propene oxide; (ii) PivCl, Et3N, CH2Cl2; i) 
KHMDS, THF, PhSeCl; j) magnesium monoperoxyphthalate, THF/MeOH; k) CSA, CH2Cl2/MeOH; 
l) Dess-Martin periodinane, pyridine, CH2Cl2. 
 Reduction  of  ester  1.152 followed by global silylation then debenzylation 
gave alcohol 1.153. A two step Swern/chlorite oxidation of alcohol 1.153 
delivered carboxylic acid 1.154.
81 The dianion of acid 1.154 was reacted with (S)-
(–)-propene oxide to give a carboxylic acid, which was cyclised via a mixed 
anhydride species to give lactone 1.155. The potassium enolate of lactone 1.155 
was reacted with phenyl selenium chloride which provided selenoether 1.156. 
Oxidisation to the selenoxide using magnesium monoperoxyphthalate  led to 
rapid elimination and formation of the α,β-unsaturated lactone 1.157. Selective 
primary desilylation and subsequent oxidation of the alcohol gave aldehyde 
1.158.  
With Wittig salt 1.150 and aldehyde 1.158 in hand, successful coupling 
using NaHMDS afforded alkene 1.159 as a mixture E/Z isomers (scheme 1.35).   30
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Scheme 1.35 Synthesis of fragment 1.132. Reagents and conditions: a) 1.150, NaHMDS, THF, 
then 1.158; b) H2, Rh(PPh3)3Cl, benzene; c) CSA, CH2Cl2/MeOH; d) Dess-Martin periodinane, 
pyridine, CH2Cl2. 
 Alkene  1.159  was selectively hydrogenated, and following desilylation 
delivered alcohol 1.160, which was oxidised to the fragment 1.132 with Dess-
Martin periodinane. Fragment 1.132 was synthesised in 17 steps from β-
ketoester 1.151 in a total yield of 8.0%.  
Koert employed a chelation-controlled Grignard addition to couple 
fragments 1.131 and 1.132 (scheme 1.36).  
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Scheme 1.36 Total synthesis of (–)-mucocin (1.113). Reagents and conditions: a) 1.131, t-BuLi, 
Et2O, then MgBr2•OEt2, then 1.132; b) HF, CH2Cl2/MeCN. 
  The key for this was careful synthesis of a Grignard from iodide 1.131, this 
was achieved by firstly iodide-lithium exchange with t-BuLi, followed by 
transmetallation with magnesium bromide which gave a Grignard reagent, 
addition of the Grignard to aldehyde 1.132 gave desired alcohol 1.161 
(major:minor 4:1 by HPLC, separable by chromatography). Global desilylation of 
alcohol 1.161 gave (–)-mucocin (1.113) in 19 steps from β-ketoester 1.151 in a 
total yield of 3.3%. 
Key aspects of Koert’s synthesis are:- 
-  Use of chelation controlled Grignard addition to couple 2 major 
fragments. 
-  Trans-THF ring established by nucleophilic substitution cyclisation, 
with key stereochemistry set-up by Sharpless asymmetric epoxidation 
and a Knochel asymmetric diorganozinc addition to aldehyde 1.114.
79    31
-  Cis-THP ring established by selective 6-endo nucleophilic substitution 
cyclisation, with key stereochemistry set-up by asymmetric 
dihydroxylation and Sharpless asymmetric epoxidation.
75  
-  C4 hydroxyl installed by enantioselective Noyori reduction.
80 
(–)-Mucocin – Nakata and Takahashi (2002) 
Nakata’s approach couples 2 main fragments 1.162 and 1.163, requiring a 
linear synthesis of the non-adjacent THP-THF core (scheme 1.37).
82 A key 
reaction in their approach was a SmI2 induced cyclisation developed by Nakata 
to install the cis-THP moiety.
83-87 
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Scheme 1.37 Nakata’s retrosynthetic analysis of (–)-mucocin (1.113). 
  The synthesis of alkyne 1.162 began with dialdehyde 1.164 (available in 
one step from (E,E,E)-cyclododecatriene in 65% yield) (scheme 1.38).
88 Acetal 
protection of dialdehyde 1.164 followed by double asymmetric dihydroxylation 
gave tetraol 1.165 ( ee = 97%, by 
1H NMR analysis of the Mosher ester 
derivative). Selective partial intramolecular acetal formation gave a bis-THF diol, 
where mono benzylation was used to effect desymmetrisation. Conversion of bis-
acetal  1.166 to a bis-dithiane gave a 1,2-diol which was protected as its 
acetonide 1.167.    32
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Scheme 1.38 Synthesis of alkyne 1.162. Reagents and conditions: a) HC(OMe)3, CSA, MeOH; b) 
AD-mix-α, MeSO2NH2, H2O/t-BuOH; c) CSA, MeOH; d) BnBr, NaH, THF; e) 1,3-propanedithiol, 
Zn(OTf)2, DCE; f) Me2C(OMe)2, CSA, CH2Cl2; g) ethyl propiolate, N-methylmorpholine, CH2Cl2; h) 
CH3I, NaHCO3, MeCN/H2O; i) SmI2, MeOH, THF; j) HC(OMe)3, CSA, MeOH; l) MOMBr, DIPEA, 
DCE; m) DIBAL-H, CH2Cl2, then C8H17PPh3Br,  n-BuLi, THF; n) 10% Pd/C, H2, MeOH; o) 
MOMBr, DIPEA, DCE; p) AcOH/H2O; q) CH3PPh3I, NaHMDS, THF; r) [Co(modp)2], O2, t-BuO2H, 
i-PrOH; s) Tf2O, 2,6-lutidine, CH2Cl2; t) TMSC≡CLi, HMPA, THF, then K2CO3, MeOH. 
Alcohol 1.167 was reacted with ethyl propiolate in a 1,4-addition to afford 
a  trans  α,β-unsaturated ester. Hydrolysis of the bis-dithiane gave key 
intermediate 1.168. With intermediate 1.168 in hand, the molecule was set-up for 
the SmI2 induced cyclisation. Under their optimum conditions intermediate 1.168 
gave  cis-THP alcohol 1.169  as the sole diastereoisomer. A selective partial 
intramolecular acetal formation gave a THP-THF alcohol, which was MOM-
protected to furnish ester 1.170. A three step protocol installed the alkyl chain, 
and subsequent acetal hydrolysis yielded lactol 1.171. Wittig olefination of lactol 
1.171 gave alkene 1.172 which set the scene for a cobalt oxidative cyclisation to 
install the trans-THF ring in alcohol 1.173.
89 Conversion of alcohol 1.173 to a 
triflate then displacement with lithiated TMS acetylene followed by in situ 
desilylation gave fragment 1.162. Fragment 1.162 was synthesised in 20 steps 
from (E,E,E)-cyclododecatriene (1.116) in a total yield of 9.9%.  
The synthesis of the butenolide fragment began with aldehyde 1.174 
(available in 2 steps from 1,4-butanediol in 86% yield) (scheme 1.39).
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Scheme 1.39 Synthesis of vinyl iodide 1.163. Reagents and conditions: a) (S)-BINOL, Ti(Oi-Pr)4, 
allyltributyltin,; b) TBSCl, imidazole, DMF; c) BH3•THF, THF then NaOH, 30% H2O2; d) Jones 
reagent, acetone then CH2N2, Et2O; e) LDA, THF, then 1.177; f) CSA, MeOH/H2O; g) MsCl, Et3N, 
CH2Cl2; h) DBU, CH2Cl2; i) DDQ, CH2Cl2/phosphate buffer (pH 7.4); j) (COCl)2, DMSO, CH2Cl2, 
then Et3N; k) CrCl2, CHI3, THF. 
  An asymmetric allylation of aldehyde 1.174 gave alcohol 1.175 (ee > 
98%).
91 Silylation followed by a three step hydroboration-oxidation-methylation 
procedure furnished ester 1.176. The butenolide portion was installed using an 
adaptation of the chemistry described by Wu.
34 Hydroxyl deprotection, oxidation 
and Takai olefination delivered butenolide fragment 1.163.
39 Butenolide fragment 
1.163 was synthesised in 13 steps from 1,4-butanediol in a total yield of 21.1%.  
 Fragments  1.162 and 1.163 were coupled using Sonogashira chemistry to 
give enyne 1.179, which was selectively hydrogenated and deprotected to afford 
(–)-mucocin (1.113) (scheme 1.40).
40 
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Scheme 1.40 Total synthesis of (–)-mucocin (1.113). Reagents and conditions: a) [PdCl2(Ph3P)2], 
CuI, Et3N; b) (Ph3P)3RhCl, H2, benzene/EtOH; c) 10% HCl/MeOH, CH2Cl2. 
 (–)-Mucocin  (1.113) was synthesised in 23 steps from (E,E,E)-
cyclododecatriene in a total yield of 6.8%. 
Key aspects of Nakata’s synthesis are:- 
-  Fragment coupling using Sonogashira chemistry.
40 
-  Cis-THP ring established by SmI2 induced cyclisation.
83-87 
-  Trans-THF ring established by cobalt oxidative cyclisation.
89 
-  C4 hydroxyl install by asymmetric allylation of aldehyde 1.174.
91   34
(–)-Mucocin – Takahashi (2002) 
Takahashi’s approach is based on a convergent coupling strategy with 3 
main fragments, using the chiral pool as the source of the fragments (scheme 
1.41).
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Scheme 1.41 Takahashi’s retrosynthetic analysis of (–)-mucocin (1.1). 
  Synthesis of THP fragment 1.180 began with commercially available 
benzyl ether 1.183 (scheme 1.42). Swern oxidation followed by Grignard addition 
installed the alkyl chain, then a Lewis acid catalysed stereoselective reduction 
furnished cis-THP ether 1.185.
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Scheme 1.42 Synthesis of THP fragment 1.180. Reagents and conditions: a) Swern oxidation; b) 
decylmagnesium bromide, Et2O; c) Et3SiH, BF3•Et2O, CH2Cl2; d) 10% Pd/C, H2, EtOAc-MeOH; e) 
TBDPSCl, imidazole, DMF; f) (i) HC(OMe)3, CSA, CH2Cl2; (ii) Ac2O, ∆; g) 10% Pd/C, H2, EtOAc; 
h) NaOMe, MeOH; i) MOMCl, DIPEA, CH2Cl2; j) TBAF, THF; k) Swern oxidation. 
Global debenzylation of ether 1.185 followed by a primary alcohol selective 
silylation gave silyl ether 1.186. Triol 1.186 was selectively deoxygenated under 
Ando’s conditions delivering acetate 1.187.
93 Hydrogenation of alkene 1.187 
followed by protecting group manipulations gave a primary alcohol, which under 
Swern conditions furnished desired THP fragment 1.180. THP fragment 1.180 
was synthesised in 12 steps from benzyl ether 1.183 in 41.3% yield.    35
The synthesis of the THF fragment 1.181 began with commercially 
available 2,5-anhydro-D-mannitol (1.188) (scheme 1.43). 
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Scheme 1.43 Synthesis of THF fragment 1.181. Reagents and conditions: a) TrCl, pyridine, then 
TBSCl, imidazole; b) Et2AlCl, hexane; c) Swern oxidation; d) HC≡CMgCl, ZnCl2, 
CH2Cl2/Et2O/THF; e) MOMCl, DIPEA, CH2Cl2.  
A one-pot procedure furnished protected 2,5-anhydro-d-mannitol  1.189, then 
selective detritylation successfully effected desymmetrisation.
94 Swern oxidation 
of the resulting alcohol 1.190 followed by a stereoselective Grignard addition, 
then protection of the resulting alcohol as its MOM ether gave THF fragment 
1.181. The observed selectivity for the Grignard addition (93:7) may be explained 
by Felkin-Anh model but with possible competing chelation control. THF fragment 
1.181 was synthesised in 5 steps from 2,5-anhydro-d-mannitol (1.188) in 44.6% 
yield.  
The synthesis of the butenolide fragment 1.182 began with phenyl 5-O-
acetyl-2,3-O-isopropylidene-1-thio-l-rhamnofuranoside (1.192) (synthesised in 3 
steps from l-rhamnose) (scheme 1.44).
95 Hydrolysis of acetate 1.192, then PMB 
protection of the free hydroxyl followed by in situ treatment with NBS gave lactol 
1.193. Stereoselective addition of a lithiated alkyne to lactol 1.193 returned 
alcohol 1.194 (selectivity 6:1).    36
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Scheme 1.44 Synthesis of butenolide fragment 1.182. Reagents and conditions: a) NaOMe, 
MeOH; b) (i) PMBCl, NaH, TBAI, DMF; (ii) NBS, THF; c) TBDPSOCH2CH2C≡CH,  n-BuLi, 
hexane/Et2O (3:1); d) MOMCl, DIPEA, CH2Cl2; e) 5% Rh/Al2O3, H2, EtOAc; f) aq AcOH; g) (i) 
HC(OMe)3, CSA, CH2Cl2; (ii) Ac2O; h) DDQ, CH2Cl2; i) triphosgene, pyridine, CH2Cl2, then 
PhSeH, Et3N; j) Bu3SnH, AIBN, toluene; k) TBAF, AcOH, THF, then DBU, CH3CN; l) Swern 
oxidation; m) CHI3, CrCl2, THF. 
Protection of the free hydroxyls as their MOM ethers, reduction of the alkyne, 
then acetal hydrolysis followed by an Ando deoxygenation gave Z-alkene 
1.195.
93 A two step conversion of Z-alkene  1.195 furnished selenocarbonate 
1.196.
96 With selenocarbonate 1.196 in hand an acyl radical cyclisation 
selectively provided lactone 1.197. Desilylation followed by treatment with DBU in 
acetonitrile afforded butenolide 1.198. Swern oxidation followed by Takai 
olefination yielded the butenolide fragment 1.182. Butenolide fragment 1.182 was 
synthesised in 18 steps from l-rhamnose.  
The coupling of THF and THP fragments were achieved by reacting 
lithiated alkyne 1.180 with aldehyde 1.181, giving a mixture of epimers in favour 
of the undesired enantiomer (scheme 1.45). Alkyne reduction, then alcohol 
oxidation followed by stereoselective hydride reduction delivered alcohol 1.200 
with the correct stereochemistry (dr 24:1).   37
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Scheme 1.45 Total synthesis of (–)-mucocin (1.113). Reagents and conditions: a) n-BuLi, CeCl3, 
THF; b) 5% PtO2, H2, EtOAc; c) TPAP, NMO, CH2Cl2; d) L-selectride, THF; e) MOMCl, DIPEA, 
CH2Cl2; f) TBAF, THF; g) MsCl, Et3N, CH2Cl2; h) Zn, NaI, DMF; i) 10% Pd/C, H2, EtOAc; j) aq 
AcOH; k) Swern oxidation; l) Ph3P, CBr4, Et3N, CH2Cl2, m) EtMgBr, THF; n) 1.182, (Ph3P)2PdCl2, 
CuI, Et3N; o) (Ph3P)3RhCl, H2, benzene/EtOH (6:1); p) BF3•Et2O, Me2S. 
Protecting group manipulations gave mesylate 1.201, which underwent reductive 
elimination to afford alkene 1.202.
97 Hydrogenation of alkene 1.202 followed by 
detritylation gave a primary alcohol that was oxidised to aldehyde 1.203. Under 
Corey-Fuchs conditions, aldehyde 1.203 was converted to alkyne 1.204 which 
was used in a Sonogashira coupling with iodide 1.182.
40,76 Finally a selective 
hydrogenolysis and global deprotection of enyne 1.205 gave (–)-mucocin (1.113) 
in 28 steps from benzyl ether 1.183 in a total yield of 6.3%.    
Key aspects of Takahashi’s synthesis are:- 
-  3 fragments synthesised using chiron approach. 
-  Non-adjacent THP-THF core constructed by acetylide addition to 
aldehyde 1.180. 
-  Cis-THP ring stereochemistry delivered from chiral starting material 
except C24 position which was installed by stereoselective reduction.
92 
-  Trans-THF stereochemistry delivered from chiral starting material, with 
C16 stereochemistry installed by chelation controlled Grignard 
addition.   38
-  C4 hydroxyl stereochemistry installed by substrate controlled acetylide 
addition to lactol 1.193. 
(–)-Mucocin – Evans (2003) 
Evans’ group employs a highly convergent coupling strategy with 3 main 
fragments (scheme 1.46).  
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Scheme 1.46 Evans retrosynthetic analysis for (–)-mucocin (1.113). 
  The synthesis of the aldehyde fragment 1.208 started with a regioselective 
opening of (S)-propylene oxide with lithiated alkyne 1.209, affording alcohol 
1.210 (scheme 1.47).  
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Scheme 1.47 Synthesis of butenolide aldehyde 1.208. Reagents and conditions a) (S)-propylene 
oxide, n-BuLi, HMPA, THF; b) COCl2, Et3N, benzene, then PhSeH, pyridine, THF/benzene; c) n-
Bu3SnH, AIBN, benzene, ∆; d) RhH(CO)(PPh3)3, benzene; e) HCOOH, pentane. 
Alcohol 1.210 was converted to the selenocarbonate 1.211, and then under free 
radical conditions a γ-lactone was formed. A ruthenium catalysed isomerisation 
followed by acid hydrolysis gave desired aldehyde 1.208 in 5 steps from alkyne 
1.209 in 36% yield.  
The synthesis of the THF fragment 1.217 began with alcohol 1.212 
(available in one step from 1,4-pentadien-3-ol in a 45% yield) (scheme 1.48).   39
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Scheme 1.48 Synthesis of THF fragment 1.217. Reagents and conditions: a) p-MeOC6H4OH, 
DIAD, PPh3, THF; b) CH2=CHCH2MgBr, CuCN, Et2O; c) Co(modp)2, O2, t-BuOOH, i-PrOH; d) 
Tf2O, Et3N, CH2Cl2; e) TMSC≡C(CH2)4MgBr, CuI, THF, then MeOH, TBAF; f) 1.207 (6 equiv.), 
Et2Zn, PhMe, ∆, then (R)-BINOL (1 equiv.), Ti(Oi-Pr)4, THF, then 1.208 (1 equiv.); g) TIPSOTf, 
pyridine, DMAP; h) (NH4)2Ce(NO3)6, MeCN/H2O. 
Mitsunobu inversion of alcohol 1.212 with p-methoxyphenol gave epoxide 1.213, 
followed by a regioselective cuprate opening delivered alcohol 1.214. Cobalt 
mediated oxidative cyclisation returned THF alcohol 1.215 ( dr  ≥ 19:1).
89 
Conversion of alcohol 1.215 to a triflate then displacement with a cuprate 
followed by in situ desilylation afforded alkyne 1.207. An asymmetric addition of 
alkyne 1.207 to aldehyde 1.208 furnished alcohol 1.216 (dr = 20:1 by HPLC).
98-
100 Protecting group manipulations then gave allylic alcohol 1.217 in 9 steps from 
1,4-pentadien-3-ol in 11.9% yield.  
The synthesis of the THP fragment 1.206 also began with alcohol 1.212 
(scheme 1.49). A Mitsunobu inversion of alcohol 1.212 with p-methoxyphenol, 
then a regioselective opening with the lithium homoenolate of TBS protected 
divinyl alcohol, followed by in situ silylation gave triene 1.218. 
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Scheme 1.49 Synthesis of THP fragment 1.206. Reagents and conditions: a) p-MeOC6H4OH, 
DIAD, PPh3, THF; b) (CH2=CH)2CHOTBS, s-BuLi, THF, then TBSOTf, 2,6-lutidine; c) AD-mix-α, t-
BuOH/H2O, MeSO2NH2; d) n-octylMgBr, CuCN, THF; e) BiBr3,  t-BuMe2SiH, MeCN, then 2,6-
lutidine, TBSOTf; f) (NH4)2Ce(NO3)6, MeCN/H2O.   40
  Asymmetric dihydroxylation furnished ketone 1.219 (dr 99:1).
101 A copper-
mediated 1,4-addition installed the alkyl chain which gave ketone 1.220. With 
ketone 1.220 in hand Evans was set up for the key THP forming reaction, a 
catalytic bismuth reductive etherification reaction. Under their optimum conditions 
ketone  1.220  was converted to a cis-THP alcohol which was silylated in situ 
furnishing silyl ether 1.221 (dr ≥ 19:1 by NMR).
102,103 Deprotection of the methyl 
phenyl ether gave THP fragment 1.206 in 7 steps from 1,4-pentadien-3-ol in 
13.3% yield.  
Central to Evans’ approach was to link temporarily fragments 1.206 and 
1.217 by a silicon tether which would allow RCM. Fragments 1.206 and 1.217 
were efficiently coupled with a diisopropylsilyl tether (scheme 1.50). 
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Scheme 1.50 Total synthesis of (–)-mucocin (1.1). Reagents and conditions: a) 1.206, i-Pr2SiCl2 
(xs), CH2Cl2, imidazole, then 1.217, imidazole; b) Grubbs’ first generation catalyst (1.8 equiv), 
1,2-DCE, ∆; c) HF/MeCN, CH2Cl2; d) TsNHNH2, NaOAc, 1,2-DME/H2O, ∆. 
  RCM reaction of the tethered diene with Grubbs’ first generation catalyst 
(1.8 equiv) returned silyl ether 1.222. A global desilylation and selective 
hydrogenolysis gave (–)-mucocin (1.113) in 13 steps from 1,4-pentadien-3-ol in 
6.2% yield. 
Key aspects of Evans synthesis are:- 
-  The non-adjacent THP-THF core constructed by silicon tethered RCM. 
- Cis-THP ring constructed by catalytic bismuth reductive 
etherification.
102,103 
-  Trans-THF ring constructed by diastereoselective cobalt oxidative 
cyclisation.
89  
-  C4 hydroxyl installed by an asymmetric acetylide addition.
98-100 
(–)-Mucocin – Mootoo (2005) 
Mootoo’s synthesis constructs mucocin (1.113) from 3 main fragments 
(scheme 1.51).
104 Mootoo uses a coupling strategy similar to his earlier 
successful total synthesis of squamostatin-C (1.79), with synthesis of fragments   41
1.81 and 1.82 previously published. THF fragment 1.81 was synthesised in 10 
steps from 1,4-pentadien-3-ol in a 10.2% yield.
57 Butenolide fragment 1.82 was 
synthesised in 13 steps from 6-iodo-1-hexene in a 2.9% yield.
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Scheme 1.51 Mootoo’s retrosynthetic analysis of (–)-mucocin (1.113). 
The synthesis of THP fragment 1.223 began with aldehyde 1.225 (scheme 
1.52).
57 Addition of lithiated dithiane 1.224 to aldehyde 1.225 gave acetal 1.226 
as an inseparable of epimers. 
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Scheme 1.52 Synthesis of THP fragment 1.223. Reagents and conditions: a) 1.224, n-BuLi, THF 
then 1.225; b) Hg(ClO4)2, THF; c) column chromatography; d) Et3SiH, BF3•OEt2, CH2Cl2. 
Acetal  1.226 was exposed to mercury(ii)perchlorate which caused acetal 
exchange affording bicyclic acetal 1.227, the alcohol epimers were separated 
using column chromatography to give the desired R alcohol. Reductive acetal 
cleavage furnished the desired fragment 1.223  as a single isomer. The THP 
fragment 1.223 was synthesised in 8 steps from 1,4-pentadien-3-ol in 6.7% yield.  
A key aspect of Mootoo’s approach was to couple fragments 1.223 and 
1.81 by CM, using similar conditions used to assemble squamostatin-C.
57 Allylic 
alcohol fragment 1.223 and a three-fold excess of acetate 1.81 were coupled in 
the presence Grubbs 2
nd generation catalyst (scheme 1.53).   42
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Scheme 1.53 Total synthesis of (–)-mucocin (1.113).  Reagents and conditions: a) 1.223  (1 
equiv.),  1.81 (3 equiv.), Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %), CH2Cl2, rt, 18h, then 
Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %), rt, 18h; b) H2, Pd/C, EtOAc; c) K2CO3, MeOH; d) MOMCl, 
DIPEA, CH2Cl2; e) NaOMe, MeOH; f) Ph3P, DIAD, 1-phenyl-1H-tetrazole-5-thiol, THF; g) m-
CPBA, NaHCO3, CH2Cl2; h) 1.230, LiHMDS, THF, then 1.82; i) H2, Rh(Ph3P)3Cl, benzene–EtOH; 
j) 5% AcCl, MeOH/CH2Cl2. 
With CM product 1.228 in hand, hydrogenolysis and protecting group 
manipulations delivered alcohol 1.229. Mootoo planned to couple the butenolide 
fragment  1.82  by Julia-Kocienski olefination. Therefore alcohol 1.229 was 
converted to sulfone 1.230 under classical conditions.
105 Lithiated sulfone 1.230 
was then reacted with an excess of aldehyde 1.82 followed by a selective 
hydrogenolysis which returned MOM ether 1.231. Finally a global deprotection 
gave (–)-mucocin (1.113) in 20 steps from 1,4-pentadien-3-ol in 0.5% yield.    
Key aspects of Mootoo’s synthesis are:- 
-  The non-adjacent THP-THF core constructed by CM.
56 
-  Cis-THP ring established by reductive acetal cleavage. 
-  Trans-THF ring established by trans-selective iodoetherification 
reaction.
59-62 
-  Butenolide portion installed by Julia-Kocienski olefination. 
(–)-Mucocin – Crimmins (2006) 
Crimmins’ approach was based on a convergent coupling strategy with 3 
main fragments (scheme 1.54).    43
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Scheme 1.54 Crimmins group’s retrosynthetic analysis of (–)-mucocin (1.113). 
The THP and THF fragments 1.232 and 1.233 were synthesised using glycolate 
aldol-RCM chemistry similar to that used by Crimmins in the total synthesis of 
(+)-gigantecin (1.1).
43 Vinyl iodide 1.40 was a known compound from the (+)-
gigantecin (1.1) synthesis.
43  
The synthesis of allylic alcohol 1.232 started with known alcohol 1.234 
(available in two steps from undecanal in 48% yield) (scheme 1.55).
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Scheme 1.55 Synthesis of THP fragment 1.232.  Reagents and conditions: a) DHP, PPTS, 
CH2Cl2; b) Me3S
+I
–,  n-BuLi, THF; c) NaH, BnBr, TBAI, THF; d) p-TsOH, MeOH, CH2Cl2; e) 
BrCH2CO2H, NaH, THF; f) Me3CCOCl, Et3N, THF, then (R)-lithio-4-benzyl-oxazolidin-2-one; g) 
TiCl4, DIPEA, NMP, acrolein, CH2Cl2; h) TESOTf, 2,6-lutidine, CH2Cl2; i) LiBH4, MeOH, Et2O; j) 
Swern oxidation; k) Ph3PCH3Br, KOt-Bu, THF; l) Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %), benzene, 
then p-TsOH, MeOH. 
Alcohol  1.234 was protected as its THP ether then exposured to Me2S=CH2 
affording allylic alcohol 1.235. Protection group manipulations gave benzyl ether 
1.236. The sodium alkoxide of allylic alcohol 1.236 was alkylated with sodium 
bromoacetate, then converted to a mixed anhydride and reacted with lithiated 
oxazolidinone to afford glycolate 1.237. Under their optimum aldol conditions, 
reaction between glycolate 1.237 and acrolein gave syn-aldol product 1.238 (dr 
11:1).
43 Silylation of the free hydroxyl, reductive cleavage of the glycolate, Swern 
oxidation of the resulting primary alcohol then Wittig olefination gave diene 1.239.   44
RCM using Grubbs 2
nd generation catalyst with acidic work up regioselectivity 
gave THP fragment 1.232 in 14 steps from undecanal in a 11.6% yield.
108  
The synthesis of the THF fragment 1.233  began with alcohol 1.240 
(scheme 1.56). Silylation of alkyne 1.240, Swern oxidation of the primary alcohol 
followed by treatment with vinyl Grignard yielded racemic alcohol 1.241. 
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Scheme 1.56 Synthesis of THF fragment 1.233. Reagents and conditions: a) EtMgCl, TIPSCl, 
THF; b) Swern oxidation; c) CH2=CHMgBr, THF; d) Ti(Oi-Pr)4, (+)-DCHT, t-BuOOH,  CH2Cl2; e) 
BrCH2CO2H, NaH, THF; f) Me3CCOCl, Et3N, THF, then (R)-lithio-4-benzyl-oxazolidin-2-one; g) 
TiCl4, DIPEA, NMP, acrolein, CH2Cl2; h) TESOTf, 2,6-lutidine, CH2Cl2; i) LiBH4, MeOH, Et2O; j) 
Swern oxidation then Ph3P=CHCO2Me; k) DIBAL-H, Et2O; l) allyl bromide, NaH, THF; m) 
Cl2(Cy3P)(IMes)Ru=CHPh (10 mol %), benzene, then p-TsOH, MeOH; n) MOMCl, DIPEA, DMAP, 
CH2Cl2.  
Sharpless kinetic resolution on secondary alcohol 1.241 delivered the R alcohol 
1.242 (ee 92%, HPLC of glycolate 1.243).
109 As previously described, alcohol 
1.242  was converted to glycolate 1.243. Again under their optimum aldol 
conditions, reaction between glycolate 1.243 and acrolein provided syn-aldol 
product 1.244 (dr 4:1). Silylation and reductive cleavage of the glycolate returned 
alcohol 1.245. To overcome selectivity problems in the forthcoming RCM step, 
Hoye’s “activation” strategy was employed.
110 The strategy required a three-step 
conversion of alcohol 1.245  to tetraene 1.246. With tetraene 1.246 in hand 
ruthenium carbene insertion could be controlled, therefore exposure of tetraene 
1.246 to Grubbs 2
nd generation catalyst followed by acidic work up, gave alcohol 
1.247 in excellent yield. A MOM protection of alcohol 1.247 then provided THF 
fragment 1.233 in 14 steps from alcohol 1.240 in 3.3% overall yield. 
  The steric hindrance of the MOM ether group deactivated allylic alcohol 
1.233 to metathesis relative to allylic alcohol 1.323. The differences in reactivity   45
allowed successful CM coupling using Hoveyda-Grubbs catalyst (scheme 
1.57).
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Scheme 1.57 Total synthesis of (–)-mucocin (1.113).  Reagents and conditions: a) Hoveyda-
Grubbs catalyst (10 mol %), CH2Cl2; b) TBAF, THF; c) 1.40, Pd(PPh3)2Cl2, CuI, Et3N; d) 
TsNHNH2, NaOAc, 1,2-DME/H2O, ∆; e) BF3•OEt2, Me2S. 
The CM product was desilylated delivering alkyne 1.248 which was used in a 
Sonogashira coupling with iodide 1.40 to secure enyne 1.249.
40 Selective global 
hydrogenation and deprotection gave (–)-mucocin (1.113) in 19 linear steps from 
alcohol 1.240 in 1.0% yield.    
Key aspects of Crimmins’ synthesis are:- 
-  The non-adjacent THP-THF core constructed by CM.
56 
- Cis-THP and trans-THF rings constructed by glycolate aldol-RCM 
chemistry.
43  
- Butenolide  portion  installed by Sonogashira coupling.
40 
Conclusion 
The Annonaceous acetogenins family of natural products have sparked 
great interest both biologically and synthetically. There is still much to be learnt 
about their inhibitive effects of mitochondrial complex 1, and selective cytotoxicity 
in cancerous cells that might lead to significant advances in therapeutics. 
Synthetically  Annonaceous acetogenins have also attracted very substantial 
interest. The synthesis of the non-adjacent bis-THF and non-adjacent THP-THF 
classes still represents a considerable challenge.  Multiple chiral centres and 
introduction of the THF-THF/THP-THF core has inspired the synthetic chemist to 
invent a plethora of adaptable and imaginative solutions.   46
1.6   Permanganate Oxidative Cyclisation of 1,5-dienes 
Permangante oxidative cyclisation of 1,5-dienes is now an established method to 
synthesize cis-2,5-bis(hydroxyalkyl) tetrahydrofurans (THF diols). The following 
section will give a brief introduction to the reaction and highlight some key 
discoveries. Klein and Rojan made the first significant observation in 1965.
111 
They described the oxidation of various 1,5-dienes by potassium permanganate. 
Importantly, for the first time the products from the permangante oxidation were 
structurally assigned as THF diols, which were obtained in a stereospecific 
manner (scheme 1.58). 
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Scheme 1.58 Oxidative cyclisation of 1,5-dienes by Klein and Rojan. Reagents and conditions: a) 
KMnO4 (1.5 equiv), 10% aq acetone, CO2 stream, 0 C. 
There was no significant work until 1979, where independent work by Baldwin 
and Walba discussed mechanistic aspects of the permanganate oxidative 
cyclisation of 1,5-dienes.
112,113 Both supported the observations made by Klein 
and Rojan with respect to the stereospecific nature of permanganate oxidative 
cyclisation, delivering cis-2,5-bis(hydroxyalkyl) tetrahydrofurans. Baldwin 
oxidised deuterium labelled (E,E) and (E,Z)-hexa-1,5-dienes, and Walba oxidised 
the three isomeric forms of octa-2,6-diene. While, both agreed on the 
stereospecifically of the reaction, their proposed mechanisms for the reaction 
differed. Walba preferred to describe the permanganate oxidative cyclisation 
reaction going through a ‘Sharpless type’ mechanism with organometallic 
intermediates (scheme 1.59). 
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Scheme 1.59 Walba’s proposed mechanism. 
Walba argued a double [2+2] cycloaddition gave a manganooxetane 
intermediate, where alkyl migration with retention of configuration and reductive   47
elimination gave a cis-THF diol. Baldwin’s mechanism began with a [3+2] 
cycloaddition producing a manganese(v) species. Subsequent oxidisation to 
manganese(vi), and a further [3+2] cycloaddition would deliver a manganese 
diester, which is hydrolysised returning a cis-THF diol (scheme 1.60). 
R2
R1
Mn
O
O
O O
R2
O
Mn
O
O O
R1
R4
R3 R3
H
R2
O
Mn
O
O O
R1
R4
R3
H
O
Mn
O O
R2 R4
R1 R3
O
H H
O
OH HO H H
R2 R3 R1 R4
[3+2]
cycloaddition
Mn
oxidation
[3+2]
cycloaddition
hydrolysis
 
Scheme 1.60 Baldwin’s proposed mechanism. 
The Baldwin mechanism is more reasonable based on related osmium tetroxide 
and ruthenium tetroxide chemistry, and is supported by density functional theory 
calculations.
114-120 
  The first synthetic application was by Walba and Edwards in their 
synthesis of ionophore monesin.
121 Oxidative cyclisation of diene 1.252 gave a 
racemic mixture of cis-THF diols 1.253 (scheme 1.61).  
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Scheme 1.61 Synthesis of THF diol 1.253. Reagents and conditions: a) KMnO4, 10% aq acetone, 
CO2 stream, 30 C. 
Initial problems with the work up of the reaction were overcome which returned 
diol  1.253 in reasonable yield. Spino and Weiler continued research in their 
synthesis of ionomycin.
122 Diene 1.254 was cyclised using similar conditions to 
Walba (scheme 1.62).   
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Scheme 1.62 Synthesis of THF diols 1.255a/b. Reagents and conditions: a) KMnO4, 10% aq 
acetone, CO2 stream, 25 C. 
THF diols 1.255a/b were returned as a racemic mixture. Separation of the 
diastereoisomers was achieved by derivatisation with (S)-(+)-O-acetyl mandelic 
acid. Although permanganate oxidative cyclisation of 1,5-dienes had been shown 
to successfully return cis-THF diols, there had been no way to control absolute 
stereochemistry. This was overcome by Walba, oxidative cyclisation of a 1,5-  48
diene  1.256  functionised with Oppolzer’s camphor sultam returned THF diol 
1.257 as the major diastereoisomer in reasonable yield and good 
diastereoselectivity (dr > 9:1) (scheme 1.63).
123 
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Scheme 1.63 Asymmetric oxidative cyclisation of 1,5-dienes. Reagents and conditions: a) 
KMnO4, 10% aq acetone, CO2 stream, 30 C. 
Facial selectivity originates from initial attack of permanganate at the electron 
deficient alkene, where the approach of permanganate is governed by the 
proximal camphor sultam auxiliary. The facial selectivity matched the 
observations made by Oppolzer in the osmylation of sultam-functionalized 
enoates.
124 Kocienski and Brown applied this strategy to their synthesis of a 
salinomycin fragment, which required intermediate 1.259.
125,126 Oxidative 
cyclisation of diene 1.258 delivered THF diol 1.259 as an inseparable mixture of 
diastereoisomers (dr 6:1) (scheme 1.64). 
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Scheme 1.64 Synthesis of THF diol 1.259. Reagents and conditions: a) KMnO4, acetate buffer 
(pH = 6), acetone/HOAc/H2O, 35 C. 
Significantly, previously well-established reaction conditions for the oxidative 
cyclisation were in their case problematic. This lead to optimisation of reaction 
conditions where they believe pH was playing a significant role. Brown continued 
research in stereo-controlled permanganate oxidative cyclisation of 1,5-dienes 
with his own group. A classic example of the work is shown in the total synthesis 
of cis-solamin (scheme 1.65).
127-129 Brown continued to use the camphor sultam 
auxiliary to gain stereo-control. Oxidative cyclisation of un-branched 1,5-diene 
1.260 gave THF diol 1.261a as the major product in good diastereoselectivity, 
which correctly set up 4 stereocentres in one synthetic step.    49
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Scheme 1.65 Synthesis of THF diol 1.261a. Reagents and conditions: a) KMnO4 (1.4 equiv), 
AcOH (8 equiv), Adogen 464 (0.1 equiv), EtOAc, 30 to 0 C. 
From THF diol intermediates 1.261a/b the total synthesis of cis-solamin A (1.262) 
and  cis-solamin B (1.263) were completed. Subsequent chiral HPLC studies 
confirmed that naturally isolated cis-solamin was a mixture of cis-solamin A 
(1.262) and cis-solamin B (1.263).
129 The key contributions by the Brown group 
have been optimisation of reaction conditions and extension of synthetic 
applications. Interestingly, Brown had also published an asymmetric 
permanganate oxidative cyclisation, where an achiral diene was oxidised by 
permanganate in the presence of a chiral phase transfer catalyst, which induced 
good levels of enantioselectivity in the THF diol product.
130 
1.7  Southampton Approach to (+)-cis-Sylvaticin 
Brown had already shown the application of stereo-controlled 
permanganate oxidative cyclisation of 1,5-dienoyl systems in the synthesis of cis-
THF Annonaceous acetogenin natural products. To date membranacin (adjacent 
bis-THF), membrarollin (adjacent bis-THF) and cis-solamin (mono-THF) have 
been synthesised using this methodology.
128,131-133 A synthesis of cis-sylvaticin 
(1.100) where stereo-controlled permanganate oxidative cyclisation of 1,5-dienes 
was a key step, would extend the utility of the reaction, while also posing fresh 
challenges with construction of the non-adjacent bis-THF core and installation of 
the C4 hydroxyl.  
Double Oxidative Cyclisation Approach 
Initial activity from the Brown lab came from Dr Riaz Bhunnoo, who used a 
naked skeleton approach to install the non-adjacent bis-THF core. The synthesis   50
began with (E,E,E)-cyclododecatriene (1.116), a selective mono-dihydroxylation, 
periodate cleavage then double cis-selective olefination delivered diester 1.264 
(scheme 1.66).
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Scheme 1.66 Synthesis of bis-THF tetraols 1.266a/b. Reagents and conditions: a) OsO4, NMO, 
H2O, CH2Cl2; b) NaIO4-SiO2, H2O, CH2Cl2; c) (PhO)2POCH2COOMe, KHMDS, 18-crown-6, THF; 
d) NaOH, NaHCO3, MeOH/H2O (1:3), then citric acid (aq), HCl (aq); e) (COCl)2, DMF, CH2Cl2; f) 
(1S,2R)-camphorsultam, NaH, toluene; e) NaMnO4, AcOH/acetone/buffer. 
Hydrolysis of diester 1.264, followed by acid chloride formation then coupling with 
the sodium salt of (1S,2R)-camphorsultam furnished tetraene 1.265. With 
tetraene  1.265 in hand, the key double permanganate oxidative cyclisation 
reaction provided tetraols 1.266a/b  as an inseparable mixture of isomers 
(1.266a:1.266b  3:1). In the oxidative cyclisation step, seven of the desired 
stereocentres had been correctly installed giving a C2 symmetric intermediate 
1.266a in 7 steps in 7.1% yield.  
Two approaches were attempted to desymmetrise intermediate 1.266a. 
Tetraols  1.266a/b  were reductively cleaved which gave hexaols 1.267a/b, a 
selective mono-tosylation followed by ring closing substitution successfully gave 
desymmetrised epoxides 1.269a/b (scheme 1.67). 
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Scheme 1.67 Synthesis of bis-THF pentols 1.270a/b. Reagents and conditions: a) LiBH4, THF; b) 
Bu2SnO, dioxane, ∆, then TsCl; c) DBU, CH2Cl2; d) nonylmagnesium bromide, CuI, THF. 
Cuprate addition to epoxide 1.269a/b installed the alkyl chain. Pentaol 1.270a/b 
was submitted to a one-off periodate cleavage followed by olefination. By TLC 
and crude 
1H NMR results were encouraging, but due to the lack of material no   51
firm conclusion could be obtained. Although desymmetrisation was successful 
the route was hampered by poor yields and an inability to separate 
diastereoisomers. 
A second approach was therefore investigated. Hexaols 1.267a/b  were 
selectively  bis-tosylated followed by ring closing substitution delivering bis-
epoxides 1.271a/b (scheme 1.68). 
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Scheme 1.68 Synthesis of bis-THF silyl ether 1.272a.  Reagents and conditions: a) Bu2SnO, 
dioxane, ∆, then TsCl; b) DBU, CH2Cl2; c) 2,6-lutidine, TBSOTf, CH2Cl2. 
Silylation of bis-epoxides  1.271a/b  gave a mixture of products, but allowed 
separation of diastereoisomers by column chromatography. A one-off cuprate 
addition to bis-epoxide 1.272a caused decomposition of material. Due to lack of 
material it was not possible to explore the cuprate addition further.  
The double permanganate oxidative cyclisation approach was attractive 
due to the relatively short access to complex hexaols 1.267a/b. However, the 
approach was hampered by low yields and desymmetrisation problems, so it was 
deemed more profitable to explore a THF fragment coupling strategy. 
Tethered RCM Approach 
The tethered RCM approach required synthesis of 3 main fragments 1.276, 
1.277 and 1.36. The 2 THF fragments 1.276 and 1.277 would be synthesised 
from suitable 1,5-diene precursors by permanganate oxidative cyclisation. The 
key coupling reaction would be a silicon tethered RCM reaction described by 
Evans (scheme 1.69).
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Scheme 1.69 Retrosynthetic analysis of cis-sylvaticin. 
Work on this strategy was started by Dr Stephen Kemp. Fragment 1.276 
synthesis began by alkylation of alkyne 1.280 (scheme 1.70). The resulting 
alkyne  1.281  was partially reduced, followed by hydrolysis of the acetal and 
olefination with camphorsultam phosphonates delivering 1,5-diene 1.278.  
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Scheme 1.70 Synthesis of fragment 1.276. Reagents and conditions: a) n-BuLi, HMPA, THF, 
then 2-(2-bromoethyl)-1,3-dioxolane; b) H2, Lindlar catalyst, quinoline, hexane; c) AcOH/H2O 4:1, 
∆; d) (EtO)2POCH2COXR, Et3N, LiCl, MeCN; e) KMnO4, AcOH/acetone (2:3); f) NaBH4, THF/H20 
(3:1); g) (i) Bn2SnO, benzene, ∆; (ii) TsCl, TBAB; h) DBU, CH2Cl2; i) MOMCl, DIPEA, CH2Cl2; j) 
Me3S
+I
–, n-BuLi, THF. 
Oxidative cyclisation of 1,5-dienoyl 1.278  with permanganate gave THF diol 
1.282 as the major diastereoisomer (dr 9:1 by crude 
1H NMR). THF diol 1.282 
was reductively cleaved, and a selective mono-tosylation allowed ring closing 
substitution followed by protection of the alcohol as its MOM ether 1.283. 
Epoxide  1.283  was converted to fragment 1.276  using the trimethylsulfonium 
ylide.   53
Fragment  1.277  synthesis began by alkylation of alkyne 1.284  with 8-
bromo-oct-1-ene. A Sharpless dihydroxylation on alkene 1.285 installed the C4 
hydroxyl (ee ≈ 80%) (scheme 1.71).  
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Scheme 1.71 Synthesis of fragment 1.277. Reagents and conditions: a) n-BuLi, HMPA, THF, 8-
bromooct-1-ene; b) AD-mix-β,  t-BuOH/H2O; c) MeOH, p-TsOH; d) acetone, p-TsOH; e) H2, 
Lindlar catalyst, quinoline; f) Dess-Martin periodinane, CH2Cl2; g) (EtO)2POCH2COXR, Et3N, LiCl, 
MeCN; h) KMnO4, AcOH/acetone (2:3); i) NaBH4, THF/H20 (3:1); j) Bn2SnO, benzene, ∆, then 
TsCl, TBAB; k) DBU, CH2Cl2; l) thiocarbonyldiimidazole, DMAP, CH2Cl2; m) (n-Bu4N)2S2O8, 
HCO2Na, Na2CO3, DMF; n) Me3S
+I
–, n-BuLi, THF. 
The THP group was removed, 1,2-diol 1.286  was protected as its acetonide, 
followed by Lindlar reduction of the alkyne, subsequent Dess-Martin oxidation 
and olefination furnished 1,5-dienoyl 1.279.  Oxidative cyclisation of 1,5-dienoyl 
sultam  1.279  with permanganate gave THF diol 1.287  as the major 
diastereoisomer (dr 9:1). THF diol 1.287 was reductively cleaved, then selective 
mono-tosylation allowed ring closing substitution delivering alcohol 1.288. A 
radical deoxygenation via the thiocarbonyl imidazole derivative 1.289  gave 
epoxide 1.290. Epoxide 1.290 was converted to fragment 1.277.  
Fragments  1.276  and  1.277  were coupled using a diphenylsilyl tether 
(scheme 1.72). RCM reaction using Grubbs 2
nd generation catalyst gave the 
desired RCM product 1.275 in poor yield. 
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Scheme 1.72 Synthesis of alkene 1.275. Reagents and conditions: a) 1.276, Ph2SiCl2, DIPEA, 
CH2Cl2, then 1.277, DIPEA, DMAP; b) Grubbs 2
nd generation catalyst (20 mol %), C6D6, 100 °C.   54
  The THF fragment coupling approach was highly attractive, and excellent 
progress had been made but there were a number of problems with the 
synthesis. The synthesis of fragment 1.277 was long at 14 steps and the 
thiocarbonyl imidazole formation/radical deoxygenation protocol was unreliable. 
Installation of the C4 hydroxyl by asymmetric dihydroxylation of terminal alkene 
1.285 proceeded with poor stereoselectivity. In addition protection of the terminal 
1,2-diol as an acetonide caused concern for later stage protecting group 
manipulations. Finally, for the THF fragment coupling approach to be viable an 
improvement to the tethering-RCM chemistry was required.    55
Chapter 2: Results and Discussion 
2.1  Kinetic Resolution Chemistry 
Hydrolytic Kinetic Resolution 
Investigations into the optimisation of Dr Kemp’s proposed synthesis of 
cis-sylvaticin (1.100) required an improved method for installing the C4 hydroxyl. 
In the original work a Sharpless asymmetric dihydroxylation on terminal alkene 
1.285 installed the C4 hydroxyl, but with disappointing ee. Also the resulting 1,2-
diol required additional steps for orthogonal protection. Initial work focused on the 
hydrolytic kinetic resolution (HKR) chemistry of terminal epoxides described by 
Jacobsen.
134  
Bromo-olefin 2.1 was used as it had the appropriate alkyl spacer, while the 
bromide gave a suitable handle for extension. Following the Haufe procedure, 
epoxidation of commercially available olefin 2.1 gave racemic epoxide 2.2 
(scheme 2.1).
135 With racemic epoxide 2.2  in hand the HKR chemistry was 
studied.  
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Scheme 2.1 Synthesis of enantio-enriched epoxide ent-2.2.  Reagents and conditions: a) m-
CPBA, CH2Cl2, 0 °C → rt; b) (i) (R,R)-Co(salen) 2.3 0.5 mol %, AcOH, CH2Cl2, (ii) 2.2, IPA, H2O 
(0.55 equiv.). 
Commercially available (R,R)-Co(salen) 2.3 was oxidised by air in the presence 
of acetic acid which gave the active Co(III)-OAc catalyst. Exposure of racemic 
epoxide 2.2 to the Co(III)-OAc catalyst in the presence of H2O (0.55 equiv.) gave 
epoxide ent-2.2 (ee determined in next step, the sense of the enantioselectivity 
was assumed to follow well established literature precedent).
134 Our plan was to 
carry out a regioselective opening of epoxide ent-2.2 with benzyl alcohol. This 
would successfully unmask the C4 hydroxyl while affording orthogonal protection 
the 1° alcohol. Under Lewis acid conditions epoxide ent-2.2 was opened with   56
benzyl alcohol which gave the desired benzyl ether 2.5 (ee >99% by HPLC) in 
poor regioselectively (1:1) and only moderate yield (scheme 2.2).  
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Scheme 2.2 Synthesis of benzyl ether 2.5. Reagents and conditions: a) BF3•OEt2, BnOH, CH2Cl2, 
–70 °C → rt; b) ClRh(Ph3P)3, benzaldehyde, Et3N, B(Et)3. 
Opening of epoxide ent-2.2 with the alkoxide of benzyl alcohol was attempted but 
no reaction was witnessed. The regioselectivity was a major problem as 
regioisomers 2.5, 2.6 and benzyl alcohol were difficult to separate by MPLC. A 
ruthenium catalysed reductive coupling described by Jamison was 
investigated.
136 Following the Jamison procedure epoxide ent-2.2 was coupled 
with benzaldehyde to give benzyl ether 2.5 (ee not determined) in disappointing 
yield (45%) but with excellent regioselectivity (>95:5 by 
1H NMR). Benzyl ether 
2.5 was an extremely attractive intermediate which would be required on a 10 to 
20 gram scale, but the current route would be impractical due to the cost of the 
starting olefin 2.1 and inefficient opening of epoxide ent-2.2.  
Oligomeric Co(salen) Catalyst 
Further work by Jacobsen had shown kinetic resolution chemistry with an 
oligomeric Co(salen) catalyst 2.13.
137,138 The more active oligomeric Co(salen) 
catalyst 2.13 had allowed direct opening of 2-butyloxirane with benzyl alcohol 
during the kinetic resolution.
138 Following the Jacobsen procedure the synthesis 
of the oligomeric Co(salen) catalyst 2.13 began with a selective mono-TIPS 
protection of bis-phenol 2.7 (scheme 2.3).
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Scheme 2.3 Synthesis of oligomeric (S,S)-Co(salen) catalyst 2.13. Reagents and conditions: a) 
TIPSCl, DMAP, imidazole, CH2Cl2; b) SnCl4, 2,6-lutidine, paraformaldehyde, toluene; c) TBAF, 
THF; d) 2.9, DIC, DMAP, CH2Cl2, DMF, 0 °C → rt; e) 2.11, K2CO3, THF/water, ∆; f) (i) Co(OAc)2, 
MeOH/toluene; (ii) nbs•H2O, CH2Cl2.  
The resulting TIPS ether was acetylated under Lewis acid conditions which was 
followed by desilylation to furnish aldehyde 2.8. 2 Equivalents of aldehyde 2.8 
were successfully coupled with bis-acid  2.9 selectively yielding bis-aldehyde 
2.10. Imide formation between (S,S) bis-ammonium salt 2.11 and bis-aldehyde 
2.10  gave (S,S) oligomeric salen ligand 2.12. Insertion of Co(II) into (S,S) 
oligomeric salen ligand 2.12  followed by oxidation by air in the presence of 
nitrobenzenesulfonic acid gave (S,S) oligomeric Co(salen) catalyst 2.13.  Either 
enantiomer of bis-ammonium salt 2.11 may be used which gave an analogous 
route to both (S,S) and (R,R) versions of the oligomeric Co(salen) catalyst.  With 
the desired enantiomers of oligomeric Co(salen) in hand the modified kinetic 
resolution studies were commenced.  
Modified Kinetic Resolution 
Bromo-olefin 2.1 was epoxidised but this time a catalytic rhenium method 
was preferred to m-CPBA (scheme 2.3).
139,140 Experimental observations 
suggested the presence of benzoic acid gave disappointing results in the 
subsequent kinetic resolution step. Presumably this was due to catalyst 
deactivation through ion exchange, as the negative counterion in the active   58
cobalt catalyst has been shown to affect kinetic resolution.
138 The advantage of 
the rhenium method is the by-product from epoxidation is H2O rather than 
benzoic acid.  
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Scheme 2.4 Synthesis of chiral building block 2.5. Reagents and conditions: a) MeReO3 0.5 mol 
%, pyrazole, 30% H2O2 aq, CH2Cl2, rt, 24h; b) (S,S) 2.13 0.25 mol %, BnOH (0.45 equiv.), MeCN, 
4 °C, 16h; c) (R,R) 2.13 0.25 mol %, BnOH (0.9 equiv.), MeCN, 4 °C, 16h; d) Ph3P, DIAD, p-
nitrobenzoic acid, THF; e) NaOH, MeOH.  
When epoxide 2.2 was exposed to benzyl alcohol (0.45 eq.) in the presence of 
(S,S) oligomeric Co(salen) catalyst 2.13 the desired benzyl ether 2.5 was 
delivered in excellent yield (ee  >99% by chiral HPLC, the sense of the 
enantioselectivity was assumed to follow well established literature precedent).
138 
The un-reacted epoxide ent-2.2  which  was recovered presumably in high 
enantioselectivity, was then opened with benzyl alcohol (0.9 eq.) in the presence 
of the (R,R) oligomeric Co(salen) catalyst 2.13 gave benzyl ether ent-2.5 (ee > 
99% by chiral HPLC). Benzyl ether ent-2.5 was converted to the desired chiral 
building block 2.5 via an efficient Mitsunobu-hydrolysis procedure.
45  
For the first time there was an extremely efficient route for chiral building 
block 2.5 (84% yield from alkene 2.1, 5 steps). More importantly the C4 hydroxyl 
of  cis-sylvaticin had been installed with excellent enantioselectivity, plus the 
terminal diol had been orthogonally protected with a robust benzyl group.  
Conclusion 
-  HKR route gave the desired chiral building block 2.5 in excellent ee but 
was impractical due to low yields and poor regiocontrol in the epoxide 
opening. 
-  An efficient alcoholytic kinetic resolution approach to chiral building 
block 2.5 was achieved installing the C4 hydroxyl group with excellent   59
enantioselectiviy (ee > 99%), while orthogonally protecting the terminal 
diol. 
With the C4 hydroxyl and terminal diol protection issues addressed attention was 
focused on synthesis of a cis-sylvaticin C3-C17 THF fragment. 
2.2 Synthesis  of  cis-Sylvaticin C3-C17 THF Fragment 
Oxidative Cyclisation Precursor 
Within the group synthesis of cis-THF diols through oxidative cyclisation of 
1,5-diene systems with permanganate is well established.
128,131,133 Initial goals 
were to convert chiral building block 2.5  to a suitable 1,5-diene for oxidative 
cyclisation.  
The synthesis began by alkylation of a 2-fold excess of lithiated alkyne 
2.15 with chiral building block 2.5 (scheme 2.5). Alkylation was achieved in good 
yield when HMPA was used as a co-solvent. Partial reduction of alkyne 2.16 
under an atmosphere of hydrogen in the presence of Lindlar catalyst gave cis-
alkene 2.17. Overexposure of the product to the reduction reaction conditions 
surprisingly gave what appeared to be isomerisation of the alkene bond, so care 
was taken to control the reaction time. 
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Scheme 2.5 Synthesis of 1,5-diene 2.20. Reagents and conditions: a) 2.15 (2 equiv.), n-BuLi, 
HMPA, THF, then 2.5; b) H2, Lindlar catalyst, quinoline, hexane; c) H2SO4:dioxane:H2O 
(1:49.5:49.5), ∆; d) (EtO)2POCH2COXR, DIPEA, LiCl, MeCN; e) TBSOTf, 2,6-lutidine, CH2Cl2.  
Acid hydrolysis of acetal 2.17 gave aldehyde 2.18 which was used crude in the 
next step. Initial attempts at hydrolysis of acetal 2.17 using aqueous acetic acid 
caused un-wanted acetylation. Olefination of crude aldehyde 2.18  with 
Oppolzer’s camphorsultam phosphonate under mild conditions described by 
Blanchette  et al. gave diene 2.19 in excellent yield.
141,142 Intermediate 2.19   60
presented an opportunity to protect the C4 hydroxyl, which was effected by   
silylation with TBSOTf to yield the oxidative cyclisation precursor 2.20.  
Permanganate Oxidative Cyclisation 
Permanganate oxidative cyclisation of diene 2.20 in a mixture of acetone 
and acetic acid delivered 3 main products (scheme 2.6).   
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Scheme 2.6 Oxidative cyclisation of diene 2.20. Reagents and conditions: a) KMnO4 (1.3 equiv), 
AcOH/acetone (1:4), –40 °C. 
The major distereoisomer was isolated in very good yield with the C12, C15, and 
C16 stereocentres correctly installed. The distereoselectivity was 9:1 in favour of 
the desired stereoisomer 2.21a.  
A possible mechanism for the oxidative cyclisation of 1,5 dienes by 
permanganate was proposed by Baldwin (figure 1).
112 Firstly the permanganate 
ion attacks the most electron deficient alkene in a [3+2] cycloaddition.  
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Figure 2.1 Baldwin’s proposed oxidative cyclisation mechanism. 
An excess of permanganate is thought to be required to oxidise the Mn(V) ion to 
the Mn(VI) ion where by a further [3+2] cycloaddition gives a manganese diester 
with addition of oxygen to one face of the diene. Hydrolysis of the manganese 
diester delivers the cis-THF diol.    61
It would seem likely that the distereoselectivity seen in the oxidative 
cyclisation of diene 2.20 is a case of preferential attack of the permanganate ion 
to one face of diene 2.20 governed by the proximate camphorsultam auxiliary. 
Under non-chelating conditions the diene may have a low energy reactive 
conformation shown in scheme 2.6. The low energy conformation shown has the 
favourable s-cis-arrangement between the C=O and C=C bonds, also dipolar 
interactions are minimised between SO2 and the carbonyl. In this conformation 
attack of permanganate from the bottom face is hindered by the sulfonyl oxygen 
making attack from the top face preferential.   
Completing the C3-C17 THF Fragment 
With major THF diol diastereoisomer 2.21a in hand, reductive cleavage in 
wet THF gave triol 2.23 (scheme 2.7). Selective mono tosylation of triol 2.23 via 
the dibutylstannylene acetal derivative, followed by base mediated ring closing 
substitution gave epoxide 2.24.
143 This was an ideal time to remove the free 
hydroxyl from the C11 position.  A radical deoxygenation via the 
thiocarbonylimidazole derivative 2.25 was planned. Previous work by Dr Kemp 
had found analogous chemistry to be unreliable. In the present case, formation of 
the thiocarbonylimidazole derivative 2.25 proceeded very cleanly and in 
reproducibly good yield.   
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Scheme 2.7 Synthesis of THF fragment 2.27. Reagents and conditions: a) NaBH4, THF/H2O; b) 
(i) Bn2SnO, benzene, ∆; (ii) TsCl, TBAB, 0 °C; c) K2CO3, MeOH; d) thiocarbonyldiimidazole, 
DMAP, CH2Cl2; e) TTMS, AIBN, toluene, 80 °C; f) Me3S
+I
–, n-BuLi, THF. 
Submission of thiocarbonate 2.25 to radical conditions resulted in highly efficient 
deoxygenation providing epoxide 2.26  in excellent yield. Fears over the 
sensitivity of an epoxide in the radical deoxygenation were unfounded and large 
amounts of thiocarbonate 2.25 were deoxygenated reliably. To complete the   62
synthesis terminal epoxide 2.26 was converted to allylic alcohol fragment 2.27 
using the trimethylsulfonium ylide. 
Conclusion   
-  Chiral building block 2.5  was efficiently converted to permanganate 
oxidative cyclisation precursor 2.20. 
-  Stereochemistry at C12, C15 and C16 correctly installed by 
stereocontrolled permanganate oxidative cyclisation of 1,5-diene 2.20. 
- THF  diol  2.21a was converted to allylic alcohol fragment 2.27, a key 
step was a radical deoxygenation at C11 position. 
-  Allylic alcohol fragment 2.27 was synthesised in 17 steps and a total 
yield of 20%, allowing for the first time synthesis of relatively large 
amounts of the fragment. 
2.3  Total Synthesis of cis-Sylvaticin 
Tethered RCM 
Central to our approach was adaptation of the work by the Evans group, 
where they utilised a silicon tethered RCM of two hetero-allylic alcohol fragments 
in their synthesis of mucocin (1.113).
98 Initial tethering experiments within our 
laboratory with suitable allylic alcohol fragments 1.276 and 1.277 showed the 
reaction to be unreliable and proceeded in generally poor yield. Extensive 
research by Dr L. Brown coupled the allylic alcohol fragments 1.276 and 2.27 
with a diisopropylsilyl tether in reliably good yield (scheme 2.8). An important 
experimental observation was that the initial coupling between fragment 1.276 
and diisopropylsilane dichloride was carried out at high concentration. This 
appeared to reduce the formation of hydrolysis and homodimerisation by-
products. Also, rigorously anhydrous conditions were necessary for high yields 
that included azeotropic drying of fragments 1.276 and 2.27 with benzene.   63
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Scheme 2.8 Synthesis of RCM product 2.29. Reagents and conditions: a) i-Pr2SiCl2, imidazole, 
CH2Cl2, then 2.27; b) G2 (10 mol %), toluene, 75 °C. 
Early work by Dr S. Kemp and Dr L. Brown had shown the RCM reaction 
of dienes 1.291 and 2.28 to be sluggish, requiring microwave heating at 100 °C 
and relatively high loading of Grubbs 2
nd generation catalyst. Catalyst loading 
was 20 mol % which was either added in 3 batches (10, 5 and 5 mol %) or 1 
batch (20 mol %). The RCM reactions did appear to be clean by TLC but 
attempts to optimise the reactions returned the RCM products in disappointing 
yields (25 – 50 %) and with poor mass recovery.  
At this stage, no improvement to the diene 2.28 synthsis was possible so 
to improve the RCM reaction focus turned to the RCM catalyst. For an efficient 
catalytic metathesis, rate of metathesis should be greater than the rate of catalyst 
decomposition. A decomposition pathway for Grubbs 2
nd generation catalyst is 
formation of a bimetallic hydride species, which has been shown to isomerise 
alkenes.
144 It would seem logical to suggest that catalyst decomposition to a 
destructive bimetallic hydride species may be a problem, although no direct 
evidence for the decomposition of the catalyst or diene 2.28 was collected. To 
suppress formation of the bimetallic species, Grubbs 2
nd generation catalyst 
concentrations and reaction temperatures were decreased. Under optimal 
conditions Grubbs 2
nd generation catalyst was added in 2 mol % batches, up to a 
total catalyst loading of 10 mol % returning RCM product 2.29 in very good yield 
with recovery of starting diene 2.28 (10%). Various ruthenium 1
st and 2
nd 
generation metathesis catalysts were tried and under the batch-wise addition 
conditions Grubbs 2
nd generation catalyst was found to be the best performing 
catalyst in terms of conversion. Under optimum conditions a direct comparison 
between Grubbs 2
nd generation catalyst and Grubbs-Hoyveda, showed Grubbs 
2
nd generation catalyst to give significantly higher conversions than Grubbs-
Hoyveda. With the higher activation energy of Grubbs-Hoyveda catalyst, higher   64
reaction temperatures and longer reaction times may have returned higher 
conversion for the RCM reaction.   
End Game 
The key decision to use benzyl alcohol in the kinetic resolution step was 
paying dividends, as debenzylation and reduction of the alkene could be done in 
one step (scheme 2.9). Exposure of RCM product 2.29 to a hydrogen 
atmosphere in the presence of a 5% Pd/C Degussa type catalyst delivered 
alcohol 2.30 in excellent yield, with rate of debenzylation appearing to be greater 
than the rate of alkene reduction by TLC. Importantly, the 5% Pd/C Degussa type 
catalyst is activated towards O-debenzylations. Initially, using a standard bench 
5% Pd/C catalyst selective reduction of the alkene was observed. Then 
debenzylation was achieved under a hydrogen atmosphere in the presence of 
Pd(OH)2/C. Attempts at a one step reduction/debenzylation of RCM product 2.29 
using Pd(OH)2/C failed to give any reaction.  
O O
H H
O MOMO
H H
O
7
OTBS H19C9
Si
i-Pr i-Pr
OH
O O
H H
O MOMO
H H
O
7
OTBS H19C9
Si
i-Pr i-Pr
OBn
O O
H H
O MOMO
H H
O
7
OTBS H19C9
Si
i-Pr i-Pr
OTf
O O
H H
O MOMO
H H
O
7
OTBS H19C9
Si
i-Pr i-Pr
O
PhS
O
2.31
2.29
2.32
2.30
a b
(95%) (99%)
c
(79%)
O
O
PhS 1.36
tBu
N
P
N
P(NMe2)3
N N P(NMe2)3 (Me2N)3P
= P4 Phosphazene base
 
Scheme 2.9 Synthesis of lactone 2.32. Reagents and conditions: a) H2, 5% Pd/C Degussa type 
E101 NO/W (15 Mol %), EtOAc; b) Tf2O, 2,6-lutidine, CH2Cl2; c) 1.36, P4-phosphazene base, 
THF, –78 °C, then 2.31. 
With all but one of the hydroxyls in THF ether 2.30 robustly protected, the 
free hydroxyl was then converted to triflate 2.31 which was used directly to 
alkylate lactone 1.36. Triflation of alcohol 2.30 proceeded in excellent yield but 
required freshly distilled triflic anhydride. Our plan was to alkylate White’s lactone 
1.36 with triflate 2.31 which would install the terminal lactone.
38 This is a common 
step in many Annonaceous acetogenin syntheses and is often reported in 
disappointing yield especially for complex examples analogous to triflate 2.31 
which has a C4 hydroxyl.
66,145 Previous work from Dr L. Brown had shown 
alkylation of the potassium enolate of lactone 1.36 with triflate 2.31 to be   65
extremely unreliable and poor yielding. The alkylation was slow but increasing 
the temperature caused decomposition of the enolate releasing thiophenoxide 
which reacted with triflate 2.31  to give a thioether by-product.  Successful 
alkylation was accomplished by deprotonation of lactone 1.36 with strong non-
nucleophilic nitrogen P4 phosphazene base. As the P4 phosphazene base has no 
counter ion, deprotonation of lactone 1.36  produces a ‘naked’ and reactive 
enolate. Experimental observations would agree with this as addition of triflate 
2.31 to P4 phosphazene deprotonated lactone 1.36 at –78 °C provides the 
alkylated product 2.32 as a mixture of diastereoisomers (dr 1:1) in good yield 
within 5 minutes. Importantly, P4 phosphazene base-mediated alkylation of 
lactone 1.36 with precious triflate 2.31 was also highly reproducible.  
 With  sulfide  2.32  in hand, an oxidation gave a sulfoxide intermediate 
which readily underwent thermal elimination to afford α,β-unsaturated lactone 
2.33 in excellent yield (scheme 2.10). Classically this type of elimination reaction 
requires significant heating, but for this example elimination occurred on removal 
of solvent on the rotary evaporator at ~ 40 °C.  
O O
H H
O MOMO
H H
O
7
OTBS H19C9
Si
i-Pr i-Pr
O
O O O
H H
HO HO
H H
OH
7
OH H19C9
O
O
(1.100) 2.33
b
(90%)
2.32
a
(93%)
1
37
35
4 12 23 15
 
Scheme 2.10 Synthesis of cis-sylvaticin (1.100). Reagents and conditions: a) m-CPBA, CH2Cl2; 
b) AcCl, MeOH, CH2Cl2. 
The final step was an acidic global deprotection which delivered cis-sylvaticn 
(1.100) in excellent yield. Spectroscopic data were in agreement with that 
published (table 2.1).
66 Noteably, 200 milligrams of this complex natural product 
was synthesised through the above route, which is testament to its efficiency.  
Carbon 
Natural
21              
Chemical shift (ppm)  
(125MHz, CDCl3) 
Donohoe
66          
Chemical shift (ppm)  
(125MHz, CDCl3) 
Our Synthetic   
Chemical shift (ppm)  
(100MHz, CDCl3) 
1 174.63  174.62  174.55 
35 151.81  151.82  151.74 
2 131.18  131.17  131.15 
23 82.99  82.99  82.96 
20 82.45  82.44  82.41 
15 82.08  82.09  82.12 
12 80.05  80.05  79.99 
36 77.97  77.99  77.92 
16 74.89  74.88  74.76   66
19 74.23  74.22  74.13 
24 72.51  72.47  72.41 
4 69.91  69.91  69.86 
5 37.38  37.38  37.37 
11 35.93  35.93  35.91 
3 33.32  33.32  33.29 
25 33.08  33.06  33.09 
37 19.11  19.12  19.08 
34 14.06  14.12  14.07 
Table 2.1 Comparision of carbon NMR data from our synthetic sample of cis-sylvaticin (1.110) 
with Donohoe’s synthetic and natural isolated samples. Carbons 6-10, 13, 14, 17, 18, 21, 22 and 
26–33 fall in the range 22.7–31.0 ppm and are unassigned.  
Conclusion 
-  A total synthesis of cis-sylvaticin (1.100) was completed in 24 steps 
and in 7.8% yield.  
-  The efficency of the synthesis was demonstrated through the 
production of more than 200 mg of cis-sylvaticin (1.100). 
Notable steps included the alcoholytic kinetic resolution of epoxide 2.2, two 
permanganate promoted oxidative cyclisation reactions, a tethered RCM to unite 
the two major fragments and the use of P4 phoshazene base to install the 
butenolide precursor. 
2.4 Abandoned Routes to a cis-Sylvaticin C3-C17 THF 
Fragment  
  A number of other approaches to the mono THF fragments were also 
investigated. For various reasons each of these routes were ultimately 
abandoned. Nonetheless, some important insight into oxidative cyclisation 
reactions was gained and these studies will be summerised in the ensuing 
sections. 
Terminal Enyne/Diene Approach 
Early strategies in the synthesis of a C3-C17 cis-sylvaticin fragment via 
permanganate oxidative cyclisation of 1,5-diene systems, required reductive 
cleavage of the chiral auxiliary after the oxidative cyclisation providing a terminal 
diol which was converted to an allylic alcohol in 3 steps (see scheme 2.7, steps   67
b, c and f). This approach was attractive due to high yields, but would require a 
radical deoxygenation at the C11 position. At the time, the radical deoxygenation 
reaction had proved to be somewhat capricious, althought this issue was later 
solved in our total synthesis. An alternative approach to the allylic alcohol 
fragment 2.27 was planned where oxidative cyclisation of triene 2.35 would give 
THF diol 2.34 more directly (scheme 2.11).  
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Scheme 2.11 Retrosynthetic analysis of C3-C17 fragment 2.27.  
With the allylic alcohol in place it was hoped that THF diol 2.34 could be 
converted to a suitable C3-C17 fragment without the need for a radical 
deoxygenation. Permanganate oxidative cyclisation of a 1,5,7-triene would also 
be novel, and the effect of the terminal diene would be intriguing. 
  The synthesis of triene 2.35 began by Claisen-Johnson rearrangement of 
commercially available penta-1,4-dien-3-ol (2.36) delivering ester 2.37 in good 
yield (E isomer only observed) (scheme 2.12).
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Scheme 2.12 Synthesis of triene 2.35.  Reagents and conditions: a) triethyl orthoacetate, 
propionic acid, ∆; b) LiAlH4, THF, 0 °C; c) DMSO, (COCl)2, Et3N, THF, –60 °C; d) 
(EtO)2POCH2COXS, DIPEA, LiCl, MeCN. 
Lithium aluminium hydride reduction of ester 2.37 returned alcohol 2.38 in 
modest yield. Swern oxidation gave a volatile aldehyde that underwent Horner-
Wadsworth-Emmons olefination under mild conditions providing triene 2.35 in 
reasonable yield.
142 The high volatility of triene 2.35 precursors was a problem 
throughout this route.  
 Permanganate  oxidative  cyclisation of triene 2.35 was studied (scheme 
2.13). Under typical conditions (table 2.1, entry 1), the oxidative cyclisation 
reaction proceeded cleanly providing THF diols 2.34a/b  as an inseparable 
mixture of distereoisomers (dr un-determined, typical dr 9:1) in poor yield. Along 
with poor yields there was poor mass recovery with no evidence of by-products.   68
It seemed logical to assume over oxidation had occurred generating highly polar 
water soluble intermediates and volatile by-products.   
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Scheme 2.13 Synthesis of THF diols 2.34a/b. Reagents and conditions: a) see table 2.1. 
Entry KMnO4 (eq)  PTC
a Solvent  Time 
(min) 
Temp. 
(°C)  Yield
b 
1 1.3 N  Acetone/AcOH  (3:2)  60  –30  22% 
2 1 N  Acetone/AcOH  (3:2)  30  –30  17% 
3 0.8 N  Acetone/AcOH  (3:2)  30  –30  11% 
4 1 Y  Acetone/AcOH  (3:2)  30  –40  9% 
5 1.4 N  Acetone/AcOH  (3:2)  60  –30  8% 
6 1.3 Y  CH2Cl2 30  –30  12% 
7 1.3 Y  CF3CH2OH 30  –30  0%
c 
8 1.3 Y  t-BuOH  30 30  0%
c 
9 0.8 Y  Et2O/H2O 75  –60  0%
c 
10 0.8  → 1.5  Y  EtOAc  145  –40  0% 
Table 2.2 Results for the oxidative cyclisation of triene 2.35 (see Scheme 2.13). 
a PTC used was 
adogen 464 (40 mol %); 
b Combined yield of THF diols 2.34a and 2.34b; 
c Starting material 
recovered. 
Initial attempts at optimisation focused on reducing the number of equivalents of 
permanganate and reaction times (table 2.1, entry 2,3), but this failed to give any 
advantage. Switching solvent systems and using a phase transfer catalyst was 
also disappointing. It was clear that the conjugated terminal alkene was causing 
significant problems in the oxidative cyclisation reaction, and optimisation to a 
suitable level would be a challenge. A solution was to substitute the terminal 
alkene for an alkyne. Results from our lab and the literature had shown the rate 
of reaction of permanganate with alkynes to be slower than alkenes.
132,147 
  The modified strategy began by lithiated TMS acetylene 1,2-addition to 
acrolein (2.39) furnishing allylic alcohol 2.40 (scheme 2.14).
148 Allylic alcohol 2.40 
was submitted to Claisen-Johnson rearrangement delivering esters 2.41a/b (E:Z 
18:1) and allene 2.42. Previous Claisen-Johnson rearrangement of allylic alcohol 
2.36 gave the E isomer only, Claisen-Johnson rearrangement of allylic alcohol 
2.40 delivered a mixture of E:Z  isomers. The lower stereoselectivity can be 
explained if you consider the reaction transition state. The Claisen-Johnson   69
rearrangement proceeds through a six member transition state. For allylic alcohol 
2.36 the sterically more demanding vinyl group would not favour the R
1 position 
in the transition state due unfavourable 1,3-diaxial interactions preventing Z 
alkene formation. For allylic alcohol 2.40, the less sterically demanding alkynyl 
group may occupy the R
1 position as there are reduced 1,3-diaxial interactions 
allowing formation of the Z isomer. 
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Scheme 2.14 Synthesis of alcohol 2.43a. Reagents and conditions: a) TMS acetylene, n-BuLi, 
THF, then 2.39; b) triethyl orthoacetate, propionic acid, ∆; c) DIBAL-H, THF, –50 °C. 
Esters 2.41a/b were obtained as an inseparable mixture by distillation, DIBAL-H 
reduction afforded alcohols 2.43a and 2.43b allowing separation by 
chromatography.  
 Swern  oxidation of alcohol 2.43a gave an aldehyde which underwent 
Horner-Wadsworth-Emmons olefination to provide dienyne 2.44  in reasonable 
yield (scheme 2.15). Desilylation of dienyne 2.44 afforded dienyne 2.45, which 
required addition of acetic acid to prevent decomposition. With dienyne’s 2.44 
and 2.45 in hand, their permanganate oxidative cyclisation was studied (table 2.2 
and 2.3). 
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Scheme 2.15 Oxidative cyclisation of dienyne systems.  Reagents and conditions: a) DMSO, 
(COCl)2, Et3N, THF, –60 °C; b) (EtO)2POCH2COXS, DIPEA, LiCl, MeCN; c) TBAF, AcOH, THF; d) 
see table 2.2 and 2.3. 
Under typical conditions (table 2.2, entry 1), the oxidative cyclisation of dienyne 
2.44 afforded THF diols 2.46a/b as an inseparable mixture of distereoisomers (dr   70
9:1 
13C NMR) in disappointing yield and mass recovery. Attempted optimisation 
focused on altering the co-solvent ratios and reaction times. No advantage was 
seen over the original conditions, but in general the yield of hydroxyl ketone 2.47 
was observed to be increased by decreasing the ratio of acetic acid. Oxidative 
cyclisation of dienyne 2.45 with the TMS group removed did not give any 
improvement (table 2.2, entry 10).  
Entry R  Solvent  Time 
(min)  Yield 2.46a/b  Yield 
2.47 
1 TMS  Acetone/AcOH  (3:2)
 a 30  41%  1% 
2 TMS  Acetone/AcOH  (4:1)
 a  30 33% 31% 
3 TMS  Acetone/AcOH  (3:2)
 a 15  39%  1% 
4 TMS  Acetone/AcOH  (3:2)
 a  5 17% 1% 
5 TMS  Acetone/AcOH  (6:5)
 a 10  33%  1% 
6 TMS  Aq  Acetone 
b 10  0%  27% 
7 TMS  Acetone/AcOH  (3:2)
 a 60  32%  9% 
8 TMS  Acetone/AcOH  (3:2)
 a  15 32% 24% 
9 TMS  Acetone/AcOH  (3:2)
 a  15 27% 22% 
10 H  Acetone/AcOH  (3:2)
 a 30  37%  1% 
Table 2.3 Results for the oxidative cyclisation of dienyne 2.44 and 2.45 (see scheme 2.15). 
a 
KMnO4 (1.3 eq.), –30 °C; 
b AcOH (5eq.) with phosphate buffer. 
Oxidative cyclisation of dienyne 2.44 was also attempted under PTC conditions 
(table 2.3). Oxidative cyclisation under bi-phasic conditions in dichloromethane 
(table 2.3 entry 1) gave THF diols 2.46a/b in poor yield.  
Entry  Solvent  AcOH (eq.)  Temp. (°C)  Yield 
2.46a/b 
Yield 
2.47 
1 CH2Cl2
a  6 0  7%  18% 
2 Diethyl  ether 
a  6 –50  → 25  1%  1% 
3 Diethyl  ether
 a,b 6  –50  → 25  1%  14% 
4 Diethyl  ether 
a  35 –50  → 25  10%  16% 
Table 2.4 Results for the solid-liquid phase transfer catalysed oxidative cyclisation of dienyne 
2.44. 
a adogen 464 (40 mol %), KMnO4 (2 eq.), 60 min; 
b H2O (10μL) added. 
Attempts at bi-phasic oxidative cyclisation in diethyl ether initially resulted in 
minimal consumption of dieyne 2.44, adding water or increased acetic acid gave   71
complete consumption of starting material but returned THF diols 2.46a/b in poor 
yield. 
To summarise, the triene/dienyne approach gave swift access to valuable 
intermediates. Unfortunately the approach suffered from poor yields for the 
oxidative cyclisation step and the resulting diastereoisomers could not be 
separated by MPLC. The oxidative cyclisation reaction of triene 2.35 and dienyne 
2.44 saw complete consumption of starting material in short reaction times but 
with poor mass recovery. The terminal alkene or alkyne prevented efficient 
oxidative cyclisation. It would seem logical to assume the major competing 
reactions were over oxidation with possible oxidative cleavage, providing a 
mixture of highly polar or volatile intermediates which were removed from the 
organic layer upon work up. Switching from a terminal alkene to a terminal alkyne 
did result in significant improvement in the oxidative cyclisation reaction yields. 
As previously stated permanganate has been shown to react with alkynes slower 
than alkenes, this effect has been shown to be important in the oxidative 
cyclisation of 1,5,7-triene relative to 1,5,7-dienynes. Optimisation of the oxidative 
cyclisation of triene 2.35 and dienyne 2.44 to a suitable level appeared unlikely, 
therefore this approach was considered impractical for the application towards a 
total synthesis of cis-sylvaticin. 
Conclusion 
- Oxidative  cyclisation of 1,5,7-triene 2.35 gave desired THF diols 
2.34a/b but in poor yield. 
-  Oxidative cyclisation of dieneyne 2.44 provided desired THF diols 
2.46a/b, showing improved efficiency relative to the triene oxidations. 
-  Due to poor yields in the permanganate oxidative cyclisation of 1,5,7-
triene  2.35 and dieneyne 2.44, neither were considered viable 
intermediates for the synthesis of cis-sylvaticin.  
Convergent Route 
A new convergent route was planned for the synthesis of THF fragment 
2.27, which entailed synthesising two main fragments 2.48 and 2.5  (scheme 
2.16).   72
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Scheme 2.16 Retrosynthetic analysis of THF fragment 2.27. 
Work on this approach was going to be carried out in collaboration with Dr L 
Brown. The synthesis began by olefination of commercially available pent-4-enal 
(2.49) under mild conditions furnishing dienoyl 2.50 in good yield (scheme 2.17). 
The stage was set for the oxidative cyclisation reaction.  
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Scheme 2.17 Synthesis of THF diol 2.48a.  Reagents and conditions: a) (EtO)2POCH2COXR, 
DIPEA, LiCl, MeCN; b) KMnO4 (1.3 equiv), AcOH/acetone (2:3), –40 °C. 
Pleasingly the oxidative cyclisation reaction of diene 2.50 gave THF diol 2.48a in 
good yield and diastereoselectivity (6:1). Elaboration of THF diol 2.48a was 
explored by Dr L Brown. 
  Elaboration of THF diol 2.48a by Dr L Brown began with a selective mono 
protection of the primary hydroxyl as its BOM ether, followed by a reductive 
cleavage to remove the chiral auxiliary affording diol 2.53 (scheme 2.18). 
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Scheme 2.18 Synthesis of aldehyde 2.55.  Reagents and conditions: a) BOMCl; b) NaBH4, 
THF/H2O; c) phosgene, CH2Cl2; d) H2, Pd/C; e) Dess-Martin periodinane, CH2Cl2. 
Conversion of diol 2.53 to a carbonate followed by cleavage of the BOM group 
delivered alcohol 2.54. The carbonate protection was chosen as it could be 
removed under basic conditions. It was hoped oxidation of alcohol 2.54 would 
give an aldehyde coupling partner. Unfortunately oxidation of alcohol 2.54 gave 
aldehyde  2.55  in poor yield. The oxidation was observed to initially proceed 
smoothly by TLC, but the product was unstable and decomposed. Efficient 
oxidation of a related THF system was shown by Donohoe.
66 In our case 
presence of the carbonate was thought to be responsible for the decomposition   73
of aldehyde 2.55. A modified protection group strategy was anticipated to 
overcome the un-reliable oxidation, but with the discovery of the efficient 
synthesis of benzyl ether 2.5 focus shifted to the route to THF fragment 2.27 that 
was ultimately successful.  
A Cross-Metathesis Approach to Diene Fragments 
Synthesis of fragment 2.27 via functionalised diene 2.20 was a desirable 
route. It was recognised that the trans enoyl system 2.20 could be constructed by 
cross-metathesis (CM) reaction (Scheme 2.19).  
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Scheme 2.19 Retrosynthetic analysis of THF fragment 2.27. 
Grubbs  et al had shown α,β-unsaturated amides and terminal olefins to be 
excellent CM partners.
149 Synthesis of N-propenoyl sultam 2.56 was carried out 
following work described by Kocienski et al (scheme 2.20).
150 Direct addition of 
(2R) camphor sultam 2.56 to acryloyl chloride provides the desired enoyl 2.58, 
but due to the enoyl sultam 2.58 having excellent Michael acceptor ability, further 
1,4-addition with (2R) camphor sultam 2.56 occurs returning enoyl sultam 2.58 in 
poor yield. 
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Scheme 2.20 Synthesis of N-propenoyl sultam 2.58. Reagents and conditions: a) TMSCl, Et3N, 
benzene, MeCN; b) acryloyl chloride, CuCl2, benzene, ∆, 16 h. 
Kocienski’s method prevented 1,4-addition by-product formation by firstly 
silylating (2R) camphor sultam 2.56, followed by a copper mediated in situ 
desilylation and acylation returning N-propenoyl sultam 2.58 in good yield. With 
N-propenoyl sultam 2.58 in hand, CM with various terminal olefins was studied 
(scheme 2.21).   74
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Scheme 2.21 Cross metatheses of N-propenoyl sultam 2.58 with terminal olefins. Reagents and 
conditions: a) Grubbs 2
nd generation catalyst (5 mol %), CH2Cl2. 
There were attempts to couple three terminal alkenes with N-propenoyl sultam 
2.58 by CM (entry 1-3, table 2.4), of these the best in terms of yield was silyl 
protected 4-penten-1-ol (entry 3, table 2.4).  
Entry R  Equiv. of terminal 
alkene  Conditions Yield 
1  CHO  1.25  40°C, 16 h  0% 
2  CH2OH  1.25  40°C, 16 h  ≈5% 
a 
3  CH2OTBS  1.25  40°C, 16 h  43% 
4  CH2OTBS  1.25  100°C, 1 h 
b  43% 
5  CH2OTBS  2  100°C, 1 h 
b 55% 
6  CH2OTBS  0.5  100°C, 1 h 
b 89% 
Table 2.5 CM of N-propenoyl sultam 2.58 with terminal olefins. 
a Yield estimated from the crude 
1H NMR spectrum 
b Microwave heating. 
Interestingly, a comparison between thermal heating and microwave heating 
(entry 3-4, table 2.4) showed no advantage with respect to yield of the product 
but did reduced reaction time considerably. Under optimum conditions a 2 fold 
excess of N-propenoyl sultam 2.58 was reacted with silyl protected 4-penten-1-ol 
(entry 6, table 2.4) which returned the CM product in excellent yield and E 
selectivity.  
  Attempts at CM between N-propenoyl sultam 2.58 and a functionalised 
1,5-diene system returning a suitable permanganate oxidative cyclisation 
precursor were unsuccessful. However, all of these reactions required significant 
amounts of the Grubbs 2
nd generation catalyst, even at 5 mol % loadings. Due to 
concerns relating to the economic viability of a CM so early in the synthesis, 
further studies were aborted.  
Enyne Epoxidation and Kinetic Resolution  
  Initially, the alkylation of chiral building block 2.5 with terminal alkyne 2.15 
gave some problems, which were later overcome. Therefore a modified route   75
which could still utilise the kinetic resolution chemistry was sought. Alkylation of 
bromide  2.1 with terminal alkyne 2.60 gave enyne 2.61  in reasonable yield 
(scheme 2.22)   
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Scheme 2.22 Synthesis of epoxide 2.62. Reagents and conditions: a) 2.60, n-BuLi, HMPA, THF, 
then 2.1; b) 0.068M DMDO in acetone. 
Next the epoxidation of enyne 2.61 was examined, using a dimethyldioxirane 
(DMDO) solution to deliver epoxide 2.62 in disappointing yield. Epoxidation of 
enyne  2.61  with  m-CPBA or DMDO returned two major by-products. 
Spectroscopic data suggested that the by-products were a α,β-unsaturated 
ketone and a ketone with a non-conjugated alkene. Independent work by Curci et 
al and Murray et al had shown alkynes to be oxidised by DMDO.
151,152 They both 
postulated one π-bond of an alkyne would form an unstable oxirene. Two 
postulated pathways are shown which give products consistent with the 
spectroscopic data (figure 2.2). 
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Figure 2.7 Proposed decomposition pathways. 
With epoxidation of enyne 2.61  proceeding with un-wanted oxidation of the 
alkyne, further optimisation was required. Work published by Mizuno et al 
reported a polyoxovanadometalate catalysed hydrogen peroxide 
epoxidation.
153,154  Interestingly the procedure was selective to terminal olefins 
over substituted olefins due to steric constraints of the polyoxovanadometalate 
catalyst. The polyoxovanadometalate catalyst ([(C4H9)4N]4[γ-1,2-
H2SiV2W10O40]·H2O) was synthesised in 3 steps from commercial available 
sodium metasilicate and sodium tungstate. (Equations 1-3).          76
 
11[WO4]
2- + [SiO3]
2- + 16H
+ + 8K
+ + 6H20 → K8[β2-SiW11O39]·14H2O   (1) 
[β2-SiW11O39]
8- + 2CO3
2- + 8K
+ + 13H2O  
→ K8[γ-SiW10O36]·12H2O + 2HCO3
- + [WO4]
2- ( 2) 
[γ-SiW10O36]
8- + 2[VO3]
- + 4[(C4H9)4N]
+ + 6H
+  
→ [(C4H9)4N]4[γ-1,2-H2SiV2W10O40]·H2O + H2O (3) 
 
Epoxidation of enyne 2.61  with the catalytic polyoxovanadometalate 
([(C4H9)4N]4[γ-1,2-H2SiV2W10O40]·H2O) did prevent the formation of by-products 
which were seen during DMDO and m-CPBA epoxidations. Unfortunately mass 
recovery was disappointing. Using 10 mol % polyoxovanadometalate and 
hydrogen peroxide (2 equiv), epoxide 2.62 was obtained in poor yield (30%) with 
recovery of starting olefin 2.61 (20%). 
The stage was set for the kinetic resolution of epoxide 2.62. Under 
analogous conditions to epoxide 2.2, kinetic resolution of epoxide 2.62  gave 
benzyl ether 2.63 in poor yield (ee not determined) and recovered epoxide 2.62 
(58%) (scheme 2.23). 
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Scheme 2.23 Synthesis of benzyl ether 2.63. Reagents and conditions: a) (S,S) 2.13 0.25 mol %, 
BnOH (0.45 equiv.), MeCN, 4 °C, 16h. 
Kinetic resolution of epoxide 2.62  proceeded with poor mass recovery in 
comparison to epoxide 2.2. No by-products were detected from the reaction so it 
is un-clear why mass recovery was poor. The presence of the alkyne and/or 
acetal would probably be an important factor to consider.   77
2.5  Approaches to Adjacent THP/THF and bis-THF 
Annonaceous Acetogenins via Cascade Oxidative Cyclisation 
Reactions  
A new approach in the synthesis of adjacent THP/THF and bis-THF 
Annonaceous acetogenins would be cascade oxidative cyclisation reaction with 
permanganate. The primary goal from this work was to construct valuable 
intermediates for the synthesis of (+)-muconin (2.64). The following section will 
discuss studies towards cascade oxidative cyclisation reactions. 
Synthesis of Adjacent THP/THF Annonaceous Acetogenin Core 
Synthesis of cis-THP diols by oxidative cyclisation of 1,6-dienes had been 
achieved by Brown and Cecil.
155 Yields and diastereoselectivities of cis-THP 
diols from oxidative cyclisation of 1,6-dienes were observed to be lower than for 
the analogous 1,5-dienes oxidative cyclisations providing cis-THF diols. Despite 
these limitations, oxidative cyclisation of 1,6-dienes is still a promising avenue for 
stereoselective synthesis of cis-THP diols. It was hoped that the cis-THP core of 
(+)-muconin (2.64) could be synthesised by oxidative cyclisation of 1,6-diene 
2.66 (scheme 2.24).
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Scheme 2.24 Retrosynthetic analysis of (+)-muconin (2.64). 
Our retrosynthetic analysis entailed construction of the central E-alkene by Julia-
Kocienski olefination, between aldehyde 2.67 and sulfone 2.68. 
  It was hoped that a permanganate oxidative cyclisation reaction of 1,6-
diene  2.66  would give a cis-THP diol, which under acidic conditions would 
provide triol 2.65 via an intramolecular cyclisation (figure 2.3).    78
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Figure 2.3 Cascade oxidative cyclisation approach. 
It is anticipated that triol 2.65 would be a valuable intermediate in the synthesis of 
(+)-mucocin (2.64).   
  Following work described by Maier, DIBAL-H reduction of ethyl 5-
bromopentanoate (2.69) providing aldehyde 2.70, which was converted to acetal 
2.71 in excellent yield (scheme 2.25).
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Scheme 2.25 Synthesis of sulfone 2.73. Reagents and conditions: a) DIBAL-H, toluene, –78 °C; 
b) ethylene glycol, p-TsOH, benzene, ∆; c)  1-phenyl-1H-tetrazole-5-thiol, K2CO3, acetone; d) 
[NH4]6Mo7O24•4H2O, 30% H2O2, EtOH. 
Under classical conditions nucleophilic substitution of bromide 2.71 with 1-
phenyl-1H-tetrazole-5-thiol followed by oxidation of sulfide 2.72 furnished sulfone 
2.73.
105 
The synthesis of two aldehydes that could be used in the Julia-Kocienski 
olefination reaction was explored. Synthesis of aldehyde 2.76 began by 
protection of propargylic alcohol as its tetrahydropyranyl ether 2.75  (scheme 
2.26).  
THPO
CHO
THPO HO
ab ,  c
(77%) (35%)
2.74 2.75 2.76  
Scheme 2.26 Synthesis of aldehyde 2.76. Reagents and conditions: a) DHP, PPTS, CH2Cl2; b) n-
BuLi, THF, –10 °C, then CuI•0.75 DMS, TMSI, –78 °C, then acrolein; c) K2CO3, MeOH, 0 °C. 
Under conditions described by Herczegh, 1,4-addition of terminal alkyne 2.75 to 
acrolein gave a silyl enol ether, which under basic conditions, furnished aldehyde 
2.76 in poor yield.
158    
 Synthesis  of  aldehyde  2.82 began by mono-protection of cis-butene-1,4-
diol (2.77) as its tetrahydropyranyl ether 2.78 (scheme 2.27). Alcohol 2.78 was   79
converted to chloride 2.79 which was used to alkylate diethyl malonate delivering 
malonate 2.80 but in rather poor yield.  
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Scheme 2.27 Synthesis of aldehyde 2.82.  Reagents and conditions: a) DHP, p-TsOH, 
CH2Cl2/THF (2:5); b) MsCl, DIPEA, CH2Cl2; c) diethyl malonate, NaH 60%, DMF, then 2.79; d) 
KOAc, DMSO/H2O (75:1) ∆; e) DIBAL-H, toluene, –78 °C. 
Malonate 2.80 was submitted to Krapcho decarboxylation which returned ester 
2.81, whereupon partial reduction with DIBAL-H gave aldehyde 2.82.
159 
 With  aldehydes  2.76, 2.82 and sulfone 2.73 in hand the Julia-Kocienski 
olefination was studied (scheme 2.28). The Julia-Kocienski olefination classically 
gives E alkenes. Selectivity for E alkenes in Julia-Kocienski olefinations can be 
increased by carrying out the reaction in polar solvents and using a base with a 
large counter-cation.
105 Initially, Julia-Kocienski olefination between 2.73 and 
2.76 in THF using KHMDS as the base gave alkene 2.83 as inseparable mixture 
of isomers in reasonable yield but poor selectively (E:Z 5:1). 
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Scheme 2.28 Synthesis of diene 2.84. Reagents and conditions: a) 2.73, KHMDS, DME, –55 °C, 
then 2.76; b) H2, Lindlar catalyst, quinoline, hexane; c) 2.73, KHMDS, DME, –55 °C, then 2.82. 
Repeating the Julia-Kocienski olefination between 2.73 and 2.76 in a more polar 
solvent such as DME gave an improvement in selectivity (E:Z 6:1). With alkyne 
2.83 in hand partial reduction gave diene 2.84 in respectable yield. Unfortunately 
repeating this reaction on a larger scale gave an inseparable mixture of over-
reduced and isomerised material. Julia-Kocienski olefination between 2.73 and 
2.82 under optimal conditions with respect to E selectivity gave diene 2.84 in very 
poor yield (E selectivity un-determined).   80
  Deprotection of allylic alcohol 2.84, followed by hydrolysis of the acetal 
gave an aldehyde which underwent olefination returning triene 2.85  in 
reasonable yield (scheme 2.29).
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Scheme 2.29 Synthesis of hydroxyl ketone 2.86. Reagents and conditions: a (i) p-TsOH, MeOH; 
(ii) H2SO4:dioxane:H2O (1:49.5:49.5), ∆; (iii) (EtO)2POCH2COXR, DIPEA, LiCl, MeCN; b) DET-(+), 
Ti(Oi-Pr)4, t-BuOOH, CH2Cl2; c) KMnO4 (1.3 equiv), AcOH/acetone (1:3), –40 °C. 
Sharpless asymmetric epoxidation of allylic alcohol 2.85 afforded epoxide 2.66 in 
disappointing yield (ee not determined, typical ee for cis allylic alcohol is between 
85 – 90%).
160 Attempted oxidative cyclisation of 1,6-dienoyl 2.66 failed to give the 
desired adjacent THF/THP core 2.65. In fact, the main product from the 
attempted oxidative cyclisation was hydroxyl ketone 2.86. It was clear that 
synthesis of a cis-THP diol by permanganate oxidative cyclisation would require 
optimisation. Due to time and material constraints the permanganate oxidative 
cyclisation of 1,6-diene 2.66 was not studied further. To test the cascade 
oxidative cyclisation approach, efforts were concentrated on synthesis of bis-THF 
structures. The main advantage was that key oxidative cyclisation reaction of a 
1,5-diene system was expected to proceed with greater efficiency.  
Conclusion 
-  A triene was successfully constructed using Julia-Kocienski olefination, 
albeit in disappointing E selectivity.  
-  Attempted cascade oxidative cyclisation of 1,6-diene 2.66  was 
unsuccessful in delivering an adjacent THP-THF core.  
Synthesis of Adjacent bis-THF Annonaceous Acetogenin Core 
There are over 100 examples of Annonaceous acetogenins with adjacent 
bis-THF cores.
2 Our cascade oxidative cyclisation approach would give relatively 
short access to triol 2.90 (figure 2.4).    81
H+
HO O XR
HO
O
OH
H H H
XR
O
HO
O
O O O XR HO
O
OH HO
H H H H
O O
C10H21
OH HO
H H H H
OH
O
O
9
Trilobacin (2.91)
2.89 2.90
 
Figure 2.4 Cascade oxidative cyclisation approach. 
Triol 2.90 has a bis-THF core with identical relative stereochemistry to trilobacin 
(2.91).
161,162 Successful cascade oxidative cyclisation of modified diene systems 
would give intermediates with relative and absolute stereochemistry matching 
many adjacent bis-THF Annonaceous acetogenins.  
  Our plan was to synthesis diene 2.89 via a 1,5-hexadienyne intermediate 
2.92 (scheme 2.30).  
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Scheme 2.30 Retrosynthetic analysis of dienoyl 2.89. 
  Initial work focused on building a 1,5-hexadienyne by alkylation. Lithiated 
alkyne  2.75 in a THF/HMPA co-solvent opened ethylene oxide in reasonable 
yield (scheme 2.31).    
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Scheme 2.31 Synthesis of bromide 2.94. Reagents and conditions: a) n-BuLi, HMPA, THF/Et2O 
(1:2), then ethylene oxide; b) CBr4, PPh3, pyridine, CH2Cl2; c) 2.15, n-BuLi, HMPA, THF, then 
2.94. 
Free hydroxyl 2.93 was efficiently converted to its corresponding bromide 2.94 
which set the scene for alkylation. Unfortunately, attempted alkylation of lithiated 
alkyne 2.15 with bromide 2.94 failed to give acetal 2.95. The favoured pathway 
was elimination of HBr resulting in a conjugated enyne, a pathway that would be 
difficult to suppress. Therefore, an alternative route was explored. 
 Bromination  of  1,5-hexadiene (2.96) delivered tetrabromide 2.98 in good 
yield (scheme 2.32). Treatment of tetrabromide 2.98 with LDA (6 equiv.) would   82
return lithiated 1,5-hexadienyne, allowing electrophile trapping. Initial 
experiments focussed on protonation of the expected dianion intermediate, but 
subsequent purification of 1,5-hexadienyne was unsuccessful. Secondly, mono 
alkylation was attempted using bromide 2.97 (1 equiv.) as the trapping 
electrophile which would provide alkyne 2.101. Unfortunately alkylation was 
unsuccessful with HBr elimination from electrophile 2.97 a preferred pathway. 
Successful trapping was eventually achieved using TMSCl as the electrophile 
affording silane 2.99 in reasonable yield.  
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Scheme 2.32 Synthesis of acetal 2.101. Reagents and conditions: a) Br2, CH2Cl2; b) LDA, THF, –
78 °C, then TMSCl; c) MeLi•LiBr, THF, –78 °C, then HMPA, 2.97; d) K2CO3, MeOH. 
Desymmetrisation of silane 2.99 was accomplished by selective desilylation, 
using MeLi•LiBr complex (1.5 equiv.) followed by alkylation with bromide 2.97 to 
provide silyl alkyne 2.100 in poor yield.
163 Efficient desilylation of silane 2.100 
returned alkyne 2.101.   
   Mono  lithiated alkyne 2.101  was reacted with an excess of 
paraformaldehyde affording propargylic alcohol 2.92 in excellent yield (scheme 
2.33). Partial reduction of dialkyne 2.92 under a hydrogen atmosphere using 
Lindlar catalyst gave Z,Z diene 2.102 in reasonable yield. Unfortunately, 
repeating this reaction on a larger scale successfully reduced the alkyne bonds 
but caused isomerisation of the alkenes to give a mixture of isomeric dienes.   
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Scheme 2.33 Synthesis of dienoyl 2.89. Reagents and conditions: a) n-BuLi, THF,  –78 °C, then 
paraformaldehyde; b) H2, Lindlar catalyst, quinoline, EtOAc; c) (i) H2SO4:dioxane:H2O 
(1:49.5:49.5), ∆; (ii) (EtO)2POCH2COXR, DIPEA, LiCl, MeCN; d) DET-(+), Ti(Oi-Pr)4, t-BuOOH, 
CH2Cl2.   83
Acid hydrolysis of acetal 2.102 provided an aldehyde which under went HWE 
olefination returning triene 2.103 in disappointing yield.
142 Allylic alcohol 2.103 
was submitted to Sharpless asymmetric epoxidation furnishing epoxide 2.89 in 
satisfactory yield (ee not determined, typical ee for cis allylic alcohol is between 
85 – 90%).
160  
With epoxydiene 2.89 in hand the key cascade oxidative cyclisation was 
studied (scheme 2.34). Oxidative cyclisation of epoxydiene 2.89 would give 2 
possible diastereoisomers from attack of permanganate from either face. 
Therefore triols 2.90a/b would be the expected major products from cascade 
oxidative cyclisation if you do not consider the epoxide isomers.  
O O XR HO
O
OH HO
H H H H
XR
O
HO
O
O O XR HO
O
OH HO
H H H H
+
a
(45%)
2.89 2.90a 2.90b  
Scheme 2.34 Synthesis of triol 2.90a/b.  Reagents and conditions: a) KMnO4 (1.3 equiv), 
AcOH/acetone (1:3), –40 °C. 
A one-off oxidative cyclisation of epoxydiene 2.89  gave triols 2.90a/b in a 
combined yield of 45%. Diastereoselectivity for the reaction is undetermined, with 
relative and absolute stereochemistry tentatively assigned. Due to time and 
material constraints no further study was possible, but the cascade oxidative 
cyclisation concept appears to provide a viable route to adjacent bis-THF core 
motifs. 
Conclusion 
- Silane  2.99 was successfully desymmetrised by a selective 
desilylation-alkylation procedure.  
-  Cascade oxidative cyclisation of diene 2.89 was achieved delivering 
adjacent bis-THF triols 2.90a/b. 
Future work 
Initially, the cascade oxidative cyclisation of epoxydiene 2.89 would need 
to be repeated on a larger scale, so diastereoselectivities and ring 
stereochemistry could be confirmed. A problem with the routes shown in section 
2.5 is the Sharpless asymmetric epoxidation of the cis-allylic alcohols, as typical 
enantioselectivity’s  are between 80-90%.
160 A possible solution would be to   84
follow work by Yamamoto, where a vanadium asymmetric epoxidation of cis-
homoallylic alcohols proceeds with excellent enantioselectivity.
164 
A more ambitious plan assuming that all aspects of the permanganate 
cascade oxidative cyclisation are satisfactory would be to again apply it to the 
synthesis of (+)-muconin (2.64). A study of the oxidative cyclisation of 1,6-dienes 
with permanganate would be required to improve our knowledge of the reaction. 
Armed with this extra knowledge, it would be hoped that cascade oxidative 
cyclisation of a suitable diene epoxide with permanganate would give the 
adjacent THP-THF core, with relative and absolute stereochemistry identical to 
(+)-muconin (2.64). From this point no major obstacles are foreseen in the total 
synthesis of (+)-muconin (2.64).     85
Chapter 3: Experimental 
General procedures 
All reactions which were air and/or moisture sensitive were run under an inert 
atmosphere of either argon or nitrogen using oven-dried glassware. THF was 
distilled over Na/benzophenone, dichloromethane was distilled over CaH2, 
benzene and toluene were distilled over sodium prior to use. All other solvents 
and reagents were purified according to standard procedures.
165 Thin-layer 
chromatography was carried out on Merck silica gel aluminium-backed plates 
with a fluoresence indicator (254 nm). Visualisation of TLC plates was carried out 
by UV light,  then by either a cerium sulphate/ammonium molybdate or KMnO4 
stain. Flash chromatography was preformed with 35–70 μm silica gel (Fisher 
Davisil). Infrared spectra were recorded using a FTIR spectrometer fitted with an 
ATR accessory. Absorption peaks were recorded in cm
-1 and were described as 
strong (s), medium (m), weak (w) or broad (br). 
1H NMR and 
13C NMR were 
recorded using a Bruker AC300 or AV300 (at 300 and 75 MHz) or a Bruker 
DPX400 (400 and 100 MHz) in CDCl3 with chloroform (7.27 ppm 
1H, 77.0 ppm 
13C) or in C6D6 with benzene (7.16 ppm 
1H, 128.4 ppm 
13C) or (CD3)2SO with 
DMSO (2.50 ppm 
1H, 39.5 ppm 
13C) as an internal reference. Chemical shifts δ 
are given in ppm; multiplicities are indicated as s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet), and br (broad); coupling constants, J, are reported in Hz. 
Proton assignments have been made using a combination of 1D and 2D 
experiments. Low resolution mass spectra using electrospray ionisation (ESI) 
were recorded on a Fisons VG platform single quadrupole mass spectrometer. 
Chiral analytical HPLC was preformed on a HP1090 series LC system with 
Chiralcel OD-H column with 254 nm detection, eluting with IPA/hexane mixtures.   86
2-(6-Bromohexyl)oxirane (2.2) 
6
Br
O C8H15BrO
Exact Mass: 206.0306
Mol. Wt.: 207.1081
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At room temperature under an atmosphere of N2, to a vigorously stirred solution 
of 8-bromooct-1-ene (9.49 g, 0.0497 mol), pyrazole (0.46 g, 5.96 mmol) and 
methyltrioxorhenium (61.9 mg, 0.248 mmol) in CH2Cl2 (23.5 mL) was added 
dropwise 30% H2O2 aq (8.45 g, 0.0746 mol), the reaction was stirred for 24 
hours. MnO2 was carefully added and reaction was diluted with CH2Cl2 (75 mL) 
and water (75 mL), the organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 75 mL). The combined organic phases were dried 
(Na2SO4) and concentrated in vacuo to afford a colourless oil. Purification on 
SiO2 (8 x 4 cm) eluting with hexane/Et2O (9:1) gave 2-(6-bromohexyl)oxirane 
(2.2) (10.1 g, 0.0493 mol, 98%) as a colourless oil.  
Spectroscopic characterisation agreed with that published.
135 
IR max (neat) cm
-1 3044 (w), 2931 (s), 2857 (s). 
1H NMR (300 MHz, CDCl3)  3.40 (2H, t, J = 6.8 Hz, C8), 2.94 – 2.83 (1H, m, 
C2), 2.74 (1H, dd, J = 5.0, 4.0 Hz, C1), 2.46 (1H, dd, J = 5.0, 2.7 Hz, C1), 1.85 
(2H, tt, J = 7.0, 6.8 Hz, C7), 1.59 – 1.31  (8H, m, C3 – C6).  
13C NMR (75 MHz, CDCl3)  52.4 (CH1), 47.2 (CH2), 34.0 (CH2), 32.8 (CH2), 32.5 
(CH2), 28.7 (CH2), 28.2 (CH2), 26.0 (CH2). 
3-tert-Butyl-2,5-dihydroxybenzaldehyde (2.8) 
OH
OH
t-Bu CHO C11H14O3
Exact Mass: 194.0943
Mol. Wt.: 194.2271
1
3 5
 
At room temperature under an atmosphere of N2, to a stirred solution of tert-butyl 
hydroquinone (50 g, 0.300 mol), DMAP (4.41 g, 0.036 mol) and imidazole (25.6 
g, 0.380 mol) in CH2Cl2 (300 mL) was added dropwise TIPSCl (59.3 g, 65.8 mL, 
0.308 mol). The reaction was stirred for 3 hours and poured into NH4Cl (sat aq, 
300 mL). The organic layer was separated, washed with brine, dried over   87
(MgSO4) and concentrated in vacuo to afford 2-(1,1-dimethylethyl)-4-
(triisopropylsilyloxy)phenol as a viscous yellow oil. 
  
At 0 °C under an atmosphere of N2, to a stirred solution of crude 2-(1,1-
dimethylethyl)-4-(triisopropylsilyloxy)phenol, toluene (700 mL) and 2,6-lutidine 
(57.3 mL, 0.492 mol) was added SnCl4 (14.2 mL, 0.120 mol) dropwise. The 
reaction was warmed to room temperature and stirred for 20 minutes then 
paraformaldehyde (55 g, 1.83 mol) was added. The reaction was heated at 100 
°C for 12 hours then cooled to room temperature. 1M HCl (500 mL) was added 
and the mixture was filtered through a pad of Celite. The collected solids were 
washed with EtOAc (500 mL). The filtrates were combined, washed with brine, 
dried over (MgSO4) and concentrated in vacuo to afford a dark oil which was 
dissolved in THF (800 mL). Under an atmosphere of N2, the solution was cooled 
to –78 °C and 1M TBAF in THF (360 mL, 0.36 mol) was added. The reaction was 
warmed to room temperature and stirred for 2 hours. The reaction was diluted 
with water (800 mL) and EtOAc (800 mL). The organic layer was separated, 
washed with brine, dried over (MgSO4) and concentrated in vacuo to afford a 
dark solid. The dark solid was suspended in CH2Cl2, filtered and washed with 
cold CH2Cl2 providing 3-tert-butyl-2,5-dihydroxybenzaldehyde (2.8) (34.9 g, 0.18 
mol, 60% yield, over 3 steps) as a yellow powder. 
Spectroscopic characterisation agreed with that published.
138 
IR max (neat) cm
-1 3329 (s), 2960 (m), 1645 (s), 1587 (s), 1297 (s). 
1H NMR (300 MHz, DMSO-d6)  11.37 – 11.14 (1H, m, OH), 9.97 – 9.77 (1H, m, 
CHO), 9.26 (1H, m, OH), 7.04 (1H, m, C3), 6.95 (1H, m, C5), 1.34 (9H, s, t-Bu). 
13C NMR (75 MHz, DMSO-d6)  198.2 (CH1), 153.0 (C), 149.6 (C), 138.4 (C), 
122.8 (CH1), 120.7 (C), 115.3 (CH1), 34.4 (C), 29.0 (CH3).   88
bis(3-tert-Butyl-5-formyl-4-hydroxyphenyl) heptanedioate (2.10) 
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At 0 °C under an atmosphere of N2, to a stirred solution of 3-tert-butyl-2,5-
dihydroxybenzaldehyde (2.8)  (5.57 g, 28.7 mmol), DMAP (0.34 g, 2.8 mmol), 
pimelic acid (2.24 g, 14 mmol) in CH2Cl2 (27 mL) and DMF (2 mL) was added 
1,3-diisopropylcarbodiimide (4.60 mL, 29.4 mmol). The reaction was stirred at 0 
°C for 5 minutes and at room temperature for 2 hours. The reaction was diluted 
with CH2Cl2 (150 mL), and washed with 0.1 M HCl (150 mL) and brine (150 mL). 
The organic phase were dried (Na2SO4) and concentrated in vacuo. The resulting 
residue was suspended in hexanes (200 mL), filtered and washed with 2% 
K2CO3 (4 x aq 50 mL). The organic phase was dried (Na2SO4) and concentrated 
in vacuo to provide bis(3-tert-butyl-5-formyl-4-hydroxyphenyl) heptanedioate 
(2.10) (7.11 g, 13.9 mmol, 99%) as a yellow oil.  
Spectroscopic characterisation agreed with that published.
138 
IR max (neat) cm
-1 2958 (m), 1755 (s), 1652 (s). 
1H NMR (300 MHz, CDCl3)  11.71 (2H, s, OH), 9.81 (2H, s, CHO), 7.21 (2H, d, J 
= 2.8 Hz, C5), 7.18 (2H, d, J = 2.8 Hz, C3), 2.63 (4H, t, J = 7.5 Hz, C8), 1.85 (4H, 
quin, J = 7.5 Hz, C9), 1.64 – 1.51 (2H, m, C10), 1.44 – 1.36  (18H, s, t-Bu). 
13C NMR (75 MHz, CDCl3)  196.5 (CH1), 172.4 (C), 159.1 (C), 142.5 (C), 140.3 
(C), 128.1 (CH1), 123.3 (CH1), 120.2 (C), 35.2 (C), 34.1 (CH2), 29.2 (CH3), 28.6 
(CH2), 24.6 (CH2).   89
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Under an atmosphere of N2, a solution of (S,S)-1,2-
diammoniumcyclohexanemono-(–)-tartrate salt (1.75 g, 6.59 mmol), K2CO3 (1.84 
g, 13.32 mmol) in THF (22 mL) and water (8.2 mL) were heated to reflux. 
Dialdehyde 2.10 (3.41 g, 6.66 mmol) in THF (22 mL) was added and the reaction 
was stirred at reflux for 2 hours, then cooled to room temperature and diluted 
with EtOAc (100 mL). The organic layer was separated, washed with brine, dried 
(Na2SO4) and concentrated in vacuo to afford oligomeric salen ligand 2.12 (3.88 
g, 99%) as a yellow solid. 
Spectroscopic characterisation agreed with that published.
138 
IR max (neat) cm
-1 2931 (s), 2860 (s), 1755 (s), 1632 (s), 1593 (m). 
1H NMR (300 MHz, CDCl3)  13.77 (2H, br s, OH), 8.24 (2H, s, C11), 6.94 (2H, d, 
J = 2.7 Hz, C2), 6.78 (2H, d, J = 2.7 Hz, C4), 3.32 (2H, m, C12), 2.54 (4H, t, J = 
7.4 Hz, C8), 2.02 – 1.62 (8H, m, C9 and C13), 1.62 – 1.23 (24H, m, C10, C14 
and t-Bu). 
13C NMR (75 MHz, CDCl3)  172.6 (C), 164.9 (CH1), 158.2 (C), 141.7 (C), 138.8 
(C), 123.1 (CH1), 121.5 (CH1), 118.3 (C), 72.4 (CH1), 35.1 (C), 34.2 (CH2), 33.2 
(CH2), 29.3 (CH3), 28.7 (CH2), 24.7 (CH2), 24.4 (CH2).   90
Oligomeric Co(salen) catalyst 2.13 
O
O
O
t-Bu
t-Bu
O
O
O
O
t-Bu
t-Bu
N N
N N
Co
Co
nbs
O O
O O
O
n = 1-3
nbs
 
At room temperature under an atmosphere of N2, to a stirred degassed solution 
of oligomeric salen ligand 2.10 (0.390 g, 0.66 mmol) in toluene (7 mL) was added 
a degassed solution of Co(OAc)2•2H2O (0.329 g, 1.32 mmol) in MeOH (7 mL) via 
canula. The reaction was stirred for 30 minutes where 3-nitrobenzenesulfonic 
acid mono hydrate (0.291 g, 1.32 mmol) in CH2Cl2 (10 mL) were added. The 
reaction was stirred open to the air for 2 hours. The reaction was concentrated in 
vacuo to afford a brown residue which was suspended in CH2Cl2. The 
suspension was filtered through a pad of celite to remove excess Co(OAc)2 and 
the celite was washed with CH2Cl2 (500 mL). The filtrate was concentrated in 
vacuo to afford the oligomeric Co(salen) catalyst 2.13  (474 mg, 0.528 mmol, 
80%) as a black solid which was used crude in the next step. 
(R)-1-(Benzyloxy)-8-bromooctan-2-ol (2.5) 
6
Br
OH
O
C15H23BrO2
Exact Mass: 314.0881
Mol. Wt.: 315.2459
1
4
7
 
At 0 °C under an atmosphere of Ar, to a stirred solution of 2-(6-
bromohexyl)oxirane (9.5 g, 0.0458 mol) and oligomeric Co(salen) (S,S) 2.13 (106 
mg, 0.118 mmol) in MeCN (3.5 mL) was added dropwise benzyl alcohol (2.14 
mL, 0.0206 mol), the reaction was stirred for 24 hours. The reaction was filtered 
through a plug of silica with Et2O (300 mL) and concentrated in vacuo to afford 
an orange oil. Purification on SiO2 (8 x 10 cm) eluting with hexane/Et2O (4:1)   91
then hexane/Et2O (0:1) gave enantiometrically enriched (S)-2-(6-
bromohexyl)oxirane (2.2) (4.82 g, 0.0233 mol) as a colourless oil and (R)-1-
(benzyloxy)-8-bromooctan-2-ol (2.5) (6.5 g, 0.0206 mol, 99%) as a orange oil. 
[α]
25
D  –1.1 (CHCl3, c 1.4). 
IR max (neat) cm
-1 3447 (br), 2931 (m), 2856 (m). 
1H NMR (400 MHz, CDCl3)  7.44 – 7.20 (5H, m, C1, C2 and C3), 4.57 (2H, s, 
C5), 3.87 – 3.76 (1H, m, C7), 3.51 (1H, dd, J = 9.4, 3.1 Hz, C6(1H)), 3.41 (2H, t, 
J = 6.8 Hz, C13), 3.34 (1H, dd, J = 9.4, 7.9 Hz, C6(1H)), 2.37 (1H, d, J = 2.9 Hz, 
OH), 1.86 (2H, br p, J = 7.1 Hz, C12), 1.51 – 1.31 (8H, m, C8 – C11).  
13C NMR
 (100 MHz, CDCl3)  138.12 (C), 128.6 (CH1), 128.0 (CH1), 127.9 (CH1), 
74.8 (CH2), 73.5 (CH2), 70.5 (CH1), 34.0 (CH2), 33.2 (CH2), 32.9 (CH2), 28.9 
(CH2), 28.2 (CH2), 25.5 (CH2). 
LRMS  ESI+  337 [M+Na]
+ (100%), 339 [M+Na]
+ (83%).   
HRMS ESI+ [M+Na]
+ calculated = 337.0774, [M+Na]
+ found = 337.0770. 
(S)-1-(Benzyloxy)-8-bromooctan-2-ol (ent-2.5) 
6
Br
OH
O
C15H23BrO2
Exact Mass: 314.0881
Mol. Wt.: 315.2459
1
4
7
 
At 0 °C under an atmosphere of Ar, to a stirred solution of enantiometrically 
enriched (S)-2-(6-bromohexyl)oxirane (4.75 g, 0.0229 mol) and oligomeric 
Co(salen) (R,R) (51 mg, 0.057 mmol) in MeCN (1.75 mL) was added dropwise 
benzyl alcohol (2.14 mL, 0.0206 mol), the reaction was stirred for 24 hours. The 
reaction was filtered through a plug of silica with Et2O (250 mL) and concentrated 
in vacuo to afford an orange oil. Purification on SiO2 (11 x 5 cm) eluting with 
hexane/Et2O (4:1) then hexane/Et2O (1:3) gave 2-(6-bromohexyl)oxirane (2.2) 
(0.375 g, 1.81 mmol, 8%) as a colourless oil and (S)-1-(benzyloxy)-8-
bromooctan-2-ol (ent-2.5) (6.47 g, 0.0206 mol, 99%) as an orange oil. 
Spectroscopic characterisation for benzyl ether ent-2.5 identical to benzyl ether 
2.5 except for the shown data.   92
[α]
25
D  +4.4 (CHCl3, c 0.94). 
(R)-1-(Benzyloxy)-8-bromooctan-2-yl 4-nitrobenzoate (2.14) 
4
O
O
1
4
7
O
Br
14
8
18
NO2
C22H26BrNO5
Exact Mass: 463.0994
Mol. Wt.: 464.3495
 
At –30 °C under an atmosphere of N2, to a stirred solution of (S)-1-(benzyloxy)-8-
bromooctan-2-ol  (ent-2.5) (6.90 g, 0.0219 mol), triphenyl phosphine (11.8 g, 
0.0449 mol) and 4-nitrobenzoic acid (12.8 g, 0.0767 mol) in dry THF (74 mL) was 
added dropwise DIAD 95% (9.08 mL, 0.0438 mol). The reaction was allowed to 
warm to room temperature over 2 hours and stirred for a further 2 hours. The 
reaction was concentrated in vacuo to afford a yellow oil. Purification on SiO2 (10 
x 10 cm) eluting with hexane/Et2O (9:1 → 4:1) gave (R)-1-(benzyloxy)-8-
bromooctan-2-yl 4-nitrobenzoate (2.14) (8.83 g, 0.019 mol, 87%) as a pale yellow 
oil. 
[α]
29
D  +11.6 (CHCl3, c 1.13). 
IR max (neat) cm
-1 2933 (m), 2858 (m), 1721 (s), 1526 (s), 1348 (m), 1271 (s). 
1H NMR (300 MHz, CDCl3)  8.30 (2H, d with fine splitting, J = 9.0 Hz,  C17), 
8.15 (2H, d with fine splitting, J = 9.0 Hz,  C16), 7.37 – 7.23 (5H, m, C1 – C3), 
5.35 (1H, br p, J = 5.3 Hz,  C7), 4.61 (1H, d, J = 12.3 Hz,  C5), 4.53 (1H, d, J = 
12.3 Hz,  C5), 3.67 (2H, d, J = 4.9 Hz, C6), 3.39 (2H, t, J = 6.8 Hz, C13), 1.81 
(4H, m, C8 and C12), 1.43 (6H, m, C9 – C11). 
13C NMR (75 MHz, CDCl3)  164.7 (C), 150.9 (C), 138.2 (C), 136.2 (C), 131.1 
(CH1), 128.7 (CH1), 128.1 (CH1), 127.9 (CH1), 123.8 (CH1) 74.9 (CH1), 73.5 (CH2) 
71.3 (CH2), 34.1 (CH2) 32.9 (CH2) 31.1 (CH2), 28.9 (CH2), 28.3 (CH2), 25.4 (CH2). 
LRMS  ESI+  488 [M+Na]
+ (100%), 486 [M+Na]
+ (93%).     
HRMS ESI+ [M+Na]
+ calculated = 486.0887, [M+Na]
+ found = 486.0884.   93
2-(But-3-ynyl)-1,3-dioxane (2.15) 
O
O
1
5 6
6
C8H12O2
Exact Mass: 140.0837
Mol. Wt.: 140.1797
 
At 0 °C under an atmosphere of N2, to a stirred solution of 2-(2-bromoethyl)-1,3-
dioxane (33.4 mL, 0.245 mol), distilled TMEDA (33.5 mL, 0.49 mol) in dry THF 
(500 mL) was added portionwise lithium acetylide ethylene diamine complex 90% 
(50 g, 0.49 mol) followed by dropwise addition of HMPA (42.6 mL, 0.245 mol), 
the reaction was allowed to warm to room temperature and stirred for 24 hours 
(Reaction monitored by GC). Reaction was slowly poured into NH4Cl (sat aq, 400 
mL), the organic layer was separated and the aqueous layer was extracted with 
Et2O (3 x 200 mL). The combined organic phases were washed with water (300 
mL). The organic phase was dried (MgSO4) and concentrated in vacuo to afford 
crude brown oil. Purification by distillation under reduced pressure (59–61 °C, 9 
mbar) gave 2-(but-3-ynyl)-1,3-dioxane (2.15) as a colourless oil (25.0g, 0.179 
mol, 73%). 
IR max (neat) cm
-1 3291 (m), 2966 (s), 2852 (s), 2118 (w), 1135 (s). 
1H NMR (300 MHz, CDCl3)  4.66 (1H, t, J = 5.2 Hz, C5), 4.11 (2H, dd, J = 10.6, 
5.1 Hz, C6
eq), 3.78 (2H, m, C6
ax), 2.30 (2H, td, J = 7.4, 2.6 Hz, C3), 2.07 (1H, dtt, 
J = 13.4, 12.5, 5.1 Hz, C7
ax), 1.94  (1H, t, J = 2.6 Hz, C1), 1.81 (2H, td, J = 7.4, 
5.2 Hz, C4), 1.35 (1H, d with fine splitting, J = 13.4 Hz, C7
eq).
 
13C NMR (75 MHz, CDCl3)  100.6 (CH1), 83.8 (CH1) 68.3 (C), 66.9 (CH2) 33.8 
(CH2), 25.8 (CH2) 13.2 (CH2). 
(R)-1-(Benzyloxy)-12-(1,3-dioxan-2-yl)dodec-9-yn-2-ol (2.16) 
O
O
18 19
19
5
OH
O 7
4
1
C23H34O4
Exact Mass: 374.2457
Mol. Wt.: 374.5137
 
At –78 °C under an atmosphere of Ar, to a stirred solution of 2-(but-3-ynyl)-1,3-
dioxane (2.15) (4.83 g, 0.0345 mol) in dry THF (42 mL) was added 2.11M n-BuLi   94
in hexane (15.9 mL, 0.0336 mol). After stirring for 15 minutes, HMPA (11.7 mL, 
0.0672 mmol) was added dropwise. After stirring for 30 minutes, bromide 2.5 (5.3 
g, 0.0168 mol) was added dropwise. The reaction was allowed to warm to room 
temperature and stirred for 90 minutes. The reaction was slowly poured into 
NH4Cl (sat aq, 50 mL), the organic layer was separated and the aqueous layer 
was extracted with EtOAc (2 x 50 mL) and CH2Cl2 (1 x 50 mL). The combined 
organic phases were concentrated in vacuo to give a yellow oil. The yellow oil 
was dissolved in Et2O (150 mL) and washed with water (3 x 150 mL). The 
organic phase was dried (MgSO4) and concentrated in vacuo to afford a yellow 
oil. Purification on SiO2 (15 x 8 cm) eluting with hexane/Et2O (1:0 → 0:1) gave 
(R)-1-(benzyloxy)-12-(1,3-dioxan-2-yl)dodec-9-yn-2-ol (2.16) (5.20 g, 0.0139 mol, 
83%) as a colourless oil.  
[α]
28
D  –2.5 (CHCl3, c 1.6). 
IR max (neat) cm
-1 3470 (br), 2932 (s), 2856 (s), 2025 (w), 1135 (s). 
1H NMR (300 MHz, CDCl3)  7.41 – 7.16 (5H, m, C1, C2 and C3), 4.64 (1H, t, J = 
5.2 Hz, C18), 4.56 (2H, s, C5), 4.09 (2H, dd, J = 10.6, 5.0 Hz, C19
eq), 3.88 – 3.69 
(3H, m, C7 and C19
ax), 3.51 (1H, dd, J = 9.4, 3.2 Hz, C6(1H)), 3.33 (1H, dd, J = 
9.4, 7.9 Hz, C6(1H)), 2.33 (1H, br s, OH), 2.25 (2H, tt, J = 7.2, 2.2 Hz, C16), 2.18 
– 1.98 (3H, m, C13 and C20
ax), 1.77 (2H, td, J = 7.2, 5.2 Hz, C17), 1.55 – 1.22 
(11H, m, C8 – C12 and C20
eq).  
 13C NMR (75 MHz, CDCl3)  138.2 (C), 128.6 (CH1), 127.9 (CH1), 127.9 (CH1), 
101.2 (CH1), 80.5 (C), 79.4 (C), 74.8 (CH2), 73.5 (CH2), 70.6 (CH1), 67.1 (CH2), 
34.7 (CH2), 33.3 (CH2), 29.3 (CH2), 29.1 (CH2), 28.9 (CH2), 26.0 (CH2), 25.6 
(CH2), 18.9 (CH2), 13.8  (CH2). 
LRMS  ESI+ 397 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 397.2349, [M+Na]
+ found = 397.2351. 
(R,Z)-1-(Benzyloxy)-12-(1,3-dioxan-2-yl)dodec-9-en-2-ol (2.17)   95
6
OH
O 7
4
1
O
O
18 19
19
C23H36O4
Exact Mass: 376.2614
Mol. Wt.: 376.5295
 
Under an atmosphere of H2, a solution of (R)-1-(benzyloxy)-12-(1,3-dioxan-2-
yl)dodec-9-yn-2-ol (2.16) (5.63 g, 15.1 mmol), Lindlar catalyst (Pd 5%, calcium 
carbonate poisoned with Pb) (0.96 g, 0.452 mol) in hexane (150 mL) was stirred 
for 4 hours. The reaction was filtered through celite and washed through with 
EtOAc (300 mL). The filtrate was dried (MgSO4) and concentrated in vacuo to 
afford a pale yellow oil. Purification on SiO2 (7 x 7 cm) eluting with hexane/Et2O 
(1:1) gave (R,Z)-1-(benzyloxy)-12-(1,3-dioxan-2-yl)dodec-9-en-2-ol (2.17) (5.48 
g, 14.6 mol, 97%) as a colourless oil.  
[α]
25
D –2.2 (CHCl3, c 1.08). 
IR max (neat) cm
-1 3472 (br), 2925 (s), 2852 (s), 1653 (w), 1136 (s), 1085 (s); 
1H NMR  (300 MHz, CDCl3)  7.44 – 7.22 (5H, m, C1, C2 and C3), 5.49 – 5.22 
(2H, m, C14 and C15), 4.56 (2H, s, C5), 4.51 (1H, t, J = 5.3 Hz, C18), 4.11 (2H, 
dd with fine splitting, J = 10.6, 5.0 Hz, C19
eq), 3.89 – 3.67 (3H, m, C7 and C19
ax), 
3.51 (1H, dd, J = 9.4, 3.0 Hz, C6(1H)), 3.32 (1H, dd, J = 9.4, 8.0 Hz, C6(1H)), 
2.42 (1H, d, J = 3.2 Hz, OH), 2.22 – 1.90 (5H, m, C13, C16 and C20
ax), 1.71 – 
1.55 (2H, m, C17), 1.53 – 1.15 (11H, m, C8 – C12 and C20
eq). 
13C NMR
 (75 MHz, CDCl3)  138.2 (C), 130.8 (CH1), 128.9 (CH1), 128.6 (CH1), 
127.9 (CH1), 102.0 (CH1), 74.9 (CH2), 73.5 (CH2), 70.6 (CH1), 67.1 (CH2), 35.2 
(CH2), 33.3 (CH2), 29.8 (CH2), 29.6 (CH2), 29.3 (CH2), 27.3 (CH2), 26.0 (CH2), 
25.6 (CH2), 22.0 (CH2). 
LRMS ESI+ 399 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 399.2506, [M+Na]
+ found = 399.2496.   96
(2E,6Z)-(R)-15-Benzyloxy-1-((R)-10,10-dimethyl-3,3-dioxo-36-thia-4-
aza-tricyclo[5.2.1.01,5]dec-4-yl)-14-hydroxy-pentadeca-2,6-dien-1-one 
(2.19) 
S
N
OO
7
4
1
O
6
OH O C32H47NO5S
Exact Mass: 557.3175
Mol. Wt.: 557.7843
14
18
21
29
22
27 28
30
 
To a solution of (R,Z)-1-(benzyloxy)-12-(1,3-dioxan-2-yl)dodec-9-en-2-ol (2.17) 
(5.48 g, 14.6 mmol) in 1,4-dioxane: water: conc. H2SO4 (49.5: 49.5: 1) (550 mL) 
was refluxed for 6 hours. The reaction was diluted with Et2O (300 mL) and 
washed with water (100 mL), NaHCO3 (sat aq, 2 x 100 mL) and brine (100 mL). 
The organic layer were dried (Na2SO4) and concentrated in vacuo to afford a 
pale yellow oil which was used crude in the next step. 
 
Under an atmosphere of N2, to a stirred solution of (1S,2R)-camphorsultam 
phosphonate (6.9 g, 17.5 mmol) in dry acetonitrile (60 mL) was added dried 
lithium chloride (170 °C/ 0.035 mbar overnight) (0.74 g, 17.5 mmol). After stirring 
for 15 minutes, dry DIPEA (3.1 mL, 17.5 mmol) was added. After stirring for 10 
minutes, crude (R,Z)-13-(benzyloxy)-12-hydroxytridec-4-enal in dry acetonitrile (5 
mL) was then added. The reaction was left to stir for 20 hours. The reaction was 
diluted with water (50 mL) and brine (50 mL) then extracted with Et2O (3 x 100 
mL). The combined organic phases were dried (MgSO4) and concentrated in 
vacuo to give an orange oil. Purification on SiO2 (10 x 10 cm) eluting with 
Et2O/hexane (3:2 → 4:1) gave diene 2.19 (8.14 g, 13.0 mmol, 89% over 2 steps) 
as a colourless oil.  
[α]
26.5
D  –52.7 (CHCl3, c 1.4). 
IR max (neat) cm
-1 3481 (br), 2928 (s), 2855 (s), 1682 (s), 1638 (s). 
1H NMR (400 MHz, CDCl3)  7.40 – 7.25 (5H, m, C1 – C3), 7.08 (1H, dt, J = 15.1, 
6.9 Hz, C18), 6.58 (1H, d, J = 15.1 Hz, C19), 5.46 – 5.30 (2H, m, C14 and C15), 
4.56 (2H, s, C5), 3.93 (1H, dd, J = 7.5, 5.1 Hz, C21), 3.86 – 3.77 (1H, m, C7), 
3.52 (1H, dd, J = 9.4, 3.1 Hz, C6(1H)), 3.50 (1H, d, J = 13.8 Hz, C30(1H)), 3.43   97
(1H, d, J = 13.8 Hz, C30(1H)), 3.34 (1H, dd, J = 9.4, 7.8 Hz, C6(1H)), 2.37 – 2.26 
(3H, m, C17 and OH), 2.25 – 2.16 (2H, m, C16), 2.15 – 2.06 (2H, m, C22), 2.05 – 
1.94 (2H, m, C13), 1.95 – 1.83 (3H, m, C23 and C24(1H) and C25(1H)), 1.52 – 
1.24 (12H, m, C8 – C12, C24(1H) and C25(1H)), 1.18 (3H, s, C29), 0.98 (3H, s, 
C28). 
13C NMR
 (75 MHz, CDCl3)  164.2 (C), 150.3 (CH1), 138.3 (C), 131.4 (CH1), 
128.6 (CH1), 127.9 (CH1), 127.9 (CH1), 121.3 (CH1), 74.9 (CH2), 73.5 (CH2), 70.6 
(CH1), 65.3 (CH1), 53.3 (CH2), 48.6 (C), 48.0 (C), 44.9 (CH1), 38.7 (CH2), 33.4 
(CH2), 33.0 (CH2), 32.8 (CH2), 29.7 (CH2), 29.3 (CH2), 27.4 (CH2), 26.7 (CH2), 
26.0 (CH2), 25.6 (CH2), 21.0 (CH3), 20.1 (CH3).    
LRMS   580.4 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 580.3067, [M+Na]
+ found = 580.3058. 
(2E,6Z)-(R)-15-Benzyloxy-14-(tert-butyl-dimethyl-silanyloxy)-1-((R)-
10,10-dimethyl-3,3-dioxo-36-thia-4-aza-tricyclo[5.2.1.01,5]dec-4-yl)-
pentadeca-2,6-dien-1-one (2.20) 
C38H61NO5SSi
Exact Mass: 671.404
Mol. Wt.: 672.0451
S
N
OO
7
4
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27 28
30
 
At –10 °C under an atmosphere of N2, to a stirred solution of alcohol 2.19 (5.00 
g, 8.98 mmol) and 2,6-lutidine (3.66 mL, 31.43 mmol) in dry CH2Cl2 (30 mL) was 
added TBSOTf (4.14 mL, 17.96 mmol). The reaction was stirred for 20 minutes 
then warmed to room temperature for 15 minutes. The reaction was diluted with 
NH4Cl (sat aq, 50 mL), the organic layer was separated and the aqueous layer 
was extracted with CH2Cl2 (3 x 50 mL). The combined organic phases were 
washed with NaHCO3 (sat aq, 50 mL), dried (MgSO4) and concentrated in vacuo 
to give a yellow oil. Purification on SiO2 (5 x 10 cm) eluting with Et2O/hexane 
(1:9) gave diene 2.20 (5.84 g, 8.71 mmol, 97%) as a colourless oil.   
[α]
28
D  –38.3 (CHCl3, c 1.28).   98
IR max (neat) cm
-1 2927 (s), 2854 (s), 1683 (s), 1639 (s). 
1H NMR (400 MHz, CDCl3)  7.34 – 7.17 (5H, m, C1 – C3), 7.02 (1H, dt, J = 15.1, 
6.9 Hz, C18), 6.52 (1H, d, J = 15.1 Hz, C19), 5.44 – 5.20 (2H, m, C14 and C15), 
4.46 (2H, s, C5), 3.86 (1H, dd, J = 7.7, 5.0 Hz, C21), 3.80 – 3.72 (1H, br p, C7), 
3.43 (1H, d, J = 13.7 Hz, C30(1H)), 3.36 (1H, d, J = 13.7 Hz, C30(1H)), 3.34 (1H, 
dd, J = 9.6, 6.0 Hz, C6(1H)), 3.31 (1H, dd, J = 9.6, 5.4 Hz, C6(1H)), 2.29 – 2.20 
(2H, m, C17), 2.18 – 2.13 (2H, m, C16), 2.12 – 2.01 (2H, m, C22), 2.01 – 1.89 
(2H, m, C13), 1.88 – 1.77 (3H, m, C23 and C24(1H) and C25(1H)), 1.53 – 1.43 
(1H, m, C8(1H)), 1.43 – 1.18 (11H, m, C9 –C12, C8(1H), C24(1H) and C25(1H)), 
1.12 (3H, s, C29), 0.91 (3H, s, C28), 0.83 (9H, s, TBS), 0.00 (3H, s, TBS), -0.01 
(3H, s, TBS). 
13C NMR
 (100 MHz, CDCl3)  164.3 (C), 150.4 (CH1), 138.8 (C), 131.5 (CH1), 
128.5 (CH1), 127.9 (CH1), 127.8 (CH1), 127.6 (CH1), 121.3 (CH1), 75.1 (CH2), 
73.5 (CH2), 71.8 (CH1), 65.4 (CH1), 53.4 (CH2), 48.6 (C), 48.0 (C), 44.9 (CH1), 
38.7 (CH2),  34.9 (CH2),  33.1 (CH2),  32.8 (CH2),  29.9 (CH2),  29.8 (CH2),  29.5 
(CH2), 27.5 (CH2), 26.7 (CH2), 26.1 (CH1), 26.0 (CH2), 25.4 (CH2), 21.1 (CH3), 
20.1 (CH3), 18.4 (C), -4.1 (CH3), -4.5 (CH3). 
LRMS  ESI+ 694.6 [M+Na]
+ (100%), 689.6 [M+NH4]
+ (67%).      
HRMS ESI+ [M+Na]
+ calculated = 694.3932, [M+Na]
+ found = 694.3915. 
(R)-2-((2S,5R)-5-[(1S,8R)-9-Benzyloxy-8-(tert-butyl-dimethyl-
silanyloxy)-1-hydroxy-nonyl]-tetrahydro-furan-2-yl)-1-((R)-10,10-
dimethyl-3,3-dioxo-3λ
6-thia-4-aza-tricyclo[5.2.1.0
1,5]dec-4-yl)-2-
hydroxy-ethanone (2.21a) 
O
H H
HO
5
OTBS
O
S
N
OO
O
OH
C38H63NO8SSi
Exact Mass: 721.4044
Mol. Wt.: 722.0592
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1
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21
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At –40 °C under an atmosphere of N2, to a stirred solution of diene 2.20 (2.95 g, 
4.4 mmol) in acetone/acetic acid (3:1 220 mL) was added powdered KMnO4 (0.9 
g, 5.72 mmol). The reaction was warmed to –30 °C over 40 minutes, the reaction   99
was quenched by addition of Na2S2O5 (sat aq, 20 mL) and neutralised by addition 
of NaHCO3 (sat aq, 100 mL). The organic layer was separated. The aqueous 
layer was re-extracted with EtOAc (3 x 150 mL) and CH2Cl2 (1 x 100 mL). The 
combined organic phases were dried (MgSO4) and concentrated in vacuo to give 
a yellow oil. Purification on SiO2 (5 x 15 cm) eluting with EtOAc/hexane (1:4 → 
3:7) gave 3 main fractions: THF diol 2.21a  (1.94 g, 2.7 mmol, 61%) as a 
colourless oil, THF diol 2.21b (0.22 g, 0.31 mmol, 7%) as a colourless oil and 
hydroxyl ketone 2.22 (0.59 g, 0.84 mmol, 19%) as a pale yellow oil. 
Spectroscopic characterisation for THF diol 2.21a.  
[α]
27
D  –15.6 (CHCl3, c 1.5); 
IR max (neat) cm
-1 3467 (br), 2929 (s), 2855 (s), 1690 (s); 
1H NMR (400 MHz, CDCl3)  7.38 – 7.21 (5H, m, C1 – C3), 4.65 – 4.61 (1H, ddd, 
J = 6.2, 5.7, 2.0 Hz, C18), 4.60 – 4.57 (1H, br d, J = 2.0 Hz, C19), 4.53 (2H, 
apparent s, C5), 4.14 (1H, br. s, OH), 3.99 – 3.90 (3H, m, C14, C15 and C21), 
3.86 – 3.76 (1H, dq, J = 6.4, 5.3 Hz, C7), 3.52 (1H, d, J = 13.8 Hz, C30(1H)), 
3.45 (1H, d, J = 13.8 Hz, C30(1H)), 3.40 (1H, dd, J = 9.7, 5.3 Hz, C6(1H)), 3.37 
(1H, dd, J = 9.7, 5.3 Hz, C6(1H)), 3.12 (1H, br d, J = 4.1 Hz, OH), 2.31 – 2.22 
(1H, m, C22(1H)), 2.15 – 1.98 (4H, m, C17, C16(1H) and C22(1H)), 1.98 – 1.83 
(3H, m, C23, C24(1H) and C25(1H)), 1.80 – 1.70 (1H, m, C16(1H)), 1.60 – 1.22 
(12H, m, C8 – C13, C24(1H) and C25(1H)), 1.16 (3H, s, C29), 0.97 (3H, s, C28), 
0.89 (9H, s, TBS), 0.06 (3H, s, TBS), 0.05 (3H, s, TBS). 
13C NMR
 (75 MHz, CDCl3)  172.0 (C), 138.7 (C), 128.5 (CH1), 127.8 (CH1), 
127.6 (CH1), 83.6 (CH1), 78.3 (CH1), 75.1 (CH2), 74.3 (CH1), 73.5 (CH2), 72.2 
(CH1), 71.7 (CH1), 66.0 (CH1), 53.2 (CH2), 49.2 (C), 48.1 (C), 44.7 (CH1), 38.4 
(CH2), 34.9 (CH2), 33.0 (CH2), 32.8 (CH2), 29.9 (CH2), 29.8 (CH2), 29.0 (CH2), 
26.6 (CH2), 26.2 (CH2), 26.1 (CH3), 25.4 (CH2), 24.2 (CH2), 20.9 (CH3), 20.1 
(CH3), 18.4 (C), -4.2 (CH3), -4.5 (CH3). 
LRMS ESI+ 745 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 744.3936, [M+Na]
+ found = 744.3925.   100
(S)-2-((2R,5S)-5-[(1R,8R)-9-Benzyloxy-8-(tert-butyl-dimethyl-
silanyloxy)-1-hydroxy-nonyl]-tetrahydro-furan-2-yl)-1-((R)-10,10-
dimethyl-3,3-dioxo-36-thia-4-aza-tricyclo[5.2.1.01,5]dec-4-yl)-2-
hydroxy-ethanone (2.21b) 
O
H H
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5
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OH
C38H63NO8SSi
Exact Mass: 721.4044
Mol. Wt.: 722.0592
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[α]
28
D  –59.0 (CHCl3, c 0.93). 
1H NMR (400 MHz, CDCl3)  7.37 – 7.24 (5H, m, C1 – C3), 4.69 (1H, br s, OH), 
4.53 (2H, apparent s, C5), 4.54 – 4.46 (2H, m, C18 and C19), 3.95 (1H, dd, J = 
7.3, 5.0 Hz, C21), 3.89 – 3.78 (3H, m, C7, C14 and C15), 3.50 (1H, d, J = 13.8 
Hz, C30(1H)), 3.45 (1H, d, J = 13.8 Hz, C30(1H)), 3.42 – 3.33 (2H, m, C6), 2.92 
(1H, br s, OH), 2.23 – 2.13 (1H, m, C22(1H)), 2.12 – 2.00 (4H, m, C17, C16(1H) 
and C22(1H)), 1.96 – 1.85 (3H, m, C23, C24(1H) and C25(1H)), 1.79 – 1.22 
(13H, m, C8 – C13, C16(1H), C24(1H) and C25(1H)), 1.17 (3H, s, C29), 0.98 
(3H, s, C28), 0.89 (9H, s, TBS), 0.06 (3H, s, TBS), 0.05 (3H, s, TBS). 
13C NMR
 (75 MHz, CDCl3)  173.1 (C), 138.5 (C), 128.3 (CH1), 127.6 (CH1), 
127.4 (CH1), 83.4 (CH1), 79.7 (CH1), 74.9 (CH2), 74.9 (CH1), 73.3 (CH2), 72.2 
(CH1), 71.5 (CH1), 64.9 (CH1), 53.0 (CH2), 49.0 (C), 47.9 (C), 44.5 (CH1), 37.7 
(CH2), 34.7 (CH2), 32.6 (CH2), 32.6 (CH2), 29.7 (CH2), 29.6 (CH2), 28.6 (CH2), 
26.6 (CH2), 26.0 (CH2), 25.9 (CH3), 25.2 (CH2), 24.3 (CH2), 20.5 (CH3), 19.9 
(CH3), 18.2 (C), -4.3 (CH3), -4.7 (CH3). 
LRMS ESI+ 745 [M+Na]
+ (100%).   101
(Z)-(R)-15-Benzyloxy-14-(tert-butyl-dimethyl-silanyloxy)-1-((R)-10,10-
dimethyl-3,3-dioxo-36-thia-4-aza-tricyclo[5.2.1.01,5]dec-4-yl)-2-
hydroxy-pentadec-6-ene-1,3-dione (2.22) 
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C38H61NO7SSi
Exact Mass: 703.3938
Mol. Wt.: 704.0439
 
Spectroscopic characterisation for hydroxy ketone 2.22 isolated as a mixture of 
stereoisomers. 
1H NMR (300 MHz, CDCl3)  7.38 – 7.24 (5H, m, C1 – C3), 5.54 – 5.16 (3H, m, 
C5, C14 and C15), 4.53 (2H, apparent s, C5), 4.22 – 4.06 + 3.95 (1H, m 4.22 – 4.06, 
dd3.95, J3.95 = 7.4, 5.2 Hz, C21), 3.82 (1H, m, C7), 3.61 – 3.33 + 3.18 – 3.06 (4H, 
2 x m, C6 and C30), 2.94 – 2.48 + 2.48 – 1.77 (12H, 2 x m, C13, C17, C16, C22, 
C23, C24(1H) and C25(1H)), 1.75 – 1.23 (12H, m, C8–C12,  C24(1H) and 
C25(1H)), 1.22 + 1.16 + 1.14 (3H, 3 x s, C29), 1.07 + 0.98 + 0.94 (3H, 3 x s, 
C28), 0.89 (9H, s, TBS), 0.06 (3H, s, TBS), 0.05 (3H, s, TBS). 
13C NMR
 (75 MHz, CDCl3)  203.2 (C), 178.0 (C), 138.5 + 138.4 (C), 131.7 + 
131.5 (CH1), 128.2 (CH1), 127.5 (CH1), 127.4 (CH1), 127.0 (CH1), 76.4 (CH1), 
74.8 + 74.8 (CH2), 73.2 (CH2), 71.5 (CH1), 65.0 + 62.8 (CH1), 52.8 + 50.3 (CH2), 
49.5 + 47.9 (C), 47.9 + 47.4 (C), 44.7 + 44.5 (CH1), 39.3 (CH2), 37.7 (CH2), 36.1 
(CH2), 34.7 (CH2), 34.6 (CH2), 34.0 (CH2), 32.7 (CH2), 31.8 (CH2), 29.6 (CH2), 
29.6 (CH2), 29.5 (CH2), 29.2 (CH2), 29.1 (CH2), 27.1 (CH2), 26.8 (CH2), 26.4 
(CH2), 25.9 (CH3), 25.5 (CH2), 25.1 (CH2), 25.1 (CH2), 22.5 (CH2), 20.4 (CH3), 
19.9 (CH3), 18.2 (C), -4.4 (CH3), -4.8 (CH3), Peaks between 39.3 – 22.5 except 
25.9 represent 11 CH2, extra peaks are assumed to come from stereoisomers. 
LRMS ESI+ 746 [M+Na]
+ (100%).     102
(S)-1-((2S,5R)-5-[(1S,8R)-9-Benzyloxy-8-(tert-butyl-dimethyl-
silanyloxy)-1-hydroxy-nonyl]-tetrahydro-furan-2-yl)-ethane-1,2-diol 
(2.23) 
O
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C28H50O6Si
Exact Mass: 510.3377
Mol. Wt.: 510.7785
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At 0 °C to a stirred solution of THF diol 2.21a (2.7 g, 3.74 mmol), water (140 μL) 
in THF (33 mL) was added NaBH4 (157 mg, 4.11 mmol). The reaction was 
allowed to warm to room temperature and stirred for 1 hour. The reaction was 
diluted with EtOAc (50 mL) and water (50 mL), the organic layer was separated 
and the aqueous layer was re-extracted with EtOAc (3 x 70 mL) and CH2Cl2 (70 
mL). The combined organic phases were dried (MgSO4) and concentrated in 
vacuo to afford a cloudy oil. Purification on SiO2 (8 x 4 cm) eluting with 
EtOAc/methanol (1:0 → 9:1) gave triol 2.23 (1.68 g, 3.29 mol, 88%) as a 
colourless oil.  
[α]
27
D  +20.1 (CHCl3, c 1). 
IR max (neat) cm
-1 3362 (br), 2928 (s), 2855 (s), 1098 (s), 1073 (s). 
1H NMR (400 MHz, CDCl3)  7.38 – 7.24 (5H, m, C1 – C3), 4.53 (2H, s, C5), 4.07 
– 3.99 (1H, td, J = 6.5, 3.3 Hz, C18), 3.97 – 3.90 (1H, td, J = 7.2, 2.6 Hz, C15), 
3.90 – 3.84 (1H, m, C14), 3.85 – 3.78 (1H, m, C7), 3.74 – 3.68 (2H, m, C20), 
3.63 – 3.56 (1H, m, C19), 3.40 (1H, dd, J = 9.7, 5.7 Hz, C6(1H)), 3.37 (1H, dd, J 
= 9.7, 5.4 Hz, C6(1H)), 3.20 (1H, broad s, OH), 2.94 (1H, broad s, OH) 2.08 – 
1.92 (3H, m, C17(2H) and C16(1H)), 1.83 – 1.74 (1H, m, C16(1H)), 1.49 – 1.26 
(12H, m, C8 – C13), 0.89 (9H, s, TBS), 0.06 (3H, s, TBS), 0.05 (3H, s, TBS). 
13C NMR
 (75 MHz, CDCl3)  138.7 (C), 128.5 (CH1), 127.8 (CH1), 127.6 (CH1), 
83.3 (CH1), 80.3 (CH1), 75.0 (CH2), 74.0 (CH1), 73.5 (CH2), 72.5 (CH1), 71.7 
(CH1), 65.5 (CH2), 34.9 (CH2), 33.4 (CH2), 29.9 (CH2), 29.8 (CH2), 28.7 (CH2), 
26.1 (CH3), 25.4 (CH2), 24.0 (CH2), 18.4 (C), -4.2 (CH3), -4.5 (CH3). 
LRMS ESI+ 533 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 533.3269, [M+Na]
+ found = 533.3263.   103
Toluene-4-sulfonic acid (S)-2-((2S,5R)-5-[(1S,8R)-9-benzyloxy-8-(tert-
butyl-dimethyl-silanyloxy)-1-hydroxy-nonyl]-tetrahydro-furan-2-yl)-2-
hydroxy-ethyl ester  
C35H56O8SSi
Exact Mass: 664.3465
Mol. Wt.: 664.9648 O
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Under an atmosphere of N2, a solution of triol 2.23 (1.525 g, 2.99 mmol) and 
Bu2SnO (0.893 g, 3.59 mmol) in dry benzene (50 mL) was refluxed for 3.5 hours 
using Dean-Stark apparatus. The reaction was cooled to 10 °C, then TsCl (0.627 
g, 3.29 mmol) and TBAB (0.48 g, 1.5 mmol) were added. The reaction was 
gradually warmed to room temperature over 1 hour then stirred for a further 1 
hour. The reaction was diluted with EtOAc (50 mL) and water (50 mL), the 
organic layer was separated and washed with NaHCO3 (sat aq, 50 mL), brine (50 
mL) and water (50 mL).  The aqueous layer was extracted with EtOAc (3 x 100 
mL). The combined organic phases were dried (MgSO4) and concentrated in 
vacuo to afford a cloudy white oil. Purification on SiO2 (5 x 12 cm) eluting with 
EtOAc/hexane (1:9 → 7:3) gave the tosylate (1.89 g, 2.84 mmol, 95%) as a 
colourless oil.  
[α]
27
D  +16.4 (CHCl3, c 1.65). 
IR max (neat) cm
-1 3365 (br), 2928 (s), 2855 (s), 1598 (w), 1135 (s). 
1H NMR (400 MHz, CDCl3)  7.81 (2H, d, J = 8.4 Hz, Tosylate), 7.40 – 7.26 (7H, 
m, C1 – C3 and Tosylate), 4.53 (2H, apparent s, C5), 4.13 (1H, dd, J = 10.3, 5.4 
Hz, C20(1H)), 4.09 (1H, dd, J = 10.3, 6.7 Hz, C20(1H)), 4.05 – 4.00 (1H, ddd, J = 
7.2, 6.0, 2.6 Hz, C18), 3.94 – 3.88 (1H, ddd, J = 6.9, 6.6, 2.6 Hz C15), 3.87 – 
3.79 (2H, m, C7 and C14), 3.79 – 3.72 (1H, m, C19), 3.40 (1H, dd, J = 9.7, 5.7 
Hz, C6(1H)), 3.36 (1H, dd, J = 9.7, 5.4 Hz, C6(1H)), 3.23 – 3.19 (1H, d, J = 2.9 
Hz, OH), 2.46 (3H, s, Tosylate), 2.42 – 2.39 (1H, d, J = 2.9 Hz, OH), 2.06 – 1.93 
(3H, m, C17(2H) and C16(1H)), 1.84 – 1.73 (1H, m, C16(1H)), 1.59 – 1.22 (12H, 
m, C8 – C13), 0.89 (9H, s, TBS), 0.06 (3H, s, TBS), 0.05 (3H, s, TBS).   104
13C NMR
 (75 MHz, CDCl3)  145.1 (C), 138.7 (C), 133.0 (C), 130.1 (CH1), 128.5 
(CH1), 128.2 (CH1), 127.8 (CH1), 127.6 (CH1), 83.3 (CH1), 78.2 (CH1), 75.0 (CH2), 
73.5 (CH2), 72.9 (CH1), 72.0 (CH1), 71.9 (CH2), 71.7 (CH1), 34.9 (CH2), 33.5   
(CH2), 29.9 (CH2), 29.7 (CH2), 28.6 (CH2), 26.1 (CH3), 26.1 (CH2), 25.3 (CH2), 
24.2 (CH2), 21.8 (CH1), 18.4 (C), -4.1 (CH3), -4.5 (CH3). 
LRMS  ESI+ 687.5 [M+Na]
+ (100%).      
HRMS ESI+ [M+Na]
+ calculated = 687.3357, [M+Na]
+ found = 687.3368. 
(1S,8R)-9-Benzyloxy-8-(tert-butyl-dimethyl-silanyloxy)-1-((2R,5S)-(S)-
5-oxiranyl-tetrahydro-furan-2-yl)-nonan-1-ol (2.24) 
C28H48O5Si
Exact Mass: 492.3271
Mol. Wt.: 492.7632 O
H H 5
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At 0 °C under an atmosphere of N2, to a stirred solution of tosylate (1.88 g, 2.83 
mmol) in dry methanol (40 mL) was added dry K2CO3 (0.43 g, 3.12 mmol). The 
reaction was stirred for 2 hours then warmed to room temperature for 30 
minutes, then the reaction was concentrated in vacuo to afford cloudy white oil. 
Purification on SiO2 (4 x 11 cm) eluting with EtOAc/hexane (1:1) gave epoxide 
2.24 (1.36 g, 2.77 mmol, 98%) as a colourless oil. 
[α]
29
D +16.7 (CHCl3, c 0.91). 
IR max (neat) cm
-1 3454 (br), 2927 (s), 2854 (s). 
1H NMR (400 MHz, CDCl3)  7.36 – 7.24 (5H, m, C1, C2 and C3), 4.53 (2H, s, 
C5), 4.09 (1H, ddd, J = 7.8, 5.4, 2.8 Hz, C18), 3.96 – 3.89 (1H, m, C15), 3.85 – 
3.77 (2H, m, C7 and C14), 3.40 (1H, dd, J = 9.5, 5.7 Hz, C6), 3.36 (1H, dd, J = 
9.5, 5.3 Hz, C6), 3.12 (1H, br s, OH), 3.04 (1H, dt, J = 4.2, 2.8 Hz, C19), 2.85 
(1H, dd, J = 5.2, 2.8 Hz, C20(1H)), 2.77 (1H, dd, J = 5.2, 4.2 Hz, C20(1H)), 2.18 
– 2.08 (1H, m, C17(1H)), 2.08 – 1.97 (2H, m, C16(1H) and C17(1H)), 1.86 – 1.74 
(1H, m, C16(1H)), 1.60 – 1.23 (12H, m, C8 – C13), 0.90 (9H, s, TBS), 0.06 (3H, 
s, TBS), 0.05 (3H, s, TBS).   105
13C NMR
 (100 MHz, CDCl3)  138.7 (C), 128.4 (CH1), 127.8 (CH1), 127.6 (CH1), 
83.9 (CH1), 76.3 (CH1), 75.1 (CH2), 73.5 (CH2), 72.5 (CH1), 71.7 (CH1), 54.8 
(CH1), 44.3 (CH2), 34.9 (CH2), 33.2 (CH2), 29.9 (CH2), 29.8 (CH2), 26.2 (CH2), 
26.1 (CH3), 25.4 (CH2), 24.0 (CH2), 18.4 (C), -4.2 (CH3), -4.5 (CH3). 
LRMS  ESI+ 515.4 [M+Na]
+ (100%).    
HRMS ESI+ [M+Na]
+ calculated = 515.3163, [M+Na]
+ found = 515.3157. 
Imidazole-1-carbothioic acid O-[(1S,8R)-9-benzyloxy-8-(tert-butyl-
dimethyl-silanyloxy)-1-((2R,5S)-(S)-5-oxiranyl-tetrahydro-furan-2-yl)-
nonyl] ester (2.25) 
C32H50N2O5SSi
Exact Mass: 602.321
Mol. Wt.: 602.9003
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Under an atmosphere of N2, a solution of alcohol 2.24 (0.21 g, 0.427 mmol), 
thioylcarbonyl diimidazole 95% (0.24 g, 1.28 mmol) and DMAP (17.2 mg, 0.141 
mmol) in dry CH2Cl2 (3.75 mL) was stirred for 18 hours. The reaction was 
concentrated in vacuo to afford yellow oil. Purification on SiO2 (10 x 3 cm) eluting 
with EtOAc/hexane (2:3) gave epoxide 2.25  (200 mg, 0.333 mol, 78%) as a 
colourless oil. 
[α]
27
D +0.6 (CHCl3, c 1.05). 
IR max (neat) cm
-1 2928 (s), 2855 (s). 
1H NMR (400 MHz, C6D6)  8.40 (1H, s, Imidazole), 7.51 (1H, t, J = 1.5 Hz, 
Imidazole), 7.31 (2H, br d, J = 7.5 Hz, C3), 7.22 – 7.17 (2H, m, C2), 7.13 – 7.08 
(1H, m, C1), 6.96 (1H, dd, J = 1.5, 0.8 Hz, Imidazole), 5.80 (1H, dt, J = 7.7, 5.0 
Hz, C14), 4.39 (1H, d, J = 12.2 Hz, C5(1H)), 4.35 (1H, d, J = 12.2 Hz, C5(1H)), 
3.94 – 3.83 (1H, m, C7), 3.76 (1H, m, C15), 3.56 (1H, td, J = 6.5, 4.0 Hz, C18), 
3.39 (1H, dd, J = 9.4, 6.2 Hz, C6(1H)), 3.32 (1H, dd, J = 9.4, 5.0 Hz, C6(1H)), 
2.50 (1H, td, J = 4.0, 2.6 Hz, C19), 2.37 (1H, dd, J = 5.6, 2.6 Hz, C20(1H)), 2.20   106
(1H, dd, J = 5.6, 4.0 Hz, C20(1H)), 1.68 – 1.60 (2H, m, C13), 1.57 – 1.49 (4H, m, 
C8, C16(1H) and C17(1H)), 1.48 (2H, m, C16(1H) and C17(1H)), 1.34 – 1.17 
(8H, m, C9 – C12), 1.02 (9H, s, TBS), 0.15 (3H, s, TBS), 0.14 (3H, s, TBS). 
13C NMR
 (100 MHz, C6D6)  185.24 (C), 139.48 (C), 137.15 (CH), 131.93 (CH), 
128.92 (CH), 128.68 (CH), 128.19 (CH), 128.08 (CH), 118.83 (CH), 84.87 (CH), 
80.55 (CH), 78.74 (CH), 75.75 (CH2), 73.84 (CH2), 72.38 (CH), 53.75 (CH), 43.66 
(CH2), 35.48 (CH2), 31.25 (CH2), 30.26 (CH2), 30.19 (CH2), 28.65 (CH2), 27.61 
(CH2), 26.57  (CH3),  25.91 (CH2), 25.65 (CH2), 18.84 (C),  -3.60 (CH3), -4.15 
(CH3). 
LRMS  ESI+ 603.5 [M+H] (100%), 625.5 [M+Na]
+ (75%).   
HRMS ESI+ [M+Na]
+ calculated = 603.3282, [M+Na]
+ found = 603.3277. 
[(R)-1-Benzyloxymethyl-8-((2S,5S)-(S)-5-oxiranyl-tetrahydro-furan-2-
yl)-octyloxy]-tert-butyl-dimethyl-silane (2.26) 
C28H48O4Si
Exact Mass: 476.3322
Mol. Wt.: 476.7638 O
H H 7
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Under an atmosphere of N2, a solution of epoxide 2.25 (187 mg, 0.31 mmol), 
tris(trimethylsilyl)silane (0.38 mL, 1.24 mmol) in dry degassed toluene (7 mL) was 
added AIBN (13 mg, 0.078 mmol) in dry degassed toluene (1.2 mL). The reaction 
was heated to 80 °C for 25 minutes then poured into NaHCO3 (sat aq, 10 mL) 
and diluted with EtOAc (10 mL). The organic layer was separated and washed 
with brine (5 mL) and water (5 mL).  The aqueous layer was re-extracted with 
EtOAc (3 x 10 mL). The combined organic phases were dried (MgSO4) and 
concentrated in vacuo to afford a pale oil. Purification on SiO2 (10 x 3 cm) eluting 
with EtOAc/hexane (0:1 → 3:17) gave epoxide 2.26 (137 mg, 0.288 mmol, 93%) 
as a colourless oil. 
[α]
27
D +13.8 (CHCl3, c 1.08). 
IR max (neat) cm
-1 2927 (s), 2854 (s).   107
1H NMR (400 MHz, CDCl3)  7.37 – 7.25 (5H, m, C1, C2 and C3), 4.53 (2H, s, 
C5), 3.91 – 3.74 (3H, m, C7, C15 and  C18), 3.41 (1H, dd, J = 9.7, 5.7 Hz, 
C6(1H)), 3.37 (1H, dd, J = 9.7, 5.4 Hz, C6(1H)), 2.97 (1H, ddd, J = 5.0, 4.1, 2.7 
Hz, C19), 2.74 (1H, dd, J = 5.3, 4.1 Hz, C20(1H)), 2.67 (1H, dd, J = 5.3, 2.7 Hz, 
C20(1H)), 2.06 – 1.90 (2H, m, C16(1H) and C17(1H)), 1.90 – 1.81 (1H, m, 
C17(1H)), 1.67 – 1.35 (5H, m, C8, C14 and C16(1H)), 1.35 – 1.23 (10H, br s, C9 
– C13), 0.89 (9H, s, TBS), 0.06 (3H, s, TBS), 0.05 (3H, s, TBS).  
13C NMR
 (75 MHz, CDCl3)  138.7 (C), 128.5 (CH1), 127.8 (CH1), 127.6 (CH1), 
80.7 (CH1), 78.7 (CH1), 75.1 (CH2), 73.5 (CH2), 71.8 (CH1), 54.4 (CH1), 44.1 
(CH2), 35.8 (CH2), 34.9 (CH2), 31.3 (CH2), 29.9 (CH2), 29.8 (CH2), 29.7 (CH2), 
28.6 (CH2), 26.4 (CH2), 26.1 (CH3), 25.4 (CH2), 18.4 (C), -4.1 (CH3), -4.5 (CH3). 
LRMS  ESI+ 499.4 [M+Na]
+ (100%), 494.5 [M+NH4] (49%). 
HRMS ESI+ [M+Na]
+ calculated = 499.3214, [M+Na]
+ found = 499.3211. 
(S)-1-((2S,5S)-5-[(R)-9-Benzyloxy-8-(tert-butyl-dimethyl-silanyloxy)-
nonyl]-tetrahydro-furan-2-yl)-prop-2-en-1-ol (2.27) 
C29H50O4Si
Exact Mass: 490.3478
Mol. Wt.: 490.7904 O
H H 7
OTBS
O
HO
1
4
7 15 18
 
At –10 °C under an atmosphere of N2, to a stirred solution of Me3S
+I
- (0.551 g, 
2.7 mmol) in dry THF (10 mL) was added 2.13M
 n-BuLi in hexane (1.3 mL, 2.7 
mmol). The reaction was stirred for 30 minutes then epoxide 2.26 (130 mg, 0.273 
mmol) in dry THF (0.25 mL) was added dropwise. The reaction was warmed to 
room temperature and stirred for 4 hours. The reaction was diluted with EtOAc 
(20 mL) and water (20 mL), the organic layer was separated and washed with 
brine (10 mL).  The aqueous layer was re-extracted with EtOAc (2 x 30 mL). The 
combined organic phases were dried (MgSO4) and concentrated in vacuo to 
afford a yellow liquid. Purification on SiO2 (3 x 8 cm) eluting with EtOAc/hexane 
(3:17) gave allylic alcohol 2.27 (130 mg, 2.65 mmol, 98%) as a colourless oil. 
[α]
29
D  +6.78 (CHCl3, c 0.87). 
IR max (neat) cm
-1 3449 (br), 2928 (s), 2855 (s), 1739 (w), 1103 (s).   108
1H NMR (400 MHz, CDCl3)  7.38 (5H, m, C1, C2 and C3), 5.85 (1H, ddd, J = 
17.2, 10.7, 6.0 Hz, C20), 5.36 (1H, dt, J = 17.2, 1.5 Hz, C21
trans), 5.21 (1H, dt, J 
= 10.7, 1.5 Hz, C21
cis), 4.53 (2H, s, C5), 3.95 – 3.86 (2H, m, C15 and C19), 3.86 
– 3.74 (2H, m, C7 and C18), 3.40 (1H, dd, J = 9.7, 5.7 Hz, C6(1H)), 3.36 (1H, dd, 
J = 9.7, 5.4 Hz, C6(1H)), 2.52 (1H, d, J = 4.0 Hz, OH), 2.05 – 1.83 (2H, m, 
C16(1H) and C17(1H)), 1.79 – 1.68 (1H, m, C17(1H)), 1.67 – 1.24 (15H, m, C8 – 
C14 and C16(1H)), 0.89 (9H, s, TBS), 0.06 (3H, s, TBS), 0.06 (3H, s, TBS). 
13C NMR
  (100 MHz, CDCl3)   138.8 (CH1), 137.6 (CH1), 128.5 (CH1), 127.8 
(CH1), 127.6 (CH1), 116.9 (CH2), 81.9 (CH1), 80.5 (CH1), 76.1 (CH1), 75.1 (CH2), 
73.5 (CH2), 71.8 (CH2), 36.2 (CH2), 34.9 (CH2), 31.4 (CH2), 29.9 (CH2), 29.8 
(CH2), 29.7 (CH2), 27.7 (CH2), 26.4 (CH2), 26.1 (CH3), 25.4 (CH2), 18.4 (C), -4.1 
(CH3), -4.5 (CH3). 
LRMS ESI+ 513 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 513.3371, [M+Na]
+ found = 513.3360. 
(2S,5R)-2-((S)-1-(((S)-1-((2S,5S)-5-((R)-9-(Benzyloxy)-8-(tert-
butyldimethylsilyloxy)nonyl)-tetrahydrofuran-2-
yl)allyloxy)diisopropylsilyloxy)allyl)-5-((S)-1-
(methoxymethyoxy)undecyl)-tetrahydrofuran (2.28) 
O O
H H
O MOMO
H H
O
OTBS
O
Si
i-Pr i-Pr
1
4
7 18 C55H100O8Si2
Exact Mass: 944.6957
Mol. Wt.: 945.5487
28 25
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At room temperature under an atmosphere of N2, to a stirred solution of allylic 
alcohol 1.262 (0.50 g, 1.02 mmol) in dry CH2Cl2 (2 mL) was added imidazole 
(0.35 g, 5.10 mmol) followed by i-Pr2SiCl2 (184 µL, 1.02 mmol). The reaction was 
stirred for 20 minutes and then the allylic alcohol 2.27 (0.35 g, 1.02 mol) in dry 
CH2Cl2 (0.4 mL) was added dropwise. The reaction was stirred for 3 hours and 
then purification directly on SiO2 (3 x 14 cm) eluting with EtOAc/hexane (0:1 → 
3:22) gave diene 2.28  (0.74g, 0.79 mmol, 78%, (95% based on recovered 
1.262)) as a colourless oil.   109
[α]
28
D  –33.6 (CHCl3, c 1.33). 
IR max (neat) cm
-1 2925 (s), 2854 (s), 1739 (w), 1465 (s), 1362 (m), 1251 (s), 
1101 (s). 
1H NMR (400 MHz, CDCl3)  7.41 – 7.21 (5H, m, C1, C2 and C3), 5.89 (2H, 2 x 
ddd, J = 17.0, 10.6, 5.4 Hz, C20 and C23), 5.32 (2H, finely split d, J = 17.0, 
C21
trans (1H) and C22
 trans (1H)), 5.22 – 5.10 (2H, finely split d, J = 10.6, C21
cis 
(1H) and C22
 cis (1H)), 4.77 (1H, d, J = 6.7 Hz, MOMO), 4.64 (1H, d, J = 6.7 Hz, 
MOMO), 4.53 (2H, apparent s, C5), 4.52 – 4.43 (2H, m, C19 and C24),  4.03 – 
3.91 (2H, m, C18 and C25), 3.86 – 3.75 (3H, m, C7, C15 and C28), 3.65 – 3.58 
(1H, m, C29), 3.43 – 3.34 (5H, m, MOMO and C6), 1.90 – 1.65 (7H, m, C16(1H), 
C17, C26 and C27), 1.65 – 1.19 (33H, m, C8 – C14, C16(1H) and C30 – C38), 
1.09 – 0.99 (14H, m, i-Pr2Si), 0.89 (12H, s, C39 and TBS), 0.06 (3H, s, TBS), 
0.06 (3H, s, TBS). 
13C NMR
 (100 MHz, CDCl3)  138.6 (C), 137.3 (CH1), 137.2 (CH1), 128.3 (CH1), 
127.6 (CH1), 127.4 (CH1), 115.7 (CH2), 115.5 (CH2), 96.8 (CH2), 82.1 (CH1), 81.7 
(CH1), 81.6 (CH1), 80.1 (CH1), 78.6 (CH1), 74.9 (CH2), 74.4 (CH1), 74.1 (CH1), 
73.3 (CH2), 71.6 (CH1), 55.6 (CH3), 35.6 (CH2), 34.7 (CH2), 31.9 (CH2), 31.2 
(CH2), 29.8 (CH2), 29.8 (CH2), 29.6 (CH2), 29.6 (CH2), 29.3 (CH2), 26.4 (CH2), 
26.3 (CH2), 26.0 (CH2), 25.9 (CH3), 25.7 (CH2), 25.4 (CH2), 25.2 (CH2), 22.7 
(CH2), 18.2 (C), 17.5 (CH1), 17.4 (CH1), 14.1 (CH3), 12.8 (CH3), –4.3 (CH3), –4.7 
(CH3). 
LRMS ESI+ 968 [M+Na]
+(100%).  
HRMS ESI+ [M+Na]
+ found = 967.6827; calculated 967.6849.   110
(4S,7S,Z)-4-((2S,5S)-5-((R)-9-(Benzyloxy)-8-(tert-
butyldimethylsilyloxy)nonyl)-tetrahydrofuran-2-yl)-2,2-diisopropyl-7-
((2S,5R)-5-((S)-1-(methoxymethyoxy)undecyl)-tetrahydrofuran-2-yl)-
4,7-dihydro-1,3,2-dioxasilepine (2.29) 
C53H96O8Si2
Exact Mass: 916.6644
Mol. Wt.: 917.4955
O O
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Under an atmosphere of N2, a stirred solution of siloxane 2.28 (0.68 g, 0.72 
mmol) and Grubbs 2nd generation catalyst (12.2 mg, 0.14 mmol, 2 mol %) in dry, 
degassed toluene (12 mL, 0.06M) was heated at 75 °C for 40 minutes. A second 
batch of Grubb’s 2nd generation catalyst (12.2 mg, 0.14 mmol, 2 mol %) was 
added and the reaction was heated again for 40 minutes. This process was 
repeated a further 3 times, to a total catalyst loading of 10 mol %. The reaction 
was concentrated in vacuo which gave a dark brown oil. Purification on SiO2 (4 x 
10 cm) eluting with EtOAc/hexane (1:19  3:17) gave alkene 2.29 (0.542 g, 0.59 
mmol, 82%) as a colourless oil. 
[α]
28
D  –45.2 (CHCl3, c 1.18). 
IR max (neat) cm
-1 2925 (s), 2854 (s), 1735 (w), 1463 (s), 1363 (m), 1250 (s). 
1H NMR (400 MHz, CDCl3)  7.29 – 7.20 (5H, m, C1, C2 and C3), 5.78 – 5.67 
(2H, m, C20 and C21), 4.73 (1H, d, J = 6.6 Hz, MOMO), 4.70 – 4.63 (2H, m, C19 
and C22), 4.58 (1H, d, J = 6.6 Hz, MOMO), 4.47 (2H, apparent s, C5), 4.00 – 
3.89 (2H, m, C18 and C23), 3.85 – 3.71 (3H, m, C7, C15 and C26), 3.65 – 3.59 
(1H, m, C27), 3.34 – 3.29 (5H, m, MOMO and C6), 1.90 – 1.70 (7H, m, C16(1H), 
C17, C24 and C25), 1.49 – 1.17 (33H, m, C8 – C14, C16(1H) and C28 – C36), 
1.09 – 0.99 (14H, m, i–Pr2Si), 0.85 – 0.78 (12H, m, C37 and TBS), 0.06 (3 H, s, 
TBS), 0.05 (3H, s, TBS). 
13C NMR
 (100 MHz, CDCl3)  138.6 (C), 131.7 (CH1), 131.5 (CH1), 128.3 (CH1), 
127.6 (CH1), 127.4 (CH1), 96.9 (CH2), 81.9 (CH1), 81.5 (CH1), 80.1 (CH1), 78.4 
(CH1), 74.9 (CH2), 73.3 (CH1), 72.8 (CH1), 71.6 (CH1), 55.7 (CH3), 35.8 (CH2),   111
34.8 (CH2), 32.0 (CH2), 31.9 (CH2), 31.3 (CH2), 29.8 (CH2), 29.8 (CH2), 29.6 
(CH2), 29.3 (CH2), 26.8 (CH2), 26.6 (CH2), 26.3 (CH2), 26.2 (CH2), 25.9 (CH3), 
25.5 (CH2), 25.2 (CH2), 22.7 (C), 18.2 (C), 17.6 (CH1), 17.3 (CH1), 17.3 (CH1), 
14.1 (CH1), 12.3 (CH3), 12.3 (CH3), -4.3 (CH3), -4.7 (CH3). 
LRMS ESI+ 940 [M+Na]
+(100%). 
HRMS ESI+ [M+Na]
+ found 939.6555; calculated 939.6536. 
(R)-2-(tert-Butyldimethylsilyloxy)-9-((2S,5S)-5-((4S,7S)-2,2-diisopropyl-
7-((2S,5R)-5-((S)-1-(methoxymethyoxy)undecyl)-tetrahydrofuran-2-yl)-
1,3,2-dioxasilepan-4-yl)-tetrahydrofuran-2-yl)nonan-1-ol (2.30) 
O O
H H
O MOMO
H H
O
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C46H92O8Si2
Exact Mass: 828.6331
Mol. Wt.: 829.3889
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Under an atmosphere of H2, a solution of olefin 2.29  (65 mg, 0.071 mmol), 
palladium/charcoal (Pd 5%, on activated carbon, wet, Degussa type E101 NO/W, 
Aldrich, 22.6 mg, 0.011 mmol, 15 mol %), in EtOAc (4 mL) was stirred for 3 
hours. The reaction was filtered through celite and washed EtOAc (20 mL). The 
organic phase was concentrated in vacuo to afford pale yellow oil. Purification on 
SiO2 (1 x 9 cm) eluting with hexane/Et2O (9:1) gave alcohol 2.30 as a colourless 
oil (55.8 mg, 0.067 mmol, 95%). 
[α]
27
D  –5.6 (CHCl3, c 1.24). 
IR max (neat) cm
-1 3462 (br), 2926 (s), 2855 (s), 1464 (s), 1371 (m), 1254 (s), 
1214 (s). 
1H NMR (400 MHz, CDCl3)  4.80 (1H, d, J = 6.7 Hz, MOMO), 4.65 (1H, d, J = 
6.7 Hz, MOMO), 3.95 – 3.79 (6H, m, C10, C13, C14, C17, C18 and C21), 3.73 
(1H, m, C2), 3.68 – 3.62 (1H, m, C22), 3.56 (1H, ddd, J = 10.9, 5.5, 4.0 Hz, 
C1(1H)), 3.44 (1H, dt, J = 10.9, 5.5 Hz, C1(1H)), 3.39 (3H, s, MOMO), 1.94 – 
1.78 (9H, m, CX and OH), 1.65 – 1.22 (36H, m, CX, C3 – C9, C23 – C31), 1.08 – 
0.94 (14H, m, i–Pr2Si), 0.91 (12H, s, C32 and TBS), 0.09 (6H, s, TBS), CX =   112
C11, C12, C15, C16, C19, C20. Represent 12H, 8H can be found in 1.94 – 1.78 
and 4H can be found in 1.65 – 1.22. 
13C NMR
 (100 MHz, CDCl3)   96.9 (CH2), 82.9 (CH1), 82.3 (CH1), 81.6 (CH1), 
79.9 (CH1), 78.5 (CH1), 77.7 (CH1), 76.3 (CH1), 73.0 (CH1), 66.3 (CH2), 55.6 
(CH1), 35.9 (CH2), 34.0 (CH2), 32.9 (CH2), 32.6 (CH2), 32.0 (CH2), 31.9 (CH2), 
31.4 (CH2), 29.8 (CH2), 29.8 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.3 
(CH2), 27.2 (CH2), 26.9 (CH2), 26.5 (CH2), 26.2 (CH2), 25.9 (CH3), 25.4 (CH2), 
25.3 (CH2), 22.7 (CH2), 18.1 (C), 17.7 (CH3), 17.5 (CH3), 17.4 (CH3), 14.1 (CH3), 
12.5 (CH1), -4.4 (CH3), -4.6 (CH3). 
LRMS ESI+ 852 [M+Na]
+(100%).     
HRMS ESI+ [M+Na]
+ found 851.6228; calculated 851.6223. 
(5S)-3-((R)-2-(tert-Butyldimethylsilyloxy)-9-((2S,5S)-5-((4S,7S)-2,2-
diisopropyl-7-((2S,5R)-5-((S)-1-(methoxymethyoxy)undecyl)-
tetrahydrofuran-2-yl)-1,3,2-dioxasilepan-4-yl)-tetrahydrofuran-2-
yl)nonyl)-5-methyl-3-phenylthio)-dihydrofuran-2(3H)-one (2.32) 
O O
H H
O MOMO
H H
O
7
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C57H102O9SSi2
Exact Mass: 1018.6783
Mol. Wt.: 1019.6504
 
At –78 °C under an atmosphere of N2, to a stirred solution of alcohol 2.30 (90 
mg, 0.109 mmol) and 2,6-lutidine (38 µL, 0.33 mmol) in dry CH2Cl2 (2 mL) was 
slowly added Tf2O (20 µL, 0.12 mmol). The reaction was stirred for 45 minutes 
then NH4Cl (sat aq, 4 mL) and CH2Cl2 (10 mL) were added. The organic phase 
was separated then with washed NaHCO3 (sat aq, 4 mL), dried (MgSO4) and 
concentrated  in vacuo. Purification on SiO2 (1 x 10 cm) eluting with 
EtOAc/hexane (1:20  1:9) gave triflate 2.31 as a colourless oil (94 mg, 0.098 
mmol, 97%) which was used directly in the next reaction. 
At –78 °C under an atmosphere of N2, to a stirred solution of (S)-5-methyl-4-
(phenylthio)-dihydrofuran-2(3H)-one (1.36) (48.6 mg, 0.23 mmol) in THF (2 mL)   113
was added 1M t-BuP4 phosphazene base in hexanes (225 µL, 0.23 mmol). After 
20 minutes a solution of triflate 2.31 (180 mg, 0.187 mmol) in THF (1 mL) was 
added. The reaction was stirred at –78 ºC for 5 minutes, then NH4Cl (sat aq, 4 
mL) and Et2O (10 mL) were added. The organic layer was separated and the 
aqueous layer was re-extracted with Et2O (3 x 7 mL). The combined organic 
layers were washed with brine, dried (MgSO4) and concentrated in vacuo. 
Purification on SiO2 (1 x 12 cm) eluting with EtOAc/hexane (7:93) gave thiol 2.32 
as a ~1:1 mixture of diastereoisomers (colourless oil, 157 mg, 0.154 mmol, 82%).  
[α]
28
D –11.2 (CHCl3, c 0.67). 
IR max (neat) cm
-1 2926 (s), 2855 (s), 1759 (s), 1464 (s), 1372 (m), 1252 (s); 
1H NMR (400 MHz, CDCl3)  7.56 (2H, t, J = 6.8 Hz, SPh), 7.42 – 7.31 (3H, m, 
SPh), 4.79 (1H, d, J = 6.5 Hz, MOMO), 4.65 (1H, d, J = 6.5 Hz, MOMO), 4.63 – 
4.56 + 4.56 – 4.48 (1H, m, C36), 4.29 – 4.23 + 3.94 – 3.91 (1H, m, C4), 3.89 – 
3.82 (6H, m, C12, C15, C16, C19, C20 and C23), 3.68–3.62 (1H, m, C24), 3.38 
(3H, s, MOMO), 3.06 + 2.45 (1H, dd, J3.06 = 14.4, 7.7 Hz, J2.45 = 13.8, 10.2 Hz, 
C35(1H)), 2.33 + 2.07 (1H, dd, J2.33 = 13.8, 5.4 Hz, J2.07 = 14.4, 6.9 Hz, C35(1H)), 
2.04 – 1.78 (10H, m, C3, CX), 1.65 – 1.20 (39H, m, CX, C5 – C11, C25 – C33, 
C37), 1.08 – 1.03 (14H, m, i–Pr2Si), 0.93 – 0.86 (12H, m, C34 and TBS), 0.17, 
0.13, 0.05, 0.04 (6H, 4 x s, TBS),  CX  =  C13, C14, C17, C18, C21,  C22. 
Represent 12H, 8H can be found in 2.04 – 1.78 and 4H can be found in 1.65 – 
1.20. 
13C NMR
 (100 MHz, CDCl3)  177.9, 175.5 (C), 137.5, 137.1 (CH1), 130.9, 130.1 
(C), 130.3, 130.0 (CH1), 129.4, 129.3 (CH1), 97.3 (CH2), 83.3 (CH1), 82.8 (CH1), 
82.1 (CH1), 80.4 (CH1), 79.0 (CH1), 77.1 (CH1), 76.8 (CH1), 74.1, 73.7 (CH1), 
70.7, 70.0 (CH1), 56.1 (CH2), 55.9, 55.5 (C), 42.9 (CH2), 42.2 (CH2), 41.7 (CH2), 
40.0 (CH2), 39.0 (CH2), 38.5 (CH2), 33.4 (CH2), 33.0 (CH2), 32.4 (CH2), 32.3 
(CH2), 31.8 (CH2), 30.3 (CH2), 30.2 (CH2), 30.2 (CH2), 30.1 (CH2), 30.0 (CH2), 
29.8 (CH2), 27.6 (CH2), 27.4 (CH2), 26.9 (CH2), 26.7 (CH2), 26.5 (CH2), 25.8 
(CH3), 24.9 (CH2), 23.1 (CH2), 21.8, 20.8 (CH3), 18.5 (C), 18.2 (CH3), 17.9 (CH3), 
17.9 (CH3), 14.5 (CH1), 13.0 (CH3), –3.4 (CH3); 19.0 (CH3), 18.0 (C), 17.7 (CH3), 
17.5 (CH3), 17.4 (CH3), 14.1 (CH1), 12.5 (CH3), -4.4 (CH3).   114
LRMS ESI+ 1041.8 [M+Na]
+(100%). 
(S)-3-((R)-2-(tert-Butyldimethylsilyloxy)-9-((2S,5S)-5-((4S,7S)-2,2-
diisopropyl-7-((2S,5R)-5-((S)-1-(methoxymethyoxy)undecyl)-
tetrahydrofuran-2-yl)-1,3,2-dioxasilepan-4-yl)-tetrahydrofuran-2-
yl)nonyl)-5-methylfuran-2(5H)-one (2.33) 
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At –10 °C under an atmosphere of N2, to a stirred solution of thiol 2.32 (140 mg, 
0.137 mmol) in CH2Cl2 (8.0 mL) was added m-CPBA (37 mg, 0.165 mmol). The 
reaction was stirred for 30 minutes then Me2S (1 mL) was added and warmed to 
room temperature. The reaction was diluted with Et2O (10 mL) and NaHCO3 (sat 
aq, 10 mL), the organic layer was separated and the aqueous layer was 
extracted with Et2O (3 x 10 mL). The combined organic phases were washed 
with brine, dried (MgSO4) and concentrated in vacuo to afford a yellow oil. 
Purification on SiO2 (2 x 8 cm) eluting with hexane/EtOAc (9:1  5:1) gave ether 
2.33 as a colourless oil (116 mg, 0.128 mmol, 93%). 
[α]
28
D   +6.1 (CHCl3, c 1.35). 
IR max (neat) cm
-1 2926 (s), 2855 (s), 1769 (s), 1464 (s), 1383 (m), 1185 (s). 
1H NMR (400 MHz, CDCl3)   7.12 (1H, s, C35), 5.00 (1H, q, J = 6.5 Hz, C36), 
4.79 (1H, d, J = 6.5 Hz, MOMO), 4.65 (1H, d, J = 6.5 Hz, MOMO), 3.95 – 3.80 
(7H, m, C4, C12, C15, C16, C19, C20 and C23), 3.68 – 3.62 (1H, m, C24), 3.39 
(3H, s, MOMO), 2.42 (2H, d, J = 5.5 Hz, C3), 1.94 – 1.78 (8H, m, CX), 1.63 – 
1.22 (39H, m, CX, C5 – C11, C25 – C33, C37), 1.08 – 0.95 (14H, m, i–Pr2Si), 
0.91 – 0.86 (12H, m, C34 and TBS), 0.06 (3H, s, TBS), 0.03 (3H, s, TBS), CX = 
C13, C14, C17, C18, C21, C22. Represent 12H, 8H can be found in 1.94 – 1.78 
and 4H can be found in 1.63 – 1.22. 
13C NMR
 (100 MHz, CDCl3)  174.0 (C), 151.4 (CH1), 130.9 (C), 96.9 (CH2), 82.9 
(CH1), 82.3 (CH1), 81.6 (CH1), 79.9 (CH1), 78.5 (CH1), 77.4 (CH1), 76.7 (CH1),   115
76.3 (CH1), 70.2 (CH1), 55.6 (CH1), 37.0 (CH2), 35.9 (CH2), 32.9 (CH2), 32.8 
(CH2), 32.5 (CH2), 32.0 (CH2), 31.9 (CH2), 31.4 (CH2), 29.8 (CH2), 29.7 (CH2), 
29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.3 (CH2), 27.1 (CH2), 26.9 (CH2), 26.5 
(CH2), 26.2 (CH2), 25.9 (CH3), 25.4 (CH2), 25.1 (CH2), 22.7 (CH2), 19.0 (CH3), 
18.0 (C), 17.7 (CH3), 17.5 (CH3), 17.4 (CH3), 14.1 (CH1), 12.5 (CH3), -4.4 (CH3). 
LRMS ESI+ 931.8 [M+Na]
+ (100%). 
cis-Sylvaticin (1.100) 
C37H66O8
Exact Mass: 638.4758
Mol. Wt.: 638.9151 O O
H H
HO HO
H H
OH
7
OH
O
O
9
1 12 15 23 4
34
35
37
 
At room temperature under an atmosphere of N2, to a solution of ether 2.33 (27 
mg, 29.7 µmol) in CH2Cl2 (1 mL) was added a 5% solution of AcCl in MeOH (1 
mL). The reaction was stirred at room temperature for 3 hours, then concentrated 
in vacuo to afford a pale yellow oil. Purification on SiO2 (0.5 x 8 cm) eluting with 
hexane/acetone (4:1  7:3) gave gave cis-sylvaticin (1.100) as a waxy solid (17 
mg, 26.6 µmol, 90%).  
Spectroscopic characterisation agreed with published data.
66 
Melting point  63 – 65 °C.  
[α]
26
D   +5.0 (CHCl3, c 0.86). 
1H NMR (400 MHz, CDCl3)  7.19 (1H, s, C35), 5.09 – 5.01 (1H, m, C36), 3.96 – 
3.77 (5H, m, C4, C12, C20, C23 and C24), 3.74 – 3.65 (1H, m, C15), 3.54 – 3.46 
(1H, m, C19), 3.41 (1H, m, C16), 3.21 (1H, br s, OH), 2.97 (1H, br s, OH), 2.57 – 
2.46 (2H, m, C3(1H) and OH), 2.44 – 2.35 (1H, m, C3(1H)), 2.04 – 1.20 (48H, m, 
C5 – C9, C13, C14, C17, C18, C21, C22, C25 – C34, C37, OH), 0.88 (3H, t, J = 
6.7 Hz, C34). 
13C NMR
 (100 MHz, CDCl3) δ 174.6 (C), 151.7 (CH1), 131.2 (C), 83.0 (CH1), 82.4 
(CH1), 82.1 (CH1), 80.0 (CH1), 77.9 (CH1), 74.8 (CH1), 74.1 (CH1), 72.4 (CH1), 
69.9 (CH1), 37.4 (CH2), 35.9 (CH2), 33.3 (CH2), 33.1 (CH2), 31.9 (CH2), 31.3   116
(CH2), 31.2 (CH2), 30.4 (CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 
29.4 (CH2), 29.3 (CH2), 28.6 (CH2), 27.8 (CH2), 26.1 (CH2), 26.0 (CH2), 25.5 
(CH2), 24.1 (CH2), 22.6 (CH2), 19.1 (CH3), 14.1 (CH3). 
LRMS ESI+ 639 [M+H]
+(59%), 661 [M+Na]
+(100%).      
HRMS ESI+ [M+Na]
+ found 661.4647; calculated 661.4650. 
(E)-Ethyl hepta-4,6-dienoate (2.37) 
O
O C9H14O2
Exact Mass: 154.0994
Mol. Wt.: 154.2063
1 4
9
 
Under an atmosphere of Ar, a stirred solution of 1,4-pentadien-3-ol (2.36) (4.72 
g, 56.1 mmol), triethyl orthoacetate (72 mL, 0.392 mol) and propionic acid (0.43 
mL, 5.61 mmol) were heated at reflux for 3 hours. Excess triethyl orthoacetate 
was removed by distillation under reduced pressure (24°C, 12 mbar). Purification 
by distillation under reduced pressure (44°C, 12 mbar) gave (E)-ethyl hepta-4,6-
dienoate (2.37) as a colourless oil (6.35 g, 41.2 mmol, 73%).  
Spectroscopic characterisation agreed with published data.
63 
IR max (neat) cm
-1 2981 (m), 1735 (s). 
1H NMR (300 MHz, CDCl3)  6.30 (1H, dt, J = 16.9, 10.3 Hz, C8), 6.09 (1H, dd, J 
= 15.0, 10.3 Hz, C7), 5.79 – 5.61 (1H, m, C6), 5.12 (1H, d, J = 16.9 Hz, C9(1H)), 
4.99 (1H, d, J = 10.3 Hz, C9(1H)), 4.14 (2H, q, J = 7.1 Hz, C2), 2.51 – 2.27 (4 H, 
m, C4 and C5), 1.26 (3H, t, J = 7.1 Hz, C1). 
13C NMR
 (75 MHz, CDCl3)  173.1 (C), 137.0 (CH), 132.8 (CH), 132.1 (CH), 
115.8 (CH2), 60.5 (CH2), 34.1 (CH2), 28.0 (CH2), 14.4 (CH3). 
(E)-Hepta-4,6-dien-1-ol (2.38) 
OH
C7H12O
Exact Mass: 112.0888
Mol. Wt.: 112.1696
1 7
 
Under an atmosphere of Ar, at 0 °C to a stirred solution of LiAlH4 (1.25 g, 33 
mmol) in Et2O (100 mL) was added (E)-ethyl hepta-4,6-dienoate (2.37) (3.2 g, 
20.9 mmol) in Et2O (7 mL) dropwise. The reaction was stirred for 1 hour then   117
carefully quenched with water. 1M HCl (80 mL) was added and the reaction was 
stirred for 1 hour. The organic layer was separated and the aqueous layer was 
re-extracted with Et2O (4 x 50 mL).  The combined organic phases were dried 
(MgSO4) and concentrated by distillation to remove Et2O. Purification by 
distillation under reduced pressure (38°C, 0.35 mbar) gave (E)-hepta-4,6-dien-1-
ol (2.38) (1.13 g, 41.2 mmol, 48%) as a colourless oil.  
Spectroscopic characterisation agreed with published data.
63 
IR max (neat) cm
-1 3321 (br), 2935 (s), 2874 (s), 1650 (w), 1597 (w). 
1H NMR (300 MHz, CDCl3)  6.30 (1H, dt, J = 16.9, 10.3 Hz, C6), 6.08 (1H, dd, J 
= 15.1, 10.3 Hz, C5), 5.72 (1H, dt, J = 15.1, 7.1 Hz, C4), 5.10 (1H, d, J = 16.9 Hz, 
C7(1H)), 4.98 (1H, d, J = 10.3 Hz, C7(1H)), 3.66 (2H, t, J = 6.4 Hz, C1), 2.19 (2H, 
q, J = 7.1 Hz, C3), 1.77 – 1.60 (2H, m, C2), 1.45 (1H, s, OH). 
13C NMR
 (75 MHz, CDCl3)  137.2 (CH), 134.5 (CH), 131.7 (CH), 115.3 (CH2), 
62.5 (CH2), 32.3 (CH2), 29.0 (CH2). 
(2E,6E)-1-((S)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-nona-2,6,8-trien-1-one (2.35) 
S
OO
N
O
1
18
9
6
19
11 13
14
16
C19H27NO3S
Exact Mass: 349.1712
Mol. Wt.: 349.4876
 
Under an atmosphere of Ar, at –60 °C to a stirred solution of DMSO (0.7 mL, 9.8 
mmol) in THF (63 mL) was added oxalyl chloride (0.85 mL, 9.8 mmol) dropwise. 
The reaction was stirred for 15 minutes then (E)-hepta-4,6-dien-1-ol (2.38) (1.00 
g, 8.92 mmol) was added dropwise. The reaction was stirred for 15 minutes then 
Et3N (3.7 mL, 26.7 mmol) was added. The reaction was stirred for 15 minutes 
then warmed to room temperature and stirred for 30 minutes. 1M HCl (60 mL) 
was added and the organic layer was separated. The aqueous layer was re-
extracted with Et2O (2 x 50 mL).  The combined organic phases were dried 
(MgSO4) and concentrated carefully in vacuo to afford crude 4,6-heptadienal 
which was used without purification in the next reaction.    118
Under an atmosphere of Ar, to a stirred solution of (1R,2S)-camphorsultam 
phosphonate (3.56 g, 9.04 mmol) in dry acetonitrile (80 mL) dried lithium chloride 
(170 °C/ 0.035 mbar overnight) (0.4 g, 9.0 mmol) was added. After stirring for 15 
minutes DIPEA (1.3 mL, 0.75 mmol) was added. After stirring for 10 minutes, the 
crude 4,6-heptadienal in dry acetonitrile (2 mL) was then added. The reaction 
was stirred for 20 hours then a solution of brine (60 mL) was added and the 
organic layer was separated. The aqueous layer was re-extracted with Et2O (3 x 
50 mL). The combined organic phases were dried (MgSO4) and concentrated in 
vacuo to give an orange oil. Purification on SiO2 (10 x 5 cm) eluting with 
hexane/EtOAc (3:1) gave triene 2.35 (1.64 g, 0.046 mmol, 52%) as a colourless 
oil.  
[α]
26.5
D +58.3 (CHCl3, c 1.00). 
IR max (neat) cm
-1 2958 (s), 1681 (s) 1638 (s). 
1H NMR (300 MHz, CDCl3)  7.07 (1H, dt, J = 15.2, 6.8 Hz, C7), 6.58 (1H, d, J = 
15.2 Hz, C8), 6.29 (1H, dt, J = 16.8, 10.2 Hz, C2), 6.08 (1H, dd, J = 15.2, 10.2 
Hz, C3), 5.68 (1H, dt, J = 15.2, 6.7 Hz, C4), 5.11  (1H, d, J = 16.8 Hz, C1(1H)), 
4.99 (1H, d, J = 10.2 Hz, C1(1H)), 3.92 (1H, dd, J = 7.4, 5.3 Hz, C10), 3.51 (1H, 
d, J = 13.7 Hz, C16(1H)), 3.43 (1H, d, J = 13.7 Hz, C16(1H)), 2.42 – 2.32 (2H, m, 
C6), 2.32 – 2.22 (2H, m, C5), 2.20 – 2.03 (2H, m, C11), 2.00 – 1.82 (3H, m, C12, 
C13(1H) and C14(1H)), 1.48 – 1.30 (2H, m, C13(1H) and C14(1H)), 1.18 (3H, s, 
C18), 0.98 (3H, s, C19). 
13C NMR
 (75 MHz, CDCl3)  164.2 (C), 149.8 (CH1), 137.1 (CH1), 133.2 (CH1), 
132.2 (CH1), 121.5 (CH1), 115.7 (CH2), 65.3 (CH1), 53.4 (CH2), 48.6 (C), 48.0 
(C), 44.9 (CH1), 38.7 (CH2), 33.1 (CH2), 32.3 (CH2), 31.1 (CH2), 26.7 (CH2), 21.0 
(CH3), 20.1 (CH3). 
LRMS ESI+ 372 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 372.1609, [M+Na]
+ found = 372.1600. 
(2S)-N-[(S)-2-Hydroxy-2-[(2S,5R)-5-((S)-1-hydroxyprop-2-enyl)tetrahydro-2-
furanyl)ethanoyl]camphor-10,2-sultam (2.34a/b)   119
O
O
HO
H H
OH S
OO
N
18 19
11 13
14
16
C19H29NO6S
Exact Mass: 399.1716
Mol. Wt.: 399.5017
1
9
74
 
At –30 °C under an atmosphere of N2, to a stirred solution of triene 2.35 (32 mg, 
0.092 mmol) in acetone/acetic acid (3:2 1.65 mL) powdered KMnO4 (19 mg, 
0.119 mmol) was added. The reaction was stirred for 40 minutes then quenched 
by addition of Na2S2O3 (sat aq, 3 mL). The organic layer was separated and the 
aqueous layer was re-extracted with EtOAc (10 x 10 mL). The combined organic 
phases were dried (MgSO4) and concentrated in vacuo to give colourless oil (16 
mg). Purification on SiO2 (1 x 18 cm) eluting with EtOAc/hexane (3:2 → 4:1) gave 
THF diols 2.34a/b (6.5 mg, 0.016 mmol, 18%) as a colourless oil.  
Spectroscopic characterisation for THF diols 2.34a/b: 
IR max (neat) cm
-1 3465 (br), 2959 (s), 1689 (s). 
1H NMR (300 MHz, CDCl3)  5.90 (1H, ddd, J = 17.2, 10.5, 6.0 Hz, C2), 5.35 (1H, 
d, J = 17.2 Hz, C1(1H)), 5.20 (1H, d, J = 10.5 Hz, C1(1H)), 4.63 – 4.55 (2H, m, 
C3 and C8), 4.06 – 3.91 (3H, m, C4, C7 and C10), 3.82 (1H, d, J = 9.1 Hz, OH), 
3.53 (1H, d, J = 13.7 Hz, C16(1H)), 3.45 (1H, d, J = 13.7 Hz, C16(1H)), 3.02 – 
2.92 (1H, s, OH), 2.32 – 2.20 (1H, m, C5 or C6 (1H)), 2.15 – 2.02 (3H, m, C5 or 
C6  (1H)  and  C11), 2.01 – 1.82 (5H, m, C5 or C6  (2H),  C12,  C13(1H) and 
C14(1H)), 1.49 – 1.31 (2H, m, C13(1H) and C14(1H)), 1.16 (3H, s, C18), 0.98 
(3H, s, C19). 
13C NMR
 (100 MHz, CDCl3)  171.7 (C) 137.9 (CH), 116.8 (CH2), 83.0 (CH), 79.1 
(CH), 75.5 (CH), 73.3 (CH), 66.0 (CH), 53.2 (CH2) 49.3 (C), 48.1 (C) 44.7 (CH), 
38.4 (CH2), 33.1 (CH2), 28.3 (CH2) 28.0 (CH2), 26.5 (CH2), 21.0 (CH3) 20.1 (CH3). 
LRMS ESI+ 422 [M+Na]
+ (100%).    
HRMS ESI+ [M+Na]
+ calculated = 422.1613, [M+Na]
+ found = 422.1616. 
5-(Trimethylsilyl)pent-1-en-4-yn-3-ol (2.40)   120
OH
TMS
C8H14OSi
Exact Mass: 154.0814
Mol. Wt.: 154.2817
1 5
 
At –78 °C under an atmosphere of Ar, to a stirred solution of 
trimethylsilylacetylene (10 g, 0.1 mol)  in dry THF (130 mL) 2.3M n-BuLi in 
hexanes (46.5 mL, 0.105 mol) was added dropwise. The reaction was stirred for 
30 minutes then acrolein (7.5 mL, 0.11 mol) was added dropwise. The reaction 
was stirred for 30 minutes then the reaction was warmed to room temperature 
over 3.5 hours. The reaction was quenched with water (40 mL). A solution of 
brine (40 mL) was added and the organic layer was separated. The aqueous 
layer was re-extracted with Et2O (3 x 100 mL).  The combined organic phases 
were dried (MgSO4) and concentrated in vacuo to give yellow oil. Purification by 
distillation under reduced pressure (32–36°C, 0.6 mbar) gave allylic alcohol 2.40 
(13.3 g, 0.086 mol, 86%) as a colourless oil.  
Spectroscopic characterisation agreed with published data.
148 
IR max (neat) cm
-1 3726 (w), 3710 (w), 3628 (w), 2360 (s), 2341 (s). 
1H NMR (300 MHz, CDCl3)  5.97 (1H, ddd, J = 17.0, 10.2, 5.3 Hz, C2), 5.47 (1H, 
d, J = 17.0 Hz, C1(1H)), 5.23 (1H, d, J = 10.2 Hz, C1(1H)), 4.90 – 4.84 (1H, m, 
C3), 2.02 (1H, d, J = 6.5 Hz, OH), 0.19 (9H, s, TMS).
 
13C NMR (75 MHz, CDCl3)  136.9 (CH1), 116.7 (CH2), 104.3 (C), 91.4 (C), 63.7 
(CH1), 0.0 (CH3). 
(E)-Ethyl 7-(trimethylsilyl)hept-4-en-6-ynoate (2.41a/b) 
O
O
TMS
C12H20O2Si
Exact Mass: 224.1233
Mol. Wt.: 224.3715
1
9
7
 
Under an atmosphere of Ar, a stirred solution of 5-(trimethylsilyl)pent-1-en-4-yn-
3-ol (2.40) (13.3 g, 0.086 mol), triethyl orthoacetate (110 mL,  0.6 mol) and 
propionic acid (0.64 mL, 8.6 mmol) were heated at reflux for 3 hours. Excess 
triethyl orthoacetate was removed by reduced pressure distillation (42–46°C, 12 
mbar). The residue was Kugelrohr distilled (60°C, 0.6 mbar) to give crude ester 
(16.2 g). Purification on SiO2 (6 x 9 cm) eluting with hexane/Et2O (19:1) gave 2   121
main fractions:  esters 2.41a/b (13.9 g, 0.062 mol, 72%) as a colourless oil, and 
allene 2.42 (600 mg, 2.7 mmol, 4%) as a colourless oil. 
Spectroscopic characterisation for esters 2.41a/b agreed with published data.
166 
IR max (neat) cm
-1 2969 (m), 2901 (s), 2360 (s), 2342 (s), 2341 (s) 1736 (s). 
1H NMR (300 MHz, CDCl3)  6.32 – 6.08 (1H, m, C4), 5.56 (1H, d with fine 
splitting, J = 15.9 Hz, C3), 4.14 (2H, q, J = 7.1 Hz, C8), 2.52 – 2.29 (4H, m, C5 
and C6), 1.27 (3H, t, J = 7.1 Hz, C9), 0.18 (9H, s, TMS). 
13C NMR (75 MHz, CDCl3)  172.7 (C), 143.6 (CH1), 111.1 (CH1), 103.7 (C), 93.7 
(C), 60.7 (CH2), 33.4 (CH2), 28.4 (CH2), 14.4 (CH3), 0.1 (CH3). 
Ethyl 3-(trimethylsilyl)hepta-3,4,6-trienoate (2.42) 
C12H20O2Si
Exact Mass: 224.1233
Mol. Wt.: 224.3715
•
TMS
CO2Et
51  
IR max (neat) cm
-1 2956 (m), 1923 (m), 1735 (s), 1614 (w); 
1H NMR (300 MHz, CDCl3)  6.14 (1H, dt, J = 17.0, 10.2 Hz, C5), 5.65 (1H, d 
with fine splitting, J = 10.2 Hz, C4), 5.11 (1H, d with fine splitting, J = 17.0 Hz, 
C6(1H)), 4.86 (1H, d with fine splitting, J = 10.2 Hz, C6(1H)), 4.14 (2H, q, J = 7.1 
Hz, OEt), 3.02 (1H, d, J = 2.4 Hz, C1), 1.25 (3H, t, J = 7.1 Hz, OEt), 0.12 (9H, s, 
TMS); 
13C NMR (75 MHz, CDCl3)  209.8 (C), 171.6 (C), 133.1 (CH1), 113.9 (CH2), 90.6 
(CH1), 60.8 (CH2), 35.9 (CH2), 14.4 (CH3), -1.4 (CH3). 
LRMS GCMS 224.1 [M]
+ (17%). 
(E)-7-(Trimethylsilyl)hept-4-en-6-yn-1-ol (2.43a) 
OH
TMS
1
7
C10H18OSi
Exact Mass: 182.1127
Mol. Wt.: 182.3348
 
At –50 °C under an atmosphere of Ar, to a stirred solution of esters 2.41a/b (5.5 
g, 24.6 mmol) in CH2Cl2 (100 mL) was added 1.0M DIBAL-H in hexanes (55 mL, 
55 mmol) dropwise. The reaction was gradually warmed to room temperature   122
over 1 hour. A solution of Rochelle’s salt (sat aq, 40 mL) was added and the 
solution was stirred for 1 hour at room temperature. The organic layer was 
separated and the aqueous layer was re-extracted with Et2O (3 x 80 mL).  The 
combined organic phases were dried (MgSO4) and concentrated in vacuo to give 
a yellow oil. Purification on SiO2 (10 x 5 cm) eluting with hexane/Et2O (3:1) gave 
3 main fractions:  (E)-7-(trimethylsilyl)hept-4-en-6-yn-1-ol  (2.43a)  (2.4 g, 13 
mmol, 53%) as a colourless oil, (Z)-7-(trimethylsilyl)hept-4-en-6-yn-1-ol (2.43b) 
(150 mg, 0.83 mmol, 3%) as a colourless oil, and aldehyde (875 mg, 4.7 mmol, 
22%) as a colourless oil: 
(E)-7-(trimethylsilyl)hept-4-en-6-yn-1-ol (2.43a):  Spectroscopic characterisation 
agreed with published data.
167 
IR max (neat) cm
-1 3319 (br), 2957 (m), 2360 (m), 2136 (m). 
1H NMR (300 MHz, CDCl3)  6.21 (1H, dt, J = 15.9, 7.0 Hz, C4), 5.53 (1H, d, J = 
15.9 Hz, C5), 3.63 (2H, t, J = 6.4 Hz, C1), 2.31 – 2.04 (2H, m, C3), 1.79 – 1.50 
(3H, m, C2 and OH), 0.17 (9H, s, TMS). 
13C NMR (75 MHz, CDCl3)  145.3 (CH1), 110.4 (CH1), 104.0 (C), 93.1 (C), 62.2 
(CH2), 31.7 (CH2), 29.5 (CH2), 0.1 (CH3). 
(Z)-7-(Trimethylsilyl)hept-4-en-6-yn-1-ol (2.43b) 
C10H18OSi
Exact Mass: 182.1127
Mol. Wt.: 182.3348
OH
TMS
1
7
 
IR max (neat) cm
-1 3319 (br), 2957 (m), 2136 (m). 
1H NMR (300 MHz, CDCl3)   5.96 (1H, dt, J = 10.9, 7.6 Hz, C4), 5.54 (1H, finely 
split d, J = 10.8 Hz, C5), 3.65 (2H, q, J = 5.9 Hz, C1), 2.48 – 2.39 (2H, m, C3), 
1.76 – 1.63 (3H, m, C2 and OH), 0.20 (9H, s, TMS). 
13C NMR (75 MHz, CDCl3)  144.4 (CH1), 110.3 (CH1), 102.1 (C), 99.3 (C), 62.0 
(CH2), 31.4 (CH2), 26.5 (CH2), 0.1 (CH3).   123
(2E,6E)-1-((S)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-9-trimethylsilanyl-nona-2,6-dien-8-yn-1-one 
(2.44) 
 
O
TMS S
O2
N
18
9 1
19
11 13
14
16
C22H33NO3SSi
Exact Mass: 419.195
Mol. Wt.: 419.6528
  
Under an atmosphere of Ar, at –60 °C to a stirred solution of DMSO (0.825 mL, 
11.6 mmol) in THF (75 mL) was added oxalyl chloride (1 mL, 11.6 mmol) 
dropwise. The reaction was stirred for 15 minutes then (E)-7-(trimethylsilyl)hept-
4-en-6-yn-1-ol (2.43a) (1.9 g, 10.4 mmol) in THF (3 mL) was added dropwise. 
The reaction was stirred for 15 minutes then Et3N (4.4 mL, 31.6 mmol) was 
added. The reaction was stirred for 15 minutes then warmed to room 
temperature and stirred for 30 minutes. The white slurry was poured into 
ether/water (1:1 140 mL) and the organic layer was separated and washed with 
NaHCO3 (sat aq, 70 mL), water (70 mL) and brine (70 mL). The organic phase 
was dried (MgSO4) and concentrated carefully in vacuo to afford crude aldehyde 
(1.45 g, 8.1 mmol, 78%) as a colourless oil. 
Under an atmosphere of Ar, to a stirred solution of (1R,2S)-camphorsultam 
phosphonate (3.7 g, 9.3 mmol) in dry acetonitrile (60 mL) dried lithium chloride 
(170 °C/ 0.035 mbar overnight) (0.4 g, 9.0 mmol) was added. After stirring for 15 
minutes DIPEA (1.4 mL, 8.15 mmol) was added. After stirring for 10 minutes, 
crude aldehyde (1.45 g, 8.1 mmol, 78%) in dry acetonitrile (2 mL) was then 
added. The reaction was stirred for 22 hours then a solution of brine (60 mL) was 
added and the organic layer was separated. The aqueous layer was re-extracted 
with Et2O (3 x 80 mL). The combined organic phases were dried (MgSO4) and 
concentrated in vacuo to give an orange oil. Purification on SiO2 (14 x 5 cm) 
eluting with hexane/Et2O (1:1) gave dieneyne 2.44 (2.50 g, 6.0 mmol, 58% over 2 
steps) as a colourless oil.  
[α]
29.5
D +57.5 (CHCl3, c 1.53). 
IR max (neat) cm
-1 2959 (m), 2360 (s), 2341(s), 1682 (s), 1638 (s).   124
1H NMR (300 MHz, CDCl3)  7.02 (1H, dt, J = 15.1, 6.7 Hz, C7), 6.56 (1H, d, J = 
15.1 Hz, C8), 6.16 (1H, dt, J = 15.9, 6.7 Hz, C4), 5.53 (1H, d, J = 15.9 Hz, C3), 
3.91 (1H, dd, J = 7.4, 5.2 Hz, C10), 3.50 (1H, d, J = 13.7 Hz, C16(1H)), 3.42 (1 
H, d, J = 13.7 Hz, C16(1H)), 2.39 – 2.21 (4H, m, C5 and C6), 2.19 – 2.01 (2H, m, 
C11), 1.98 – 1.82 (3H, m, C12, C13(1H) and C14(1H)), 1.47 – 1.29 (2H, m, 
C13(1H) and C14(1H)), 1.16 (3H, s, C18), 0.96 (3H, s, C19), 0.16 (9 H, s, TMS). 
13C NMR (100 MHz, CDCl3)  164.0 (C), 148.9 (CH), 143.7 (CH), 121.7 (CH), 
111.1 (CH), 103.7 (C), 93.5 (C), 65.3 (CH), 53.3 (CH2), 48.6 (C), 47.9 (C), 44.9 
(CH1), 38.6 (CH2), 33.0 (CH2), 31.6 (CH2), 31.5 (CH2), 26.6 (CH2), 21.0 (CH3), 
20.0 (CH3), 0.1 (CH3). 
LRMS ESI+ 442 [M+Na]
+ (100%).      
HRMS ESI+ [M+Na]
+ calculated = 442.1843, [M+Na]
+ found = 442.1842. 
(2E,6E)-1-((S)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-nona-2,6-dien-8-yn-1-one (2.45) 
 
O
H S
N
OO
18
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11 13
14
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C19H25NO3S
Exact Mass: 347.1555
Mol. Wt.: 347.4717
 
To a stirred solution of dieneyne 2.44 (140 mg, 0.33 mmol), acetic acid (40 μL, 
0.67 mmol) in THF (75 mL) was added dropwise 1M TBAF in THF (670 μL, 0.67 
mmol). The reaction was stirred for 4 hours and concentrated in vacuo to give a 
yellow oil. Purification on SiO2 (6 x 3 cm) eluting with hexane/Et2O (6:4) gave 
dieneyne 2.45 (85.8 mg, 0.25 mmol, 75%) as a colourless oil.  
[α]
29.5
D +103.1 (CHCl3, c 0.24). 
IR max (neat) cm
-1 3278 (w), 2960 (m), 2360 (s), 2342(s), 1680 (s), 1638 (s). 
1H NMR (300 MHz, CDCl3)  7.05 (1H, dt, J = 15.1, 6.6 Hz, C7), 6.59 (1H, d, J = 
15.1 Hz, C8), 6.23 (1H, dt, J = 15.9, 6.6 Hz, C4), 5.51 (1H, d, J = 15.9 Hz, C3),
 
3.93 (1H, dd, J = 7.4, 5.2 Hz, C10), 3.52 (1H, d, J = 13.8 Hz, C16(1H)), 3.44 (1H, 
d, J = 13.8 Hz, C16(1H)), 2.81 (1H, d, J = 2.2 Hz, C1), 2.44 – 2.25 (4H, m, C5   125
and  C6), 2.21 – 2.05 (2H, m, C11), 2.00 – 1.83 (3H, m, C12,  C13(1H) and 
C14(1H)), 1.49 – 1.31 (2H, m, C13(1H) and C14(1H)), 1.19 (3H, s, C18), 0.99 
(3H, s, C19). 
13C NMR (100 MHz, CDCl3)  164.1 (C), 148.9 (CH), 144.5 (CH), 121.8 (CH), 
110.1 (CH), 82.3 (CH), 76.5 (C), 65.4 (CH), 53.4 (CH2), 48.7 (C), 48.0 (C), 44.9 
(CH1), 38.7 (CH2), 33.1 (CH2), 31.5 (CH2), 31.5 (CH2), 26.7 (CH2), 21.1 (CH3), 
20.1 (CH3). 
LRMS ESI+ 370 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 370.1447, [M+Na]
+ found = 370.1456. 
(S)-1-((S)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-2-hydroxy-2-[(2R,5S)-5-((S)-1-hydroxy-3-
trimethylsilanyl-prop-2-ynyl)-tetrahydro-furan-2-yl]-ethanone (2.46a/b) 
O
S
O2
N
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9
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C22H35NO6SSi
Exact Mass: 469.1954
Mol. Wt.: 469.6669
1
7 4
 
Method A: 
At –30 °C under an atmosphere of N2, to a stirred solution of dieneyne 2.44 (317 
mg, 0.75 mmol) in acetone/acetic acid (3:2 7.4 mL) was added powdered KMnO4 
(156 mg, 0.1 mmol). The reaction was stirred for 30 minutes then quenched by 
addition of Na2S2O3 (sat aq, 3 mL). The organic layer was separated and the 
aqueous layer was re-extracted with EtOAc (5 x 5 mL). The combined organic 
phases were dried (MgSO4) and concentrated in vacuo to give a yellow oil. 
Purification on SiO2 (11 x 2.5 cm) eluting with EtOAc/hexane (1:4 → 1:1) gave 
gave 2 main fractions: THF diols 2.46a/b  (114 mg, 0.24 mmol, 32%) as a 
colourless oil, and hydroxy ketone 2.47 (83.4 mg, 0.19 mmol, 25%) as a pale 
yellow oil. 
 
Method B: 
At –50 °C under an atmosphere of N2, to a stirred solution of KMnO4 (45 mg, 
0.28 mmol), adogen 464 (26 mg, 0.06 mmol), acetic acid (50μL, 0.84 mmol) and   126
CH2Cl2 (2 mL) was added dieneyne 2.44 (0.52 mg, 0.11 mmol) in CH2Cl2 (1 mL) 
dropwise. The reaction was allowed to warm to room temperature over 1 hour 
then Na2S2O3 (sat aq, 3 mL) was added and the organic layer was separated. 
The aqueous layer was re-extracted with EtOAc (5 x 5 mL). The combined 
organic phases were dried (MgSO4) and concentrated in vacuo to give a yellow 
oil (73.4 mg). Purification on SiO2 (9 x 2 cm) eluting with hexane/EtOAc (4:1 → 
1:1) gave 2 main fractions: THF diols 2.46a/b (8 mg, 0.045 mmol, 7%) as a 
colourless oil, and hydroxy ketone 2.47 (18 mg, 0.04 mmol, 17%) as a pale 
yellow oil.  
Spectroscopic characterisation for THF diols 2.46a/b, isolated as a 9:1 mixture of 
diastereoisomers: 
IR max (neat) cm
-1 3470 (br), 2959 (s), 2359 (w), 1686 (s). 
1H NMR (400 MHz, CDCl3)  4.60 – 4.52 (2H, m, C7 and C8), 4.32 (1H, dd, J = 
6.7, 4.6 Hz, C3), 4.10 – 4.02 (1H, m, C4), 3.95 (1H, dd, J = 7.8, 5.1 Hz, C10), 
3.86 (1H, d, J = 9.3 Hz, OH), 3.51 (1H, d, J = 13.8 Hz, C16(1H)), 3.44 (1H, d, J = 
13.8 Hz, C16(1H)), 3.37 (1H, d, J = 4.6 Hz, OH), 2.32 – 2.22 (1H, m, C5(1H)), 
2.13 – 1.93 (5H, m, C5(1H), C6 and C11), 1.94 – 1.82 (3H, m, C12, C13(1H) and 
C14(1H)), 1.49 – 1.27 (2H, m, C13(1H) and C14(1H)), 1.14 (3H, s, C18), 0.96 
(3H, s, C19), 0.16 (9H, s, TMS).  
13C NMR (100 MHz, CDCl3)  171.6 (C), 103.9 (C), 90.6 (C), 83.0 (CH), 79.5 
(CH), 72.4 (CH), 65.9 (CH), 65.9 (CH), 53.1 (CH2), 49.2 (C), 48.0 (C), 44.7 (CH1), 
38.3 (CH2), 33.0 (CH2), 28.1 (CH2), 27.8 (CH2), 26.5 (CH2), 21.0 (CH3), 20.0 
(CH3), 0.0 (CH3), 
Minor isomer peaks  171.9 (C), 102.1 (C), 91.2 (C), 82.5 (CH), 79.3 (CH), 70.2 
(CH), 64.8 (CH). 
LRMS ESI+ 492 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 492.1847, [M+Na]
+ found = 492.1838.   127
(E)-1-((S)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-2-hydroxy-9-trimethylsilanyl-non-6-en-8-
yne-1,3-dione (2.47) 
O
TMS S
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N
18
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C22H33NO5SSi
Exact Mass: 451.1849
Mol. Wt.: 451.6516
 
Spectroscopic characterisation for hydroxy ketone 2.47, isolated as a 3:2 mixture 
of epimers. 
IR max (neat) cm
-1 3465 (br), 2959 (m), 2131 (w), 1729 (s), 1686 (s). 
1H NMR (300 MHz, CDCl3)  6.15 (1H, dt, J = 15.9, 6.8 Hz, C4), 5.53 (1H, d, J = 
15.9 Hz, C3),
 5.16 (1H, s, C8), 3.99 – 3.91 (3H, m, OH and C10), 3.59 – 3.46 
(2H, m, C16), 2.73 – 2.65 (2H, m, C6), 2.48 – 2.37 (2H, m, C5), 2.21 – 2.05 (2H, 
m, C11), 2.00 – 1.83 (3H, m, C12, C13(1H) and C14(1H)), 1.49 – 1.31 (2H, m, 
C13(1H) and C14(1H)), 1.17 (3H, s, C18), 0.99 (3H, s, C19),
 
Minor isomer peaks  5.21 (1H, s, C8), 1.14 (3H, s, C18), 0.98 (3H, s, C19).
 
13C NMR
 (75 MHz, CDCl3)  203.1 (C), 167.8 (C), 143.4 (CH), 111.5 (CH), 103.8 
(C), 93.9 (C), 76.2 (CH), 65.7 (CH), 53.2 (CH2), 49.5 (C), 48.2 (C), 44.9 (CH1), 
38.5 (CH2), 38.1 (CH2), 33.2 (CH2), 33.1 (CH2), 26.7 (CH2), 20.7 (CH3), 20.2 
(CH3), 0.3 (CH3), 
Minor isomer peaks  202.8 (C), 168.4 (C), 65.4 (CH), 20.3 (CH3). 
LRMS ESI+ 469 [M+NH4]
+ (100%), 474 [M+Na]
+ (40%).    
(S)-1-((S)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-2-hydroxy-2-[(2R,5S)-5-((S)-1-hydroxy-
prop-2-ynyl)-tetrahydro-furan-2-yl]-ethanone 
O
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7 4 C19H27NO6S
Exact Mass: 397.1559
Mol. Wt.: 397.4858
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For procedure see method A THF diols 2.46a/b.  
[α]
29.5
D +47.7 (CHCl3, c 0.93). 
IR max (neat) cm
-1 3465 (br), 3300 (br), 2959 (s), 2883 (m), 2360 (m), 2342 (m), 
1686 (s). 
1H NMR (300 MHz, CDCl3)  4.63 – 4.55 (2H, m, C7 and C8), 4.32 (1H, dd, J = 
5.9, 2.2 Hz, C3), 4.16 – 4.07 (1H, m, C4), 3.96 (1H, dd, J = 7.9, 5.0 Hz, C10), 
3.52 (1H, d, J = 13.7 Hz, C16(1H)), 3.45 (1H, d, J = 13.7 Hz, C16(1H)), 2.45 (1H, 
d, J = 2.3 Hz, C1), 2.33 – 2.20 (1H, m, C5(1H)), 2.15 – 1.95 (5H, m, C5(1H), C6 
and C11), 1.95 – 1.83 (3H, m, C12, C13(1H) and C14(1H)), 1.50 – 1.30 (2H, m, 
C13(1H) and C14(1H)), 1.15 (3H, s, C18), 0.97 (3H, s, C19). 
13C NMR (75 MHz, CDCl3)  171.6 (C), 82.8 (CH), 82.5 (C), 79.5 (CH), 73.8 (C), 
72.7 (CH), 66.0 (CH), 65.1 (CH), 53.2 (CH2), 49.3 (C), 48.1 (C), 44.7 (CH1), 38.3 
(CH2), 33.1 (CH2), 27.9 (CH2), 26.5 (CH2), 21.0 (CH3), 20.1 (CH3). 
LRMS ESI+ 420 [M+Na]
+ (100%).   
HRMS ESI+ [M+Na]
+ calculated = 420.1451, [M+Na]
+ found = 420.1450. 
(E)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-hepta-2,6-dien-1-one (2.50) 
 
O
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C17H25NO3S
Exact Mass: 323.1555
Mol. Wt.: 323.4503
 
Under an atmosphere of Ar, to a stirred solution of (1S,2R)-camphorsultam 
phosphonate (4.95 g, 12.6 mmol) in dry acetonitrile (80 mL) dried lithium chloride 
(170 °C/ 0.035 mbar overnight) (0.56 mg, 13.2 mmol) was added. After stirring 
for 15 minutes, DIPEA (2.2 mL, 12.6 mmol) was added. After stirring for 10 
minutes, 4-pentenal (2.49) (1.2 mL, 12 mmol) in dry acetonitrile (2 mL) was 
added. The reaction was stirred for 20 hours. A solution of brine (50 mL) and 
water (30mL) were added and the organic layer was separated. The aqueous 
layer was re-extracted with Et2O (3 x 80 mL). The combined organic phases were 
dried (MgSO4) and concentrated in vacuo to give an orange oil. Purification on   129
SiO2 (5 x 15 cm) eluting with hexane/Et2O (7:3) gave diene 2.50 (2.95 g, 9.1 
mmol, 76%) as a colourless oil.  
[α]
27
D –54.0 (CHCl3, c 1.05). 
IR max (neat) 2959 (m), 1682 (s), 1638 (s) cm
-1. 
1H NMR (300 MHz, CDCl3)  7.07 (1H, dt, J = 15.1, 6.6 Hz, C5), 6.57 (1H, d, J = 
15.1 Hz, C6), 6.22 (1H, ddt, J = 17.2, 10.3, 6.6 Hz, C2), 5.05 (1H, d, J = 17.2 Hz, 
C1(1H)), 5.00 (1H, d, J = 10.3 Hz, C1(1H)), 3.92 (1H, dd, J = 7.3, 5.1 Hz, C8) 
3.51 (1H, d, J = 13.7 Hz, C14(1H)), 3.43 (1H, d, J = 13.7 Hz, C14(1H)), 2.40 – 
2.30 (2H, m, C3), 2.29 – 2.19 (2H, m, C4), 2.15 – 2.05 (2H, m, C9), 1.99 – 1.84 
(3H, m, C10 and C11(1H) and C12(1H)), 1.47 – 1.34 (2H, m, C11(1H) and 
C12(1H)), 1.18 (3H, s, C16), 0.97 (3H, s, C17). 
13C NMR (100 MHz, CDCl3)  164.4 (C), 150.1 (CH), 137.3 (CH), 132.2 (CH), 
121.6 (CH), 115.9 (CH2), 65.5 (CH), 53.5 (CH2), 48.8 (C), 48.1(C), 45.0 (CH), 
38.8 (CH2), 33.2 (CH2), 32.3 (CH2), 32.1 (CH2), 26.8 (CH2), 21.2 (CH3), 20.2 
(CH3). 
LRMS ESI+ 346 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 346.1453, [M+Na]
+ found = 346.1449. 
(R)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-2-hydroxy-2-((2S,5R)-5-hydroxymethyl-
tetrahydro-furan-2-yl)-ethanone (2.48a) 
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C17H27NO6S
Exact Mass: 373.1559
Mol. Wt.: 373.4644
 
At –40 °C under an atmosphere of Ar, to a stirred solution of diene 2.50 (666 mg, 
2.03 mmol) in acetone/acetic acid (4:1 65 mL) was added powdered KMnO4 (417 
mg, 2.6 mmol). The reaction was stirred for 1 hour, then quenched by addition of 
Na2S2O3 (sat aq, 20 mL). The organic layer was separated and the aqueous layer   130
was re-extracted with CH2Cl2 (4 x 100 mL). The combined organic phases were 
dried (MgSO4) and concentrated in vacuo to give a yellow oil. Purification on SiO2 
(3 x 11 cm) eluting with hexane/EtOAc (3:1 → 0:1) gave 3 main fractions: THF 
diol 2.48a (430 mg, 1.16 mmol, 57%) as a colourless oil, THF diol 2.48b (75 mg, 
0.20 mmol, 9.9%) as a colourless oil and hydroxy ketone 2.52 (160 mg, 0.45 
mmol, 22%) as a pale yellow oil. 
Spectroscopic characterisation for THF diol 2.48a. 
[α]
27
D –54.0 (CHCl3, c 1.97). 
IR max (neat) 3442 (br), 2958 (s), 1691 (s) cm
-1. 
1H NMR (300 MHz, CDCl3)  4.54 (2H, m, C5 and C6), 4.16 – 4.04 (2H, m, C2 
and C1(1H)), 3.81 (1H, dd, J = 11.7, 2.9 Hz, C1(1H)), 3.94 (1H, dd, J = 7.9, 5.1 
Hz  C8),  3.57 – 3.47 (2H, m, C14(1H) and OH),  3.52 (1H, d, J = 13.7 Hz, 
C14(1H)), 3.43 (1H, d, J = 13.7 Hz, C14(1H)), 3.18 (1H, br s, OH), 2.15 – 1.99 
(4H, m, C3 and C4), 1.95 – 1.83 (5H, m, C9, C10, C11(1H) and C12(1H)), 1.45 – 
1.35 (2H, m, C11(1H) and C12(1H)), 1.14 (3H, s, C16), 0.97 (3H, s, C17). 
13C NMR (75 MHz, CDCl3)  172.0 (C) 80.9 (CH), 79.0 (CH), 73.5 (CH), 66.1 
(CH), 64.8 (CH2), 53.3 (CH2), 49.3 (C) 48.2 (C), 44.9 (CH), 38.5 (CH2), 33.2 
(CH2), 28.8 (CH2), 27.3 (CH2), 26.7 (CH2), 21.1 (CH3), 20.2 (CH3). 
LRMS ESI+ 396 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 396.1451, [M+Na]
+ found = 396.1452. 
(S)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-2-hydroxy-2-((2R,5S)-5-hydroxymethyl-
tetrahydro-furan-2-yl)-ethanone (2.48b) 
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Exact Mass: 373.1559
Mol. Wt.: 373.4644
 
[α]
25
D –137.8 (CHCl3, c 1.55).   131
IR max (neat) 3475 (br), 2958 (s), 1698 (s) cm
-1. 
1H NMR (300 MHz, CDCl3)  4.69 (1H, br s, C6), 4.52 – 4.43 (1H, m, C5), 4.03 
(1H, m, C2), 3.96 (1H, dd, J = 7.1, 5.3 Hz, C8), 3.76 (1H, dd, J = 11.8, 3.1 Hz, 
C1(1H)), 3.64 (1H, br s, OH), 3.55 – 3.38 (3H, m, C1(1H) and C14), 2.23 – 1.83 
(9H, m, C3, C4, C9, C10, C11(1H) and C12(1H)), 1.53 – 1.31 (2H, m, C11(1H) 
and C12(1H)), 1.16 (3H, s, C16), 0.99 (3H, s, C17). 
13C NMR (75 MHz, CDCl3)  173.1 (C), 80.4 (CH), 80.3 (CH), 73.8 (CH), 65.0 
(CH), 64.7 (CH2), 53.0 (CH2), 49.0 (C), 47.9 (C), 44.5 (CH), 37.7 (CH2), 32.6 
(CH2), 28.1 (CH2), 27.2 (CH2), 26.5 (CH2), 20.4 (CH3), 19.9 (CH3). 
LRMS ESI+ 396 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 396.1451, [M+Na]
+ found = 396.1450. 
1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-tricyclo[5.2.1.01,5]dec-4-
yl)-2-hydroxy-hept-6-ene-1,3-dione (2.52) 
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C17H25NO5S
Exact Mass: 355.1453
Mol. Wt.: 355.4491
 
IR max (neat) 3464 (br), 2958 (s), 1728 (s), 1686 (s) cm
-1. 
1H NMR (300 MHz, CDCl3)  5.91 – 5.69 (1H, m, C2), 5.24 (1H, s, C6), 5.12 – 
4.93 (2H, m, C1), 4.00 – 3.72 (2H, m, C8 and OH), 3.57 – 3.43 (2H, m, C14), 
3.03 – 2.78 (1H, m, C4(1H)), 2.76 – 2.62 (1H, m, C4(1H)), 2.42 – 2.30 (2H, m, 
C3), 2.21 – 2.03 (2H, m, C9), 2.00 – 1.84 (3H, m, C10, C11(1H) and C12(1H)), 
1.52 – 1.30 (2H, m, C11(1H) and C12(1H)), 1.16 (3H, s, C16), 0.98 (3H, s, C17). 
13C NMR (75 MHz, CDCl3)  203.1 (C), 168.3 (C), 136.6 (CH), 115.7 (CH2), 76.6 
(CH1), 65.3 (CH1), 53.0 (CH2), 49.3 (C), 48.1 (C), 44.8 (CH1), 38.6 (CH2), 37.9 
(CH2), 33.0 (CH2), 27.2 (CH2), 26.6 (CH2), 20.6 (CH3), 20.1 (CH3). 
LRMS ESI+ 373 [M+NH4]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 378.1346, [M+Na]
+ found = 378.1349.   132
1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-tricyclo[5.2.1.01,5]dec-4-
yl)-propenone (2.58) 
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C13H19NO3S
Exact Mass: 269.1086
Mol. Wt.: 269.3599
 
At 0 °C under an atmosphere of Ar, to a stirred solution of (2R)-camphor sultam 
2.56 (2.0 g, 9.2 mmol) in dry benzene (24 mL) and dry acetonitrile (4 mL) was 
added dropwise TMSCl (5.6 mL, 44.2 mmol), followed by Et3N (1.4 mL, 10.1 
mmol). The reaction was stirred for 45 minutes then warmed to room 
temperature and stirred for 4 hours. The reaction was concentrated in vacuo, the 
creamy solid was suspended in toluene (40 mL) and filtered. The filtrate was 
concentrated in vacuo and the white solid was used crude in the next step. 
Under an atmosphere of Ar, a stirred solution of the crude white solid, acryloyl 
chloride (3.0 mL, 36.8 mmol), and CuCl2 (123.4 mg, 0.92 mmol) in dry benzene 
(13 mL) were heated to reflux for 16 hours. The reaction was filtered while still 
warm and then washed through with EtOAc (20 mL). The filtrate was 
concentrated in vacuo to give a white solid. Purification on SiO2 (4 x 12 cm) 
eluting with EtOAc/hexane (1:4) gave 1-((R)-10,10-dimethyl-3,3-dioxo-36-thia-4-
aza-tricyclo[5.2.1.01,5]dec-4-yl)-propenone (2.58) (1.71 g, 6.35 mmol, 69%) as a 
white solid.  
Spectroscopic characterisation agreed with that published.
150  
[α]
25
D –101.5 (CHCl3, c 0.96). 
IR max (neat) cm
-1 2958 (s), 2924 (s), 1674 (s), 1619 (m). 
1H NMR (300 MHz, CDCl3)  6.87 (1H, dd, J = 16.6, 10.3 Hz, C2), 6.50 (1H, dd, J 
= 16.6, 1.6 Hz, C1(1H trans to C2)), 5.85 (1H, dd, J = 10.3, 1.6 Hz, C1(1H cis to 
C2)), 3.94 (1H, dd, J = 7.4, 5.3 Hz, C4), 3.52 (1H, d, J = 13.7 Hz, C10(1H)), 3.45 
(1H, d, J = 13.7 Hz, C10(1H)), 2.24 – 2.02 (2H, m, C5), 2.00 – 1.81 (3H, m, C6, 
C7(1H) and C8(1H)), 1.50 – 1.30 (2 H, m, C7(1H) and C8(1H)), 1.18 (3H, s, 
C12), 0.98 (3H, s, C13).   133
13C NMR
 (75 MHz, CDCl3)  164.0 (C), 131.4 (CH2), 128.0 (CH1), 65.3 (CH1), 
53.3 (CH2), 48.7 (C), 48.0 (C), 44.9 (CH1), 38.6 (CH2), 33.1 (CH2), 26.7 (CH2), 
21.0 (CH3), 20.1 (CH3). 
2-(Dodec-11-en-3-ynyl)-1,3-dioxolane (2.61) 
O
O
5
1
13
14
14
C15H24O2
Exact Mass: 236.1776
Mol. Wt.: 236.3499
 
At –78 °C under an atmosphere of Ar, to a stirred solution of 2-(but-3-ynyl)-1,3-
dioxolane (2.60) (16.3 g, 0.129 mol) in dry THF (500 mL) was added 2.45M n-
BuLi in hexane (52.6 mL, 0.129 mol). After stirring for 40 minutes, HMPA (37 mL, 
0.2 mmol) was added dropwise. After stirring for 30 minutes, bromide 2.1 (20 g, 
0.104 mol) was added dropwise. The reaction was allowed to warm to room 
temperature and stirred for 3 hours. The reaction was slowly poured into NH4Cl 
(sat aq, 250 mL) and the organic layer was separated. The aqueous layer was 
extracted with Et2O (2 x 250 mL) and CH2Cl2 (1 x 150 mL). The combined 
organic phases were concentrated in vacuo to give a yellow oil. The yellow oil 
was dissolved in Et2O (150 mL) and washed with water (3 x 150 mL). The 
organic phase was dried (MgSO4) and concentrated in vacuo to afford a yellow 
oil. Purification on SiO2 (15 x 8 cm) eluting with hexane/Et2O (4:1) gave 2-
(dodec-11-en-3-ynyl)-1,3-dioxolane  (2.61) (21.3 g, 0.090 mol, 70%) as a 
colourless oil.  
IR max (neat) cm
-1 2930 (s), 2856 (s), 1640 (w). 
1H NMR (400 MHz, CDCl3)  5.82 (1H, ddt, J = 17.1, 10.3, 6.7 Hz, C2), 5.05 – 
4.89 (3H, m, C1 and C13), 4.01 – 3.80 (4H, m, C14), 2.30 (2H, tt, J = 7.5, 2.3 Hz, 
C11), 2.14 (2H, tt, J = 7.0, 2.3 Hz, C8), 2.10 – 2.00 (2H, m, C3), 1.84 (2H, td, J = 
7.4, 4.8 Hz, C12), 1.54 – 1.22 (8H, m, C4 – C7). 
13C NMR
 (100 MHz, CDCl3)  139.1 (CH1), 114.2 (CH2), 103.4 (CH1), 80.5 (C), 
78.9 (C), 64.9 (CH2), 33.7 (CH2), 33.5 (CH2), 29.0 (CH2), 28.8 (CH2), 28.7 (CH2), 
28.6 (CH2), 18.7 (CH2), 13.8 (CH2). 
2-(10-(Oxiran-2-yl)dec-3-ynyl)-1,3-dioxolane (2.62)   134
O
O
5 1
13
O
14
14
C15H24O3
Exact Mass: 252.1725
Mol. Wt.: 252.3493
 
Under an atmosphere of N2 at 0 °C, to stirred alkene 2.61 (113 mg, 0.476 mmol), 
was added dropwise 0.068M DDO (11 mL, 0.75 mmol), a further portion of 
0.068M DDO (2.2 mL, 0.15 mmol) was added every hour, 3 times. After 4 hours 
the reaction was concentrated in vacuo to afford a yellow oil. Purification on SiO2 
(8 x 2 cm) eluting with hexane/Et2O (3:2 → 0:1) gave 2-(10-(oxiran-2-yl)dec-3-
ynyl)-1,3-dioxolane (2.62) (70 mg, 0.276 mmol, 58%) as a colourless oil.  
1H NMR (400 MHz, CDCl3)  4.90 (1H, t, J = 4.8 Hz, C13), 3.94 – 3.73 (4H, m, 
C14), 2.87 – 2.78 (1H, m, C2), 2.67 (1H, dd, J = 5.0, 4.1 Hz, C1(1H)), 2.39 (1H, 
dd, J = 5.0, 2.7 Hz, C1(1H)), 2.22 (2H, tt, J = 7.4, 2.4 Hz, C11), 2.06 (2H, tt, J = 
6.9, 2.4 Hz, C8), 1.77 (2H, td, J = 7.4, 4.8 Hz, C12), 1.54 – 1.17 (10H, m, C3 – 
C7). 
13C NMR
 (100 MHz, CDCl3)  103.4 (CH1), 80.4 (C), 79.0 (C), 64.9 (CH2), 52.3 
(CH1), 47.1 (CH2), 33.5 (CH2), 32.4 (CH2), 28.9 (CH2), 28.9 (CH2), 28.7 (CH2), 
25.9 (CH2), 18.7 (CH2), 13.7 (CH2); 
LRMS ESI+ 275 [M+Na]
+ (100%). 
(R)-1-(Benzyloxy)-12-(1,3-dioxolan-2-yl)dodec-9-yn-2-ol 
C22H32O4
Exact Mass: 360.2301
Mol. Wt.: 360.4871
O
O
18 19
19
5
OH
O 7
4
1
 
At 0 °C under an atmosphere of Ar, to a stirred solution of 2-(10-(oxiran-2-yl)dec-
3-ynyl)-1,3-dioxolane (2.62) (8.83 g, 0.035 mol) and oligomeric (S,S)-Co(salen) 
(2.13) (75 mg, 0.088 mmol) in MeCN (2.3 mL) was added dropwise benzyl 
alcohol (1.64 mL, 0.0158 mol), the reaction was stirred for 24 hours. The reaction 
was filtered through a plug of silica with Et2O (300 mL) and concentrated in 
vacuo to afford an orange oil. Purification on SiO2 (15 x 4 cm) eluting with 
hexane/Et2O (7:3 → 0:1) gave 2 main fractions: (R)-1-(benzyloxy)-12-(1,3-  135
dioxolan-2-yl)dodec-9-yn-2-ol (2.63) (3.53 g, 0.0098 mol, 28%) as an orange oil 
and 2-(10-(oxiran-2-yl)dec-3-ynyl)-1,3-dioxolane (2.62) (5.12 g, 0.0203 mol, 58%) 
as a colourless oil. 
1H NMR (400 MHz, CDCl3)  7.44 – 7.22 (5H, m, C1 – C3), 4.98 (1H, t, J = 4.8 
Hz, C18), 4.56 (2H, apparent  s, C5), 4.02 – 3.75 (5H, m, C7 and C19), 3.51 (1H, 
dd, J = 9.4, 3.0 Hz, C6(1H)), 3.33 (1H, dd, J = 9.4, 7.9 Hz, C6(1H)), 2.37 (1H, br 
s, OH), 2.29 (2H, tt, J = 7.4, 2.3 Hz, C16), 2.13 (2H, tt, J = 6.9, 2.3 Hz, C13), 1.84 
(2H, td, J = 7.4, 4.8 Hz, C17), 1.53 – 1.26 (10H, m, C8 – C12). 
13C NMR
 (100 MHz, CDCl3)  138.0 (C), 128.4 (CH1), 127.7 (CH1), 127.7 (CH1), 
103.4 (CH1), 80.5 (C), 78.9 (C), 74.6 (CH2), 73.3 (CH2), 70.4 (CH1), 64.9 (CH2), 
33.4 (CH2), 33.1 (CH2), 29.1 (CH2), 28.9 (CH2), 28.7 (CH2), 25.4 (CH2), 18.7 
(CH2), 13.7 (CH2). 
LRMS ESI+ 383 [M+Na]
+ (100%). 
2-(4-Bromobutyl)-1,3-dioxolane (2.71) 
Br O
O C7H13BrO2
Exact Mass: 208.0099
Mol. Wt.: 209.0809
1
2 6
 
Under an atmosphere of Ar at –78 °C, a stirred solution of 5-bromopentanoate 
(2.69) (10.0 g, 0.0478 mol) in dry toluene (260 mL) was added dropwise 1.5M 
DIBAL-H in toluene (35.1 mL, 0.0526 mol) over 1.5 hours. The reaction was 
stirred for a further 1.5 hours at –78 °C at which point the reaction was quenched 
with MeOH (20 mL). The reaction mixture was warmed to room temperature, 5% 
HCl (150 mL) was added and the reaction was stirred for 40 minutes. The 
organic layer was separated and washed with water (150 mL). The organic 
phase was dried (MgSO4) and carefully concentrated in vacuo to afford a solution 
of crude aldehyde 2.70 in toluene (12g). 
The solution of crude aldehyde 2.70 in toluene was dissolved in dry benzene 
(170 mL), to this ethylene glycol (6.2 g, 0.1 mol) and TsOH (50mg, 0.3 mmol) 
were added. Using Dean-Stark apparatus the reaction mixture was heated to 
reflux for 15 hours. The reaction was diluted with NaHCO3 (sat aq, 170 mL), the 
organic layer was separated and dried (MgSO4) and concentrated by distillation.   136
Purification on SiO2 (8 x 7 cm) eluting with pentane/Et2O (9:1) gave 2-(4-
bromobutyl)-1,3-dioxolane (2.71) (8.14 g, 0.0392 mol, 82%) as a colourless 
liquid. 
Spectroscopic characterisation agreed with that published.
157 
IR max (neat) cm
-1 2977 (w), 2871 (w), 907 (s), 728(s). 
1H NMR (300 MHz, CDCl3)  4.86 (1H, t, J = 4.5 Hz, C2), 4.03 – 3.91 (2H, m, C1 
(1H)), 3.91 – 3.79 (2H, m, C1(1H)), 3.41 (2H, t, J = 6.8 Hz, C6), 1.92 (2H, tt, J = 
7.3, 6.8 Hz, C5), 1.74 –1.64 (2H, m, C3), 1.64 – 1.50 (2H, m, C4). 
13C NMR
 (75 MHz, CDCl3)  104.2 (CH1), 64.9 (CH2), 33.5 (CH2), 32.9 (CH2), 
32.6 (CH2), 22.6 (CH2). 
5-(4-(1,3-Dioxolan-2-yl)butylthio)-1-phenyl-1H-tetrazole (2.72) 
S O
O N N
N
N C14H18N4O2S
Exact Mass: 306.115
Mol. Wt.: 306.3833
1
2 6
10
7
 
At 40 °C under an atmosphere of Ar, a solution of 2-(4-bromobutyl)-1,3-dioxolane 
(2.71) (3.75 g, 18 mmol), 1-phenyl-1H-tetrazole-5-thiol (3.20 g, 18 mmol) and dry 
K2CO3 (61.9 mg, 0.248 mmol) in dry (dried with MgSO4) acetone (90 mL) were 
vigorously stirred for 3 hours, then at room temperature for 3 hours. The reaction 
was filtered and the collected white solid was washed with acetone (90 mL). The 
filtrate was concentrated in vacuo to afford colourless oil. The colourless oil was 
dissolved in CH2Cl2/water (1:1 250 mL), the organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 100 mL). The combined organic 
phases were washed with water (200 mL) then dried (MgSO4) and concentrated 
in vacuo to afford a colourless oil. Purification on SiO2 (7 x 10 cm) eluting with 
Et2O/hexane (3:2 → 9:1) gave 5-(4-(1,3-dioxolan-2-yl)butylthio)-1-phenyl-1H-
tetrazole (2.72) (5.06 g, 16.5 mmol, 92%) as a colourless oil. 
IR max (neat) cm
-1 2947 (s), 2872 (s), 1596 (m).   137
1H NMR (300 MHz, CDCl3)  7.69 – 7.42 (5H, m, C8 – C10), 4.85 (1H, t, J = 4.5 
Hz, C2), 4.01 – 3.89 (2H, m, C1(1H)), 3.89 – 3.78 (2H, m, C1(1H)), 3.40 (2H, t, J 
= 7.3 Hz, C6), 1.89 (2H, quin, J = 7.3 Hz, C5), 1.75 – 1.65 (2H, m, C3), 1.65 – 
1.51(2H, m, C4). 
13C NMR
 (75 MHz, CDCl3)  154.3 (CH), 133.7 (CH), 130.0 (CH1), 129.7 (CH1), 
123.8 (CH1), 104.1 (CH1), 64.8 (CH2), 33.1 (CH2), 28.9 (CH2), 22.9 (CH2). 
LRMS ESI+ 329 [M+Na]
+ (63%), 635 [2M+Na] (100%).    
HRMS ESI+ [M+Na]
+ calculated = 329.1043, [M+Na]
+ found = 329.1045. 
5-(4-(1,3-Dioxolan-2-yl)butylsulfonyl)-1-phenyl-1H-tetrazole (2.73) 
S O
O N N
N
N
OO
C14H18N4O4S
Exact Mass: 338.1049
Mol. Wt.: 338.3821
1
2 6
10
7
 
At 0 °C under an atmosphere of Ar, to a stirred solution of 5-(4-(1,3-dioxolan-2-
yl)butylthio)-1-phenyl-1H-tetrazole (2.72) (2.8 g, 9.18 mmol) in ethanol (200 mL) 
was added [NH4]6Mo7O24•4H2O (6.8 g, 5.5 mmol) in 30% H2O2 (aq 3.5 mL). The 
reaction was warmed to room temperature and stirred for 63 hours. CH2Cl2 (100 
mL) and K2CO3  (sat aq, 100 mL) were added, and the organic phase was 
separated. The aqueous layer was re-extracted with CH2Cl2 (3 x 100 mL). The 
combined organic phases were dried (Na2SO4) and concentrated in vacuo to 
afford a yellow oil. Purification on SiO2 (8 x 8 cm) eluting with EtOAc/hexane (1:1) 
gave 5-(4-(1,3-dioxolan-2-yl)butylsulfonyl)-1-phenyl-1H-tetrazole (2.73) (3.09 g, 
9.13 mmol, 99%) as a white solid. 
IR max (neat) cm
-1 2954 (s), 2881 (s), 1595 (m). 
1H NMR (400 MHz, CDCl3)  7.72 – 7.66 (2H, m, C8), 7.64 – 7.54 (3H, m, C9 
and C10), 4.86 (1H, t, J = 4.3 Hz, C2), 4.00 – 3.87 (2H, m, C1(1H)), 3.89 – 3.79 
(2H, m, C1(1H)), 3.78 – 3.70 (2H, m, C6), 2.07 – 1.96 (2H, m, C3), 1.76 – 1.69   
(2H, m, C5), 1.69 – 1.59 (2H, m, C4).   138
13C NMR
 (101 MHz, CDCl3)  153.6 (C), 133.2 (C), 131.6 (CH1), 129.8 (CH1), 
125.2 (CH1), 103.9 (CH1), 65.1 (CH2), 56.0 (CH2), 33.0 (CH2), 22.6 (CH2), 22.1 
(CH2). 
LRMS ESI+ 361 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 329.0941, [M+Na]
+ found = 361.0936. 
Tetrahydro-2-(prop-2-ynyloxy)-2H-pyran (2.75) 
O O
C8H12O2
Exact Mass: 140.0837
Mol. Wt.: 140.1797 1
3 4 8
 
At room temperature under an atmosphere of Ar, to a stirred solution of 
propargylic alcohol (2.74) (12.56 g, 0.224 mol) and dihydropyran (17 mL, 0.187 
mol) in dry CH2Cl2 (150 mL) was added PPTS (4.7 g, 0.0187 mol). After stirring 
for 16 hours the reaction was poured into NaHCO3 (sat aq, 150 mL), the organic 
layer was separated and the aqueous layer was re-extracted with CH2Cl2 (2 x 
150 mL). The combined organic phases were dried (Na2SO4) and concentrated 
in vacuo to afford a red oil. Purification by reduced pressure (12 mbar) distillation, 
collection at 68–70 °C gave tetrahydro-2-(prop-2-ynyloxy)-2H-pyran (2.75) (20.08 
g, 0.143 mol, 77%) as a colourless oil. 
Spectroscopic characterisation agreed with that published.
168 
IR max (neat) cm
-1 3291 (s), 2942 (s), 2870 (s), 2359 (w). 
1H NMR (300 MHz, CDCl3)  4.83 (1H, t, J = 3.1 Hz, C4), 4.31 (1H, dd, J = 15.7, 
2.5 Hz, C3(1H)), 4.23 (1H, dd, J = 15.7, 2.5 Hz, C3(1H)), 3.94 – 3.75 (1H, m, 
C8(1H)), 3.62 – 3.47 (1H, m, C8(1H)), 2.42 (1H, t, J = 2.5 Hz, C1), 1.92 – 1.77 
(1H, m, C5(1H)), 1.77 – 1.69 (1H, m, C5(1H)), 1.69 – 1.47 (4H, m, C6 and C7). 
13C NMR
 (75 MHz, CDCl3)  97.0 (CH1), 79.9 (CH1), 74.1 (CH1), 62.2 (CH2), 54.2 
(CH2), 30.4 (CH2), 25.5 (CH2), 19.2 (CH2). 
6-(Tetrahydro-2H-pyran-2-yloxy)hex-4-ynal (2.76)   139
O O
O
H
C11H16O3
Exact Mass: 196.1099
Mol. Wt.: 196.2429
1
6 7 11
 
At –10 °C under an atmosphere of Ar, to a stirred solution of alkyne 2.75 (3.5 g, 
24.9 mmol) in dry THF (83 mL) was added 2.26M n-BuLi in hexane (11 mL, 24.9 
mmol). After stirring for 20 minutes, CuI•0.75DMS (6.5 g, 27.4 mmol) was added 
in one batch. After stirring for 45 minutes, the reaction was cooled to –78 °C and 
TMSI (5 g, 24.9 mmol) was added. After stirring for 5 minutes, acrolein (0.93 g, 
24.9 mmol) in dry THF (5 mL) was added. The reaction was stirred at –78 °C for 
2 hours, then NH4Cl (sat aq, 100 mL) was added and the reaction was stirred at 
room temperature for 30 minutes. The organic layer was separated and the 
aqueous layer was re-extracted with Et2O (2 x 100 mL). The combined organic 
phases were washed with Na2S2O3 (sat aq, 100 mL) and brine, dried (MgSO4) 
and concentrated in vacuo to give an orange oil. 
At 0 °C under an atmosphere of Ar, to a stirred solution of the orange oil in 
methanol (150 mL) was added K2CO3 (100 mg, 1 mmol).  After 20 minutes NH4Cl 
(sat aq, 50 mL) and Et2O (100 mL) were added. The organic layer was separated 
and the aqueous layer was re-extracted with Et2O (2 x 100 mL). The combined 
organic phases were dried (MgSO4) and concentrated in vacuo to give a yellow 
oil. Purification on SiO2 (4 x 10 cm) eluting with EtOAc/hexane (3:7) gave 6-
(tetrahydro-2H-pyran-2-yloxy)hex-4-ynal (2.76) (1.71 g, 8.72 mmol, 35%) as a 
pale yellow oil. 
Spectroscopic characterisation agreed with that published.
158 
IR max (neat) cm
-1 2941 (s), 2852 (s), 1726 (s). 
1H NMR (300 MHz, CDCl3)  9.78 (1H, t, J = 1.1 Hz, C1), 4.77 (1H, t, J = 3.2 Hz, 
C7), 4.31 – 4.11 (2H, m, C6), 3.89 – 3.76 (1H, m, C11(1H)), 3.57 – 3.45 (1H, m, 
C11(1H)), 2.74 – 2.60 (2H, m, C2), 2.60 – 2.45 (2H, m, C3), 1.92 – 1.77 (1H, m, 
C8(1H)), 1.77 – 1.69 (1H, m, C8(1H)), 1.69 – 1.47 (4H, m, C9 and C10). 
13C NMR
 (75 MHz, CDCl3)  200.5 (CH1), 96.9 (CH1), 84.4 (C), 77.1 (C), 62.2 
(CH2), 54.6 (CH2), 42.6 (CH2), 30.4 (CH2), 25.5 (CH2), 19.2 (CH2), 12.2 (CH2).   140
(Z)-4-(Tetrahydro-2H-pyran-2-yloxy)but-2-en-1-ol (2.78) 
OH O
1
9
54
O
C9H16O3
Exact Mass: 172.1099
Mol. Wt.: 172.2215
 
Under an atmosphere of Ar at 0 °C, to a solution of cis-but-2-ene-1,4-diol (17.2 g, 
0.195 mol), dihydropyran (16.4 g, 0.195 mol) in CH2Cl2 (170 mL) and THF (430 
mL) was added TsOH•H2O (2.6 g, 13.7 mmol). The reaction was stirred for 2 
hours at room temperature. NaHCO3 (sat aq, 250 mL) was added, the organic 
layer was separated and the aqueous layer was extracted with Et2O (2 x 200 
mL). The combined organic phases were washed with brine, dried (MgSO4) and 
concentrated in vacuo to afford a yellow liquid. Purification on SiO2 (8 x 8 cm) 
eluting with Et2O/hexane (1:1 → 4:1) gave (Z)-4-(tetrahydro-2H-pyran-2-
yloxy)but-2-en-1-ol (2.78) (19.07 g, 0.110 mol, 57%) as a colourless oil. 
Spectroscopic characterisation agreed with that published.
169 
IR max (neat) cm
-1 3397 (br), 2941 (s), 2870 (s) 1620 (w). 
1H NMR (300 MHz, CDCl3)  5.85 (1H, dt with fine splitting, J = 11.2, 6.7 Hz, C2), 
5.70 (1H, dt with fine splitting, J = 11.2, 5.9 Hz, C3), 4.68 (1H, t, J = 3.3 Hz, C5), 
4.32 – 4.08 (4H, m, C1 and C4), 3.92 – 3.80 (1H, m, C9(1H)), 3.58 – 3.47 (1H, 
m, C9(1H)), 2.31 (1H, t, J = 5.7 Hz, OH), 1.91 – 1.74 (1H, m, C6(1H)), 1.74 – 
1.66 (1H, m, C6(1H)), 1.65 – 1.46 (4H, m, C7 – C8). 
13C NMR
 (75 MHz, CDCl3)  132.4 (CH1), 128.1 (CH1), 97.5 (CH1), 62.4 (CH2), 
62.1 (CH2), 58.3 (CH2), 30.4 (CH2), 25.3 (CH2), 19.2 (CH2). 
2-((Z)-4-Chlorobut-2-enyloxy)-tetrahydro-2H-pyran (2.79) 
Cl O
1
9
54
O
C9H15ClO2
Exact Mass: 190.0761
Mol. Wt.: 190.6672
 
At 0 °C under an atmosphere of Ar, to a solution of 4-(tetrahydro-2H-pyran-2-
yloxy)but-2-en-1-ol (2.78) (17.33 g, 0.1 mol), DIPEA (19.2 mL, 0.11 mol) in 
CH2Cl2 (100 mL) was added dropwise MsCl (8.1 mL, 0.105 mol). The reaction   141
was stirred for 15 minutes at 0 °C, then at room temperature for 2 hours. 
NaHCO3 (sat aq, 250 mL) was added, the organic layer was separated and the 
aqueous layer was re-extracted with Et2O (2 x 100 mL). The combined organic 
phases were washed with brine, dried (MgSO4) and concentrated in vacuo to 
afford an orange oil. Purification on SiO2 (10 x 10 cm) eluting with Et2O/hexane 
(0:1 → 1:4) gave 2-((Z)-4-chlorobut-2-enyloxy)-tetrahydro-2H-pyran (2.79) (13.4 
g, 0.070 mol, 70%) as a colourless oil. 
Spectroscopic characterisation agreed with that published.
170 
IR max (neat) cm
-1 2942 (s), 2870 (s). 
1H NMR (300 MHz, CDCl3)  5.86 – 5.72 (2H, m, C2 and C3), 4.63 (1H, t, J = 3.4 
Hz, C5), 4.36 – 4.27 (1H, m, C4(1H)), 4.18 – 4.10 (3H, m, C1 and C4(1H)), 3.92 
– 3.80 (1H, m, C9(1H)), 3.58 – 3.47 (1H, m, C9(1H)), 1.92 – 1.74 (1H, m, 
C6(1H)), 1.74 – 1.66 (1H, m, C6(1H)), 1.65 – 1.46 (4H, m, C7 – C8). 
13C NMR
 (75 MHz, CDCl3)  130.5 (CH1), 128.3 (CH1), 97.9 (CH1), 62.2 (CH2), 
62.0 (CH2), 39.2 (CH2), 30.5 (CH2), 25.4 (CH2), 19.4 (CH2). 
Dimethyl 2-((Z)-4-(tetrahydro-2H-pyran-2-yloxy)but-2-enyl)malonate 
(2.80) 
O
3
11
7 6
O
1
CO2Me
CO2Me
C14H22O6
Exact Mass: 286.1416
Mol. Wt.: 286.3209
 
At room temperature under an atmosphere of Ar, to a solution of dimethyl 
malonate (10.2 g, 0.077 mol) in DMF (700 mL) was added portion-wise NaH 
dispensed in 60% mineral oil (4.2 g, 0.105 mol). The reaction was stirred for 1.5 
hours until no further gas evolved. 2-((Z)-4-Chlorobut-2-enyloxy)-tetrahydro-2H-
pyran (2.79) (13.4 g, 0.070 mol) was added and the reaction was stirred 
overnight (16 hours). Water (250 mL) was added followed by extraction with Et2O 
(4 x 300 mL). The combined organic phases were washed with brine, dried 
(MgSO4) and concentrated in vacuo to afford a heterogeneous yellow liquid. The 
heterogeneous yellow liquid was re-dissolved in Et2O (250 mL) and washed with 
water (5 x 100 mL), dried (MgSO4) and concentrated in vacuo to afford a yellow   142
liquid. Purification on SiO2 (10 x 10 cm) eluting with Et2O/hexane (0:1 → 1:0) 
gave dimethyl 2-((Z)-4-(tetrahydro-2H-pyran-2-yloxy)but-2-enyl)malonate (2.80) 
(3.58 g, 12.5 mmol, 18%) as a colourless oil. 
Spectroscopic characterisation agreed with that published.
170 
IR max (neat) cm
-1 2950 (m), 2850 (m), 1733 (s). 
1H NMR (300 MHz, CDCl3)  5.73 – 5.63 (1H, m, C4), 5.56 – 5.45 (1H, m, C5), 
4.65 – 4.60 (1H, m, C7), 4.32 – 4.23 (1H, m, C6(1H) ), 4.14 – 4.05 (1H, m, 
C6(1H)), 3.92 – 3.80 (1H, m, C11(1H)), 3.73 (6H, s, OMe), 3.56 – 3.47 (1H, m, 
C11(1H)), 3.43 (1H, t, J = 7.5 Hz, C2), 2.69 (2H, t, J = 7.5 Hz, C3), 1.88 – 1.73 
(1H, m, C8(1H)), 1.73 – 1.64 (1H, m, C8(1H)), 1.63 – 1.46 (4H, m, C9 – C10). 
13C NMR
 (75 MHz, CDCl3)  169.2 (C), 129.4 (CH1), 127.8 (CH1), 98.0 (CH1), 
62.6 (CH2), 62.2 (CH2), 52.5 (CH3), 51.5 (CH1), 30.6 (CH2), 27.0 (CH2), 25.4 
(CH2), 19.4 (CH2). 
(Z)-Methyl 6-(tetrahydro-2H-pyran-2-yloxy)hex-4-enoate (2.81) 
O
3
11
7 6
O
1
CO2Me
C12H20O4
Exact Mass: 228.1362
Mol. Wt.: 228.2848
 
Under an atmosphere of Ar, a solution of dimethyl 2-((Z)-4-(tetrahydro-2H-pyran-
2-yloxy)but-2-enyl)malonate (2.80) (3.5 g, 12.2 mmol), potassium acetate (2.4 g, 
24.2 mmol) in DMSO (33 mL) and water (0.44 mL) were heated to reflux for 5 
hours. The reaction was poured into water (30 mL) and extracted with Et2O (3 x 
50 mL). The combined organic phases were washed with water and brine, dried 
(MgSO4) and concentrated in vacuo to afford an orange oil. Purification on SiO2 
(5 x 10 cm) eluting with Et2O/hexane (3:7) gave (Z)-methyl 6-(tetrahydro-2H-
pyran-2-yloxy)hex-4-enoate (2.81) (2.08 g, 9.11 mmol, 75%) as a colourless oil. 
Spectroscopic characterisation agreed with that published.
170 
IR max (neat) cm
-1 2944 (s), 2871 (m), 1736 (s).   143
1H NMR (300 MHz, CDCl3)  5.67 – 5.49 (2H, m, C4 and C5), 4.65 – 4.60 (1H, m, 
C7), 4.27 (1H, dd, J = 11.9, 4.9 Hz, C6(1H)), 4.08 (1H, dd, J = 11.9, 6.1 Hz, 
C6(1H)), 3.92 – 3.80 (1H, m, C11(1H)), 3.67 (3H, s, OMe), 3.56 – 3.47 (1H, m, 
C11(1H)), 2.47 – 2.33 (4H, m, C2 – C3), 1.91 – 1.73 (1H, m, C8(1H)), 1.73 – 
1.66 (1H, m, C8(1H)), 1.66 – 1.45 (4H, m, C9 – C10). 
13C NMR
 (75 MHz, CDCl3)  173.5 (C), 131.2 (CH1), 127.7 (CH1), 98.1 (CH1), 
62.8 (CH2), 62.4 (CH2), 51.7 (CH3), 34.1 (CH2), 30.8 (CH2), 25.6 (CH2), 23.2 
(CH2), 19.7 (CH2). 
(Z)-6-(Tetrahydro-2H-pyran-2-yloxy)hex-4-enal (2.82) 
O
3
11
7 6
O
1
CHO
C11H18O3
Exact Mass: 198.1256
Mol. Wt.: 198.2588
 
At –78 °C under an atmosphere of Ar, a stirred solution of (Z)-methyl 6-
(tetrahydro-2H-pyran-2-yloxy)hex-4-enoate (2.81) (1.0 g, 4.38 mmol) in dry 
toluene (20 mL) was added dropwise 1M DIBAL-H in hexane (4.6 mL, 4.6 mmol). 
The reaction was stirred for a further 1.5 hour at –78 °C at which point the 
reaction was quenched with EtOAc (3 mL). Rochelles salt (sat aq, 50 mL) was 
added and the reaction was stirred at room temperature for 1 hour. The organic 
layer was separated and the aqueous layer was re-extracted with Et2O (2 x 50 
mL). The combined organic phases were washed with water, dried (MgSO4) and 
concentrated in vacuo to afford a yellow oil. Purification on SiO2 (3 x 13 cm) 
eluting with Et2O/hexane (0:1 → 3:7) gave (Z)-6-(tetrahydro-2H-pyran-2-
yloxy)hex-4-enal (2.82) (720 mg, 3.63 mmol, 83%) as a colourless oil which was 
used directly in the next step. 
2-((E)-10-(1,3-Dioxolan-2-yl)dec-6-en-2-ynyloxy)-tetrahydro-2H-pyran 
(2.83) 
O O
O
O
C18H28O4
Exact Mass: 308.1988
Mol. Wt.: 308.4125
1
2
17
13 12
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At –55 °C under an atmosphere of Ar, to a stirred solution of sulfone 2.73 (1.35 g, 
4 mmol) in dry DME (25 mL) was added 0.5M KHMDS in toluene (8 mL, 4 mmol). 
After stirring for 1 hour, aldehyde 2.76 (790 mg, 4 mmol) in dry DME (5 mL) was 
added dropwise. After stirring for 1 hour, the reaction was gradually warmed to 
room temperature. The reaction was diluted with water/Et2O (1:1 50 mL), the 
organic layer was separated and the aqueous layer was re-extracted with Et2O (3 
x 50 mL). The combined organic phases were washed with brine, dried (MgSO4) 
and concentrated in vacuo to give a yellow oil. Purification on SiO2 (15 x 4 cm) 
eluting with hexane/EtOAc (48:1 → 23:2) gave 2-((E)-10-(1,3-dioxolan-2-yl)dec-
6-en-2-ynyloxy)-tetrahydro-2H-pyran (2.83) (622 mg, 2.02 mmol, 51%) as a 
colourless oil which  was a mixture of stereoisomers (E:Z = 6:1) 
IR max (neat) cm
-1 2940 (s), 2869 (s), 1736 (w).  
1H NMR (400 MHz, CDCl3)  5.52 – 5.39 (2H, m, C6 and C7), 4.85 (1H, t, J = 4.8 
Hz, C2), 4.81 (1H, t, J = 3 3 Hz, C13), 4.25 (2H, m, C12), 4.01 – 3.91 (2H, m, 
C1(2H)), 3.90 – 3.80 (3H, m, C1(2H) and C17(1H)), 3.57 – 3.49 (1H, m, 
C17(1H)), 2.30 – 2.15 (4H, m, C8 and C9), 2.13 – 2.00 (2H, m, C5), 1.91 – 1.79 
(1H, m, C14(1H)), 1.79 – 1.43 (9H, m, C3, C4, C14(1H), C15 and C16). 
13C NMR
 (101 MHz, CDCl3)  131.4 (CH1), 129.0 (CH1), 104.7 (CH1), 96.8 (CH1), 
86.3 (C), 76.3 (C), 65.0 (CH2), 62.2 (CH2), 54.8 (CH2), 33.5 (CH2), 32.5 (CH2), 
31.9 (CH2), 30.5 (CH2), 25.6 (CH2), 24.0 (CH2), 19.5 (CH2), 19.3 (CH2), 
Z isomer peaks  130.9 (CH1), 128.4 (CH1), 33.6 (CH2), 27.3 (CH2), 26.7 (CH2), 
24.2 (CH2), 19.4 (CH2). 
LRMS ESI+ 331 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 331.1880, [M+Na]
+ found = 331.1880.   145
2-((2Z,6E)-10-[1,3]Dioxolan-2-yl-deca-2,6-dienyloxy)-tetrahydro-pyran 
(2.84) 
1
2
17
13
7
12 O
O
O
O
C18H30O4
Exact Mass: 310.2144
Mol. Wt.: 310.4284
 
Under an atmosphere of H2, a solution of alkyne 2.83 (200 mg, 0.65 mmol), 
quinoline (15 μL, 0.13 mmol) and Lindlar catalyst (Pd 5%, calcium carbonate 
poisoned with Pb) (43 mg, 0.02 mmol) in hexane (10 mL) was stirred for 2 hours. 
The reaction was filtered through celite and washed through with EtOAc (30 mL). 
The organic phase was dried (MgSO4) and concentrated in vacuo to afford a pale 
yellow oil. Purification on SiO2 (12 x 2 cm) eluting with hexane/EtOAc (23:2) gave 
2-((2Z,6E)-10-[1,3]dioxolan-2-yl-deca-2,6-dienyloxy)-tetrahydropyran (2.84) (141 
mg, 0.454 mmol, 70%) as a colourless oil.  
1H NMR (400 MHz, CDCl3)  5.63 – 5.52 (2H, m, C10 and C11), 5.44 – 5.35 (2H, 
m, C6 and C7), 4.85 (1H, t, J = 4.8 Hz, C2), 4.63 (1H, br t, J = 3.5 Hz, C13), 4.29 
– 4.22 (1H, m, C12(1H)), 4.12 – 4.03 (1H, m, C12(1H)), 3.99 – 3.93 (2H, m, 
C1(2H)), 3.93 – 3.80 (3H, m, C1(2H) and C17(1H)), 3.56 – 3.46 (1H, m, 
C17(1H)), 2.18 – 2.09 (2H, m, C9), 2.09 – 1.98 (4H, m, C5 and C8), 1.90 – 1.78 
(1H, m, C14(1H)), 1.76 – 1.42 (9H, m, C3, C4, C14(1H), C15 and C16). 
13C NMR
  (101 MHz, CDCl3)    133.1 (CH1), 130.6 (CH1), 130.0 (CH1), 126.3 
(CH1), 104.7 (CH1), 98.1 (CH1), 65.0 (CH2), 63.0 (CH2), 62.4 (CH2), 33.5 (CH2), 
32.7 (CH2), 32.5 (CH2), 30.9 (CH2), 27.8 (CH2), 25.7 (CH2), 24.1 (CH2), 19.7 
(CH2). 
(2E,7E,11Z)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-13-hydroxy-trideca-2,7,11-trien-1-one (2.85) 
OH
1
6
S
OO
N
O
22
13
23
15 17
18
20
C23H35NO4S
Exact Mass: 421.2287
Mol. Wt.: 421.5933
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At 0 °C under an atmosphere of Ar, to a stirred solution of acetal 2.84 (100 mg, 
0.324 mmol) in methanol (3.7 mL) was added TsOH•H2O (12.3 mg, 0.0648 
mmol). The reaction was stirred for 3 hours, then NaHCO3 (sat aq, 4 mL) was 
added and extracted with Et2O (3 x 10 mL). The combined organic phases were 
dried (MgSO4) and concentrated in vacuo to give a yellow oil. 
The yellow oil was dissolved in 1,4-dioxane: water: conc. H2SO4 (49.5: 49.5: 1) (4 
mL) and heated to refluxed for 4.5 hours. The reaction was diluted with Et2O (20 
mL) and washed with water (10 mL), NaHCO3 (sat aq, 2 x 5 mL) and brine (5 
mL). The organic layer were dried (Na2SO4) and concentrated in vacuo to afford 
a pale yellow oil which was used crude in the next step. 
Under an atmosphere of N2, to a stirred solution of (1S,2R)-camphorsultam 
phosphonate (104 mg, 0.27 mmol) in dry acetonitrile (4 mL) was added dried 
lithium chloride (170 °C/ 0.035 mbar overnight) (11.4 mg, 0.27 mmol). After 
stirring for 15 minutes, dry DIPEA (47 μL, 0.27 mmol) was added. After stirring 
for 10 minutes, the pale yellow oil in dry acetonitrile (0.25 mL) was added. The 
reaction was stirred for 20 hours. The reaction was diluted with water (5 mL), 
brine (5 mL) and extracted with Et2O (3 x 10 mL). The combined organic phases 
were dried (MgSO4) and concentrated in vacuo to give a yellow oil. Purification 
on SiO2 (1 x 14 cm) eluting with Et2O/hexane (1:1) gave triene 2.85 (50 mg, 
0.119 mmol, 37%) as a colourless oil.  
[α]
25.5
D  –44.5 (CHCl3, c 1.0). 
IR max (neat) cm
-1 3460 (br), 2958 (s), 1681 (s), 1637 (s). 
1H NMR (300 MHz, CDCl3)  7.08 (1H, dt, J = 15.1, 7.0 Hz, C11), 6.55 (1H, d, J = 
15.1 Hz, C12), 5.70 – 5.47 (2H, m, C2 and C3), 5.46 – 5.34 (2H, m, C6 and C7), 
4.19 (2H, d, J = 5.9 Hz, C1), 3.93 (1H, dd, J = 7.4, 5.4 Hz, C14), 3.52 (1H, d, J = 
13.7 Hz, C20(1H)), 3.44 (1H, d, J = 13.7 Hz, C20(1H)), 2.30 – 2.20 (2H, m, C10), 
2.20 – 1.97 (8H, m, C8, C4, C5 and C15), 1.97 – 1.83 (3H, m, C16, C17(1H) and 
C18(1H)), 1.63 (1H, br s, OH), 1.60 – 1.48 (2H, m, C9), 1.48 – 1.30 (2H, m, 
C17(1H) and C18(1H)), 1.18 (3H, s, C22), 0.98 (3H, s, C23).   147
13C NMR
 (75 MHz, CDCl3)  164.3 (C), 150.9 (CH1), 132.4 (CH1), 130.4 (CH1), 
130.4 (CH1), 129.0 (CH1), 121.2 (CH1), 65.4 (CH1), 58.8 (CH2), 53.4 (CH2), 48.6 
(C), 48.0 (C), 44.9 (CH1), 38.7 (CH2), 33.1 (CH2), 32.6 (CH2), 32.0 (CH2), 32.0 
(CH2), 27.8 (CH2), 27.6 (CH2), 26.7 (CH2), 21.0 (CH3), 20.1 (CH3). 
LRMS ESI+ 444 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 444.2179, [M+Na]
+ found = 444.2173. 
(2E,7E)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-10-((2R,3S)-3-hydroxymethyl-oxiranyl)-
deca-2,7-dien-1-one (2.66) 
OH
1
6
S
OO
N
O
22
13
23
15 17
18
20
O
C23H35NO5S
Exact Mass: 437.2236
Mol. Wt.: 437.5927
 
At –25 °C under an atmosphere of Ar, to a stirred solution of DET-(+) (106 μL, 
0.624 mmol) and powdered 4Å molecular sieves (100 mg) in dry CH2Cl2 (1.9 mL) 
was added Ti(Oi-Pr)4 (152 μL, 0.52 mmol). The reaction was stirred for 10 
minutes then allylic alcohol 2.85 (55 mg, 0.13 mmol) was added. The reaction 
was stirred for 5 minutes then ~5.5M t-BuCOOH (260 μL, 1.4 mmol) in nonane 
was added, the reaction was stirred at –25 °C for 67 hours. 10% Tartaric acid (aq 
2 mL) was added, the reaction was stirred at –25 °C for 30 minutes then at room 
temperature for 1 hour. The organic layer was collected, washed with water then 
dried (Na2SO4) and concentrated in vacuo to give a colourless oil. At 0 °C under 
an atmosphere of Ar, the colourless oil was dissolved in Et2O (2 mL) and 1M 
NaOH (1 mL) was added. The reaction was stirred for 30 minutes then washed 
with brine (1 mL). The organic layer was dried (Na2SO4) and concentrated in 
vacuo to give a colourless oil. Purification on SiO2 (10 x 1.5 cm) eluting with 
hexane/Et2O (1:1 → 0:1) gave epoxide 2.66 (25.6 mg, 0.059 mmol, 45%) as a 
colourless oil.  
[α]
25.5
D  –60.6 (CHCl3, c 1.25). 
IR max (neat) cm
-1 3451 (br), 2935 (s), 1681 (s), 1637 (s).   148
1H NMR (400 MHz, CDCl3)  7.08 (1H, dt, J = 15.1, 7.0 Hz, C11), 6.55 (1H, d, J = 
15.1 Hz, C12), 5.47 – 5.41 (2H, m, C6 and C7), 3.93 (1H, dd, J = 7.4, 5.4 Hz, 
C14), 3.89 – 3.77 (1H, m, C1(1H)), 3.72 – 3.63 (1H, m, C1(1H)), 3.52 (1H, d, J = 
13.7 Hz, C20(1H)), 3.44 (1H, d, J = 13.78 Hz, C20(1H)), 3.19 – 3.12 (1H, m, C2), 
3.07 – 3.00 (1H, m, C3), 2.32 – 1.99 (8H, m, C5, C8, C10 and C15), 1.99 – 1.83 
(3H, m, C16, C17(1H) and C18(1H)), 1.80 – 1.49 (5H, m, C4, C9 and OH), 1.48 – 
1.31 (2H, m, C17(1H) and C18(1H)), 1.17 (3H, s, C22), 0.98 (3H, s, C23). 
13C NMR
 (100 MHz, CDCl3)  164.3 (C), 150.7 (CH1), 130.7 (CH1), 129.9 (CH1), 
121.2 (CH1), 65.3 (CH1), 61.1 (CH2), 57.0 (CH1), 53.3 (CH2), 48.6 (C), 47.9 (C), 
44.9 (CH1), 38.7 (CH2), 33.0 (CH2), 31.9 (CH2), 31.9 (CH2), 29.7 (CH2), 28.1 
(CH2), 27.7 (CH2), 26.7 (CH2), 21.0 (CH3), 20.1 (CH3). 
LRMS ESI+ 460 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 460.2128, [M+Na]
+ found = 460.2128. 
(E)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-2-hydroxy-10-((2R,3S)-3-hydroxymethyl-
oxiranyl)-dec-7-ene-1,3-dione (2.86) 
OH
1
6 S
OO
N
O
22
13
23
15 17
18
20
O
O
OH C23H35NO7S
Exact Mass: 469.2134
Mol. Wt.: 469.5915
 
At –40 °C under an atmosphere of Ar, to a stirred solution of diene 2.66 (23 mg, 
0.0515 mmol) in acetone/acetic acid (3:1 1.3 mL) was added powdered KMnO4 
(8.6 mg, 0.067 mmol). The reaction was stirred for 1 hour, then quenched by 
addition of Na2S2O3 (sat aq, 1 mL). The organic layer was separated and the 
aqueous layer was re-extracted with EtOAc (5 x 1 mL). The combined organic 
phases were dried (MgSO4) and concentrated in vacuo to give a yellow oil. 
Purification on SiO2 (1 x 7 cm) eluting with EtOAc/hexane (1:1) gave hydroxy 
ketone 2.86 (7.2 mg, 0.015 mmol, 30%) as a colourless oil. 
IR max (neat) cm
-1 3431 (br), 2940 (s), 1726 (s), 1689 (s).   149
1H NMR (400 MHz, CDCl3)  5.50 – 5.37 (2H, m, C6 and C7), 5.22 (1H, br d, J = 
6.7 Hz, C12), 3.95 (1H, dd, J = 7.7, 4.9 Hz, C14), 3.85 (1H, dd, J = 12.1, 4.3 Hz, 
C1(1H)), 3.69 (1H, dd, J = 12.1, 6.8 Hz, C1(1H)), 3.53 (1H, d, J = 13.8 Hz, 
C20(1H)), 3.47 (1H, d, J = 13.8 Hz, C20(1H)), 3.19 – 3.14 (1H, m, C2), 3.07 – 
3.01 (1H, m, C3), 2.76 (1H, dt, J = 18.1, 7.4 Hz, C10(1H)), 2.62 – 2.53 (1H, m, 
C10(1H)), 2.27 – 1.98 (6H, m, C8,  C5 and C15), 1.98 – 1.85 (3H, m, C16, 
C17(1H) and C18(1H)), 1.81 – 1.54 (5H, m, C4, C9 and OH), 1.50 – 1.31 (2H, m, 
C17(1H) and C18(1H)), 1.17 (3H, s, C22), 0.99 (3H, s, C23). 
13C NMR (100 MHz, CDCl3)  204.0 (C), 168.5 (C), 130.5 (CH1), 130.2 (CH1), 
76.6 (CH1), 65.2 (CH1), 61.1 (CH2), 57.1 (CH1), 56.9 (CH1), 53.0 (CH2), 49.3 (C), 
48.1 (C), 44.7 (CH1), 38.6 (CH2), 38.0 (CH2), 33.0 (CH2), 31.7 (CH2), 29.8 (CH2), 
28.1 (CH2), 26.6 (CH2), 22.8 (CH2), 20.6 (CH3), 20.1 (CH3). 
LRMS ESI+ 492 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 492.2026, [M+Na]
+ found = 492.2031. 
5-(Tetrahydro-2H-pyran-2-yloxy)pent-3-yn-1-ol (2.93) 
O
OH
O C10H16O3
Exact Mass: 184.1099
Mol. Wt.: 184.2322 5
10
1 6
 
At –40 °C under an atmosphere of Ar, to a stirred solution of alkyne 2.75 (10.0 g, 
0.071 mol) in dry THF/Et2O (1:2 30mL) was added 2.41M n-BuLi in hexane (32 
mL, 0.078 mol). After stirring for 30 minutes, dry HMPA (10 mL) was added 
producing a clear orange solution. The reaction was warmed to room 
temperature, ethylene oxide (~15 mL, 0.4 mol) added via a cannula. A cold finger 
reflux condenser (solid CO2/acetone) was attached. The reaction was stirred 
overnight (16 hours). Et2O (200 mL) was added, then reaction mixture was 
washed with brine/water (4:1 3 x 100 mL), dried (Na2SO4) and concentrated in 
vacuo  to give an orange oil. Purification on SiO2 (10 x 10 cm) eluting with 
hexane/Et2O (1:1) gave 5-(tetrahydro-2H-pyran-2-yloxy)pent-3-yn-1-ol  (2.93) 
(8.30 g, 0.045 mol, 63%). 
Spectroscopic characterisation agreed with that published.
171   150
IR max (neat) cm
-1 3408 (br), 2941 (s), 2870 (s), 1345 (w). 
1H NMR (300 MHz, CDCl3)  4.80 (1H, t, J = 3.1 Hz, C6), 4.36 – 4.16 (2H, m, 
C5), 3.92 – 3.78 (1H, m, C10(1H)), 3.73 (2H, t, J = 6.3 Hz, C1), 3.59 – 3.49 (1H, 
m, C10(1H), 2.50 (2H, tt, J = 6.3, 2.1 Hz, C2), 2.03 (1H, br s, OH), 1.92 – 1.45 
(6H, m, C7 – C9). 
13C NMR
 (100 MHz, CDCl3)  96.7 (CH1), 83.2 (C), 77.3 (C), 61.8 (CH2), 60.6 
(CH2), 54.5 (CH2), 30.0 (CH2), 25.1 (CH2), 29.9 (CH2), 19.1 (CH2). 
2-(5-Bromopent-2-ynyloxy)-tetrahydro-2H-pyran (2.94) 
O
Br
O
5
10
1 6 C10H15BrO2
Exact Mass: 246.0255
Mol. Wt.: 247.1289
 
At 0 °C under an atmosphere of Ar, to a stirred solution of alcohol 2.93 (2 g, 
10.86 mmol), tetrabromomethane (4.15 g, 12.49 mmol) and pyridine (200 μL) in 
CH2Cl2 (30 mL) was added PPh3 (3.7 g, 14.12 mmol) in CH2Cl2 (5 mL). The 
reaction was stirred for 2 hours, then warmed to room temperature and stirred for 
a further 2 hours. The reaction was concentrated in vacuo, the residue was 
suspended in CH2Cl2/hexane (1:5 30 mL) then filtered, the filtrate was 
concentrated  in vacuo to gave a yellow oil. Purification on SiO2 (3 x 10 cm) 
eluting with hexane/Et2O (9:1) gave 2-(5-bromopent-2-ynyloxy)-tetrahydro-2H-
pyran (2.94) (2.19 g, 8.86 mmol, 82%) as a colourless oil. 
Spectroscopic characterisation agreed with that published.
171 
IR max (neat) cm
-1 2240 (w). 
1H NMR (300 MHz, CDCl3)  4.82 (1H, t, J = 3.2 Hz, C6), 4.37 – 4.15 (2H, m, 
C5), 3.91 – 3.76 (1H, m, C10(1H)), 3.59 – 3.49 (1H, m, C10(1H)), 3.44 (2H, t, J = 
7.3 Hz, C1), 2.80 (2H, tt, J = 7.3, 2.1 Hz, C2), 1.88 – 1.48 (6H, m, C7 – C9). 
13C NMR
 (100 MHz, CDCl3)  96.7 (CH1), 83.0 (C), 78.1 (C), 62.0 (CH2), 54.3 
(CH2), 30.2 (CH2), 29.4 (CH2), 25.3 (CH2), 23.3 (CH2), 19.1 (CH2). 
1,2,5,6-Tetrabromohexane (2.98)   151
Br
Br
Br
Br
1
2
3
C6H10Br4
Exact Mass: 397.7516
Mol. Wt.: 401.7596
 
Under an atmosphere of Ar at –70 °C, to a solution of hexa-1,5-diene (24 g, 
0.292 mol) in CH2Cl2 (400 mL) was added bromine (93.3 g, 0.584 mol) in CH2Cl2 
(100 mL) via a dropping funnel. The reaction was gradually warmed to room 
temperature and stirred for 16 hours. The reaction was concentrated in vacuo to 
afford a brown solid. Purification by recrystallisation with methanol gave bromide 
2.98 as a white solid (97.12 g, 0.244 mol, 83%). 
Melting point 57–65  °C.   
IR max (neat) cm
-1 2945 (w), 2915 (w), 1436 (s). 
1H NMR  (300 MHz, CDCl3)  4.27 – 4.11 (2H, m, C2), 3.89 (2H, 2 x dd, J = 10.2, 
4.3 Hz, C1(2H)), 3.65 (2H, 2 x t, J = 10.2 Hz, C1(2H)), 2.61 – 2.46 (1H, m, C3), 
2.44 – 2.28 (1H, m, C3), 2.20 – 2.01 (1H, m, C3), 2.01 – 1.84 (1H, m, C3). 
13C NMR
 (75 MHz, CDCl3)  51.7 (CH1), 51.2 (CH1), 36.0 (CH2), 35.9 (CH2), 33.8 
(CH2), 33.7 (CH2). 
1,6-Bis(trimethylsilyl)hexa-1,5-diyne 
TMS
TMS C12H22Si2
Exact Mass: 222.126
Mol. Wt.: 222.4741
1
 
At –78 °C under an atmosphere of Ar, to a stirred solution of dry DIPA (70 mL, 
0.5 mol) in dry THF (300 mL) was added 2.5M n-BuLi in hexane (200 mL, 0.5 
mol). The reaction was warmed to room temperature for 5 minutes then re-
cooled to –78 °C then bromide 2.98 (32.7 mL, 0.082 mol) in THF (50 mL) was 
added slowly. The reaction was warmed to room temperature and stirred for 1 
hour then re-cooled to –78 °C. TMSCl (21.9 mL, 0.172 mol) was then added 
slowly and the reaction was warmed to room temperature and stirred for 1 hour. 
The reaction was carefully quenched with water and diluted with Et2O (300 mL), 
the organic layer was collected then washed with 2M HCl (250 mL x 2), dried 
(MgSO4) and concentrated in vacuo to afford a yellow oil. Purification on SiO2 (8   152
x 4 cm) eluting with hexane gave 1,6-bis(trimethylsilyl)hexa-1,5-diyne  (2.99) 
(5.88 g, 0.0265 mol, 32%) as a white solid. 
Spectroscopic characterisation agreed with that published.
172 
Melting point  58 – 62 °C. 
1H NMR (300 MHz, CDCl3)  2.44 (4H, s, C1), 0.16 (18H, s, TMS). 
13C NMR
 (75 MHz, CDCl3)  105.3 (C), 85.7 (C), 20.2 (CH2), 0.3 (CH3). 
(8-(1,3-Dioxan-2-yl)octa-1,5-diynyl)trimethylsilane (2.100) 
O
O
TMS
C15H24O2Si
Exact Mass: 264.1546
Mol. Wt.: 264.4354
1
2
3
4
5
6
7
 
At –78 °C under an atmosphere of Ar, to a stirred solution of TMS alkyne 2.99 
(4.12 g, 18.6 mmol) in dry THF (30 mL) was added 1.5M methyl lithium-lithium 
bromide complex in Et2O (18.5 mL, 27.8 mmol). The reaction was warmed to 
room temperature and stirred for 3 hours, dark cloudy orange solution was 
produced. The reaction was re-cooled to –78 °C then dry HMPA (15 mL) was 
added, after 15 minutes 2-(2-bromoethyl)-1,3-dioxane (5 mL, 37.1 mmol) was 
added. The reaction was gradually warmed to room temperature and stirred for 
16 hours. The reaction was slowly poured into NH4Cl (sat aq, 50 mL), the organic 
layer was separated and the aqueous layer was extracted with CH2Cl2 (3 x 50 
mL). The combined organic phases were concentrated in vacuo to give an 
orange oil. The orange oil was dissolved in Et2O (150 mL) and washed with water 
(3 x 150 mL). The organic phase was dried (MgSO4) and concentrated in vacuo 
to afford an orange oil. Purification on SiO2 (13 x 4 cm) eluting with 
hexane/EtOAc (9:1 → 1:1) gave (8-(1,3-dioxan-2-yl)octa-1,5-
diynyl)trimethylsilane (2.100) (900 mg, 3.40 mmol, 18%) as a colourless oil.  
IR max (neat) cm
-1 2959 (s), 2850 (s), 2176 (s); 
1H NMR  (300 MHz, CDCl3)  4.63 (1H, t, J = 5.3 Hz, C5), 4.10 (2H, m, C6(1H)), 
3.77 (2H, m, C6(1H)), 2.46 – 2.31 (4H, m, C1 and C2), 2.25 (2H, t with fine   153
splitting, J = 7.2 Hz, C3), 2.18 – 1.98 (1H, m, C7(1H)), 1.76 (2H, dt, J = 7.2, 5.3 
Hz, C4), 1.34 (1H, d with fine splitting, J = 13.5 Hz, C7(1H)), 0.15 (9H, s, TMS). 
13C NMR
 (75 MHz, CDCl3)  105.9 (C), 101.1 (CH1), 85.5 (C), 80.5 (C), 78.7 (C), 
67.1 (CH2), 34.5 (CH2), 26.0 (CH2), 20.7 (CH2), 19.2 (CH2), 13.8 (CH2), 0.3 (CH3). 
LRMS ESI+ 287 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 287.1438, [M+Na]
+ found = 287.1436. 
2-(Octa-3,7-diynyl)-1,3-dioxane (2.101) 
O
O
H
C12H16O2
Exact Mass: 192.115
Mol. Wt.: 192.2542
1
3
4
7
8
9
10
11
 
At room temperature under an atmosphere of Ar, to a stirred solution of acetal 
2.100 (900 mg, 3.41 mmol) in dry methanol (13 mL) was added dry K2CO3 (471 
mg, 3.41 mmol). The reaction was stirred for 4 hours then concentrated in vacuo 
to afford a white solid. The white solid was dissolved in water (20 mL) and 
extracted with EtOAc (3 x 30 mL). The organic phases were dried (MgSO4) and 
concentrated in vacuo to afford a colourless oil. Purification on SiO2 (12 x 3.5 cm) 
eluting with hexane/EtOAc (9:1) gave 2-(octa-3,7-diynyl)-1,3-dioxane (2.101) 
(617 mg, 3.21 mmol, 94%) as a colourless oil. 
IR max (neat) cm
-1 3287 (s), 2964 (s), 2851 (s). 
1H NMR  (300 MHz, CDCl3)  4.65 (1H, t, J = 5.3 Hz, C9), 4.09 (2H, m, C10(1H)), 
3.77 (2H, m, C10(1H)), 2.42 – 2.32 (4H, m, C3 and C4), 2.25 (2H, t, J = 7.2 Hz, 
C7), 2.16 – 1.97 (1H, m, C11(1H)), 2.01 (1H, s, C1), 1.76 (2H, dt, J = 7.2, 5.3 Hz, 
C8), 1.34 (1H, d with fine splitting, J = 13.4 Hz, C11(1H)). 
13C NMR
 (75 MHz, CDCl3)  101.1 (CH1), 83.2 (CH2), 80.7 (CH2), 78.5 (CH2), 
69.2 (CH1), 67.0 (CH2), 34.5 (CH2), 26.0 (CH2), 19.3 (CH2), 19.1 (CH2), 13.8 
(CH2). 
LRMS ESI+ 215 [M+Na]
+ (100%). 
HRMS ESI+ [M+H] calculated = 193.1223, [M+H] found = 193.1224.   154
9-(1,3-Dioxan-2-yl)nona-2,6-diyn-1-ol (2.92) 
O
O
OH
C13H18O3
Exact Mass: 222.1256
Mol. Wt.: 222.2802 1
11
10
4
12
 
At –78 °C under an atmosphere of Ar, to a stirred solution of alkyne 2.101 (600 
mg, 3.12 mmol) in dry THF (10 mL) was added 2.5M n-BuLi in hexane (1.45 mL, 
3.6 mmol). The reaction was stirred for 45 minutes then paraformaldehyde (560 
mg, 18.7 mmol) was added. The reaction was gradually warmed to room 
temperature and stirred for 3 hours. The reaction was slowly poured into NH4Cl 
(sat aq, 20 mL), the organic layer was separated and the aqueous layer was 
extracted with EtOAc (3 x 30 mL). The combined organic phases were 
concentrated in vacuo to give a yellow oil. Purification on SiO2 (12 x 4 cm) eluting 
with hexane/EtOAc (7:3 → 1:1) gave 9-(1,3-dioxan-2-yl)nona-2,6-diyn-1-ol (2.92) 
(683 mg, 3.07 mmol, 98%) as a colourless oil.  
IR max (neat) cm
-1 3416 (br), 2963 (s), 2927 (s), 2852 (s). 
1H NMR  (300 MHz, CDCl3)  4.65 (1H, t, J = 5.2 Hz, C10), 4.29 – 4.20 (2H, m, 
C1), 4.10 (2H, m, C11(1H)), 3.77 (2H, m, C11(1H)), 2.47 – 2.30 (4H, m, C4 and 
C5), 2.25 (2H, t with fine splitting, J = 7.3 Hz, C8), 2.07 (1H, dtt, J = 13.5, 12.4, 
4.9 Hz, C12(1H)), 1.86 (1H, t, J = 6.1 Hz, OH), 1.77 (2H, dt, J = 7.3, 5.2 Hz, C9), 
1.34 (1H, d with fine splitting, J = 13.5 Hz, C12(1H)). 
13C NMR
 (75 MHz, CDCl3)  101.1 (CH1), 85.0 (C), 80.7 (C), 79.4 (C), 78.8 (C), 
67.1 (CH2), 51.4 (CH2), 34.5 (CH2), 26.0 (CH2), 19.6 (CH2), 19.1 (CH2), 13.8 
(CH2). 
LRMS ESI+ 245 [M+Na]
+ (100%).  
HRMS ESI+ [M+Na]
+ calculated = 245.1148, [M+Na]
+ found = 245.1150. 
(2Z,6Z)-9-(1,3-Dioxan-2-yl)nona-2,6-dien-1-ol (2.102) 
OH
O
O
1
11
10 6
12
C13H22O3
Exact Mass: 226.1569
Mol. Wt.: 226.312
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Under an atmosphere of H2, a solution of alkyne 2.92 (60 mg, 0.27 mmol), Lindlar 
catalyst (Pd 5%, calcium carbonate poisoned with Pb) (30 mg, 0.014 mmol) in 
EtOAc (4 mL) was stirred for 30 minutes. The reaction was filtered through celite 
and washed through with EtOAc (50 mL). The filtrate was dried (MgSO4) and 
concentrated in vacuo to afford a pale yellow oil. Purification on SiO2 (12 x 1.5 
cm) eluting with hexane/EtOAc (1:1) gave (2Z,6Z)-9-(1,3-dioxan-2-yl)nona-2,6-
dien-1-ol (2.102) (50 mg, 0.22 mmol, 82%) as a colourless oil.  
IR max (neat) cm
-1 3406 (br), 3009 (s), 2956 (s), 2926 (s), 2851 (s), 1653 (w). 
1H NMR  (300 MHz, CDCl3)  5.76 – 5.47 (2H, m, C2 and C3), 5.47 – 5.29 (2H, 
m, C6 and C7), 4.51 (1H, t, J = 5.2 Hz, C10), 4.17 (2H, d, J = 6.3 Hz, C1), 4.10 
(2H, dd with fine splitting, J = 12.0, 4.9 Hz, C11
eq), 3.75 (2H, td, J = 12.0, 2.5 Hz, 
C11
ax), 2.18 – 1.98 (8H, m, C4, C5, C8 and C12
ax), 1.70 – 1.56 (2H, m, C9), 1.52 
(1H, br s, OH), 1.33 (1H, d with fine splitting, J = 13.5 Hz, C12
eq). 
13C NMR
 (75 MHz, CDCl3)  132.4 (CH1), 129.9 (CH1), 129.5 (CH1), 129.1 (CH1), 
101.9 (CH1), 67.1 (CH2), 58.6 (CH2), 35.2 (CH2), 27.6 (CH2), 27.2 (CH2), 26.0 
(CH2), 22.0 (CH2). 
LRMS ESI+ 249 [M+Na]
+ (100%).  
HRMS ESI+ [M+Na]
+ calculated = 249. 1461, [M+Na]
+ found = 249.1462. 
(2E,6Z,10Z)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-12-hydroxy-dodeca-2,6,10-trien-1-one 
(2.103) 
 
S
OO OH
N
O
C22H33NO4S
Exact Mass: 407.213
Mol. Wt.: 407.5667
1
21
12 6
22
14 16
17
19
 
To a solution of acetal 2.102 (47 mg, 0.21 mmol) in 1,4-dioxane: water: conc. 
H2SO4 (49.5 : 49.5: 1) (1 mL) was refluxed for 5 hours. The reaction was diluted 
with Et2O (10 mL) and washed with water (5 mL), NaHCO3 (sat aq, 2 x 5 mL) and   156
brine (5 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo to 
afford a pale yellow oil which was used in the next step.  
Under an atmosphere of Ar, to a stirred solution of (1S,2R)-camphorsultam 
phosphonate (90 mg, 0.23 mmol) in dry acetonitrile (1 mL) was added dried 
lithium chloride (170 °C/ 0.035 mbar overnight) (10 mg, 0.23 mmol). After stirring 
for 15 minutes, dry DIPEA (40 μL, 0.23 mmol) was added. After stirring for 10 
minutes, the crude aldehyde in dry acetonitrile (0.1 mL) was then added. The 
reaction was stirred for 20 hours. The reaction was diluted with water (5 mL) and 
brine (5 mL) then extracted with Et2O (3 x 10 mL). The combined organic phases 
were dried (MgSO4) and concentrated in vacuo to give a yellow oil. Purification 
on SiO2 (14 x 1.5 cm) eluting with EtOAc/hexane (1:1) gave triene 2.103 (25.3 
mg, 0.062 mmol, 30%) as a colourless oil. 
[α]
28
D –69.6 (CHCl3, c 1.25). 
IR max (neat) cm
-1 3416 (br), 2939 (s), 1681 (s), 1637 (s). 
1H NMR (300 MHz, CDCl3)  7.07 (1H, dt, J = 15.1, 6.7 Hz, C10), 6.56 (1H, d, J = 
15.1 Hz, C11), 5.64 (1H, dt, J = 11.0, 6.5 Hz, C2), 5.58 – 5.47 (1H, m, C3), 5.47 
– 5.32 (2H, m, C6 and C7), 4.18 (2H, d, J = 6.5 Hz, C1), 3.93 (1H, dd, J = 7.2, 
5.4 Hz, C13), 3.52 (1H, d, J = 13.8 Hz, C19(1H)), 3.44 (1H, d, J = 13.8 Hz, 
C19(1H)), 2.37 – 2.26 (2H, m, C9), 2.26 – 2.17 (2H, m, C8), 2.18 – 2.02 (6H, m, 
C4, C5 and C14), 2.00 – 1.81 (3H, m, C15, C16(1H) and C17(1H)), 1.68 (1H, br 
s, OH), 1.49 – 1.29 (2H, m, C16(1H) and C17(1H)), 1.17 (3H, s, C21), 0.98 (3H, 
s, C22). 
13C NMR
 (75 MHz, CDCl3)  164.2 (C), 150.3 (CH1), 132.2 (CH1), 130.3 (CH1), 
129.3 (CH1), 128.8 (CH1), 121.3 (CH1), 65.3 (CH1), 58.6 (CH2), 53.3 (CH2), 48.6 
(C), 48.0 (C), 44.9 (CH1), 38.7 (CH2), 33.0 (CH2), 32.6 (CH2), 27.5 (CH2), 27.4 
(CH2), 26.7 (CH2), 26.0 (CH2), 21.0 (CH3), 20.1 (CH3). 
LRMS ESI+ 430 [M+Na]
+ (100%).   
HRMS ESI+ [M+Na]
+ calculated = 430.2023, [M+Na]
+ found = 430.2023.   157
(2E,6Z)-1-((R)-10,10-Dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-9-((2R,3S)-3-hydroxymethyl-oxiranyl)-nona-
2,6-dien-1-one (2.89) 
 
S
OO OH
N
O
O
C22H33NO5S
Exact Mass: 423.2079
Mol. Wt.: 423.5661
1
21
12
6
22
14 16
17
19
 
At –25 °C under an atmosphere of Ar, to a stirred solution of DET-(+) (16.6 mg, 
0.081 mmol) and powdered 4Å molecular sieves (30 mg) in dry CH2Cl2 (1 mL) 
was added Ti(Oi-Pr)4 (20 μL, 0.067 mmol). The reaction was stirred for 10 
minutes then allylic alcohol 2.103 (25 mg, 0.061 mmol) was added. The reaction 
was stirred for 5 minutes then ~5.5M t-BuCO3H (25 μL, 0.123 mmol) in nonane 
was added, the reaction was stirred at –25 °C for 24 hours. 10% Tartaric acid (aq 
1 mL) was added, the reaction was stirred at –25 °C for 30 minutes then room 
temperature for 1 hour. The organic layer was collected, washed with water then 
dried (Na2SO4) and concentrated in vacuo to give a colourless oil. At 0 °C under 
an atmosphere of Ar, the colourless oil was dissolved in Et2O (2 mL) and 1M 
NaOH (1 mL) was added. The reaction was stirred for 30 minutes then washed 
with brine (1 mL). The organic phase was dried (Na2SO4) and concentrated in 
vacuo  to give a colourless oil. Purification on SiO2 (7 x 1 cm) eluting with 
hexane/EtOAc (1:1) gave epoxide 2.89 (17.6 mg, 0.042 mmol, 68%) as a 
colourless oil.  
[α]
27
D  –63.9 (CHCl3, c 0.88). 
IR max (neat) cm
-1 3460 (br), 2958 (s), 1681 (s), 1637 (s). 
1H NMR  (300 MHz, CDCl3)  7.07 (1H, dt, J = 15.1, 6.6 Hz, C10), 6.57 (1H, d, J 
= 15.1 Hz, C11), 5.52 – 5.35 (2H, m, C6 and C7), 3.93 (1H, dd, J = 7.2, 5.4 Hz, 
C13), 3.88 – 3.76 (1H, m, C1 (1H)), 3.76 – 3.64 (1H, m, C1 (1H)), 3.52 (1H, d, J 
= 13.8 Hz, C19(1H)), 3.44 (1H, d, J = 13.8 Hz, C19(1H)), 3.19 – 3.11 (1H, m, 
C2), 3.03 (1H, td, J = 6.4, 4.4 Hz, C3), 2.38 – 2.16 (6H, m, C5, C8 and C9), 2.16 
– 2.02 (2H, m, C14), 2.02 – 1.82 (3H, m, C15, C16(1H) and C17(1H)), 1.78 –   158
1.49 (3H, m, C4 and OH), 1.49 – 1.30 (2H, m, C16(1H) and C17(1H)), 1.18 (3H, 
s, C21), 0.98 (3H, s, C22). 
13C NMR
 (75 MHz, CDCl3)  164.2 (C), 150.1 (CH1), 129.7 (CH1), 129.3 (CH1), 
121.4 (CH1), 65.4 (CH1), 60.9 (CH2), 56.8 (CH1), 53.4 (CH2), 48.6 (C), 48.0 (C), 
44.9 (CH1), 38.7 (CH2), 33.0 (CH2), 32.5 (CH2), 28.1 (CH2), 26.7 (CH2), 25.9 
(CH2), 24.5 (CH2), 21.0 (CH3), 20.1 (CH3). 
LRMS ESI+ 446 [M+Na]
+ (100%).  
HRMS ESI+ [M+Na]
+ calculated = 446.1972, [M+Na]
+ found = 446.1965. 
(R)-2-[(2R,5S,2'R,5'R)-5'-((S)-1,2-Dihydroxy-ethyl)-octahydro-
[2,2']bifuranyl-5-yl]-1-((R)-10,10-dimethyl-3,3-dioxo-36-thia-4-aza-
tricyclo[5.2.1.01,5]dec-4-yl)-2-hydroxy-ethanone (2.90a/b) 
S
OO
N
21 22
14 16
17
19
O O OH
O
HO
H H H H
OH
1 3 6 10
12
C22H35NO8S
Exact Mass: 473.2083
Mol. Wt.: 473.5802
 
At –40 °C under an atmosphere of Ar, to a stirred solution of diene 2.89 (17 mg, 
0.04 mmol) in acetone/acetic acid (3:1 1 mL) was added powdered KMnO4 (8.26 
mg, 0.053 mmol). The reaction was stirred for 1 hour, then quenched by addition 
of Na2S2O3 (sat aq, 1 mL). The organic layer was separated and the aqueous 
layer was re-extracted with EtOAc (5 x 1 mL). The combined organic phases 
were dried (MgSO4) and concentrated in vacuo to give a yellow oil. Purification 
on SiO2 (1 x 7 cm) eluting with EtOAc/methanol (1:0 → 20:1) gave triols 2.90a/b 
(8.6 mg, 0.24 mmol, 45%) as a colourless oil. 
IR max (neat) cm
-1 3408 (br), 2957 (s), 1695 (s). 
1H NMR (400 MHz, CDCl3)  4.76 (1H, br s, OH), 4.74 – 4.67 (1H, m, C10), 4.49 
– 4.40 (1H, m, C11), 4.31 – 4.24 (1H, m, C7) 4.14 – 4.03 (2H, m, C3, C6), 4.02 – 
3.96 (1H, m, C15), 3.73 – 3.65 (1H, m, C1(1H)), 3.65 – 3.58 (1H, m, C1(1H)), 
3.58 – 3.48 (2H, m, C2 and C19(1H)), 3.48 – 3.40 (1H, m, C19(1H)), 2.25 – 2.15 
(1H, m, C14(1H)), 
 2.15 – 1.98 (5H, m, C8, C9 and C14(1H)), 1.98 – 1.83 (7H, m,   159
C4, C5, C15, C16(1H) and C17(1H)), 1.50 – 1.30 (2H, m, C16(1H) and C17(1H)), 
1.19 (3H, s, C21), 0.98 (3H, s, C22).
 
13C NMR (100 MHz, CDCl3)  173.0 (C), 82.4 (CH1), 81.3 (CH1), 81.1 (CH1), 79.6 
(CH1), 75.3 (CH1), 73.8 (CH1), 66.5 (CH1), 64.0 (CH2), 53.6 (CH2), 48.9 (C), 48.0 
(C), 45.1 (CH1), 38.7 (CH2), 33.4 (CH2), 28.9 (CH2) 2 overlaying peaks, 28.2 
(CH2), 26.5 (CH2), 25.3 (CH2), 21.3 (CH3), 20.1 (CH3). 
LRMS ESI+ 496 [M+Na]
+ (100%). 
HRMS ESI+ [M+Na]
+ calculated = 496.1976, [M+Na]
+ found = 496.1967. 
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